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The transcriptional program of poxviruses is divided into early, intermediate 
and late phases enabled by a multisubunit DNA-dependent RNA polymerase and 
stage-specific transcription factors that recognize cognate promoters. Although 
promoter sequences are highly conserved among the different chordopoxvirus genera, 
the transcription factors exhibit considerable amino acid divergence that parallels the 
evolutionary distance of the host species. Thus, the large/small subunits of the 
intermediate transcription factors (ITFs) of salmon gill poxvirus, crocodilepox, 
canarypox, and myxoma have 23/29, 40/31, 51/38 and 58/65 % amino acid identity, 
respectively, to the vaccinia virus (VACV) orthologs. The purpose of the present 
study was to determine the functional interchangeability of the ITF subunits and their 
putative interactions with other elements of the transcriptional machinery. A 
  
quantitative readout of ITF function using firefly luciferase (Fluc) was obtained.  The 
activity of the large subunit orthologs was greater than that of the small subunit 
orthologs, with both sets following the degree of sequence similarity in relation to 
VACV. The same pattern was obtained with both heterospecific (e.g., myxoma large 
and VACV small subunits) and homospecific (e.g., myxoma large and small subunits) 
pairings, suggesting inefficient interactions with other elements of the transcription 
system. When recombinant hybrid VACV expressing the Myxoma virus (MYXV) 
ortholog of the small subunit (A8) were blind passaged multiple times, their 
replicative abilities were enhanced. Complete genome sequencing of the virus 
populations revealed five mutations present in the two largest subunits of the viral 
RNA polymerase (RNAP) and two predicted expression-enhancing mutations around 
the translation initiation site of the MYXV A8 ortholog.  Amplicon sequencing was 
used to quantify the frequency of each mutation in its respective population, which 
revealed that they increased as passaging occurred.  This indicated a correlation with 
increased fitness, which then needed to be confirmed, so these mutations were all 
experimentally introduced into the original hybrid virus and demonstrated to enhance 
virus replication independently.  These mutations were then characterized to 
determine their specific effects on the viral RNAP (vRNAP) and viral replication and 
transcription.  This approach could have broader applications for studying essential 
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Chapter 1: Introduction 
Poxviruses (POXVs) are a family of large double-stranded DNA (dsDNA) 
viruses that are able to replicate entirely in the cytoplasm of the cells they infect (7), a 
feature which distinguishes them from most other DNA viruses that must replicate in 
the nucleus of cells.  The most notorious member of the family is Variola virus 
(VARV), the causative agent of Smallpox, one of the most devastating diseases in 
human history.  It is estimated that this virus was responsible for no less than 300 
million deaths and as many as 500 million during the 20th century (8, 9), while 
possibly killing off 10% of the world’s population over the course of the last 
millennium (9).  Through an aggressive vaccination campaign led by the World 
Health Organization (WHO) that started in 1967, however, Smallpox was declared 
eradicated in 1980 (8-15) with the last natural case of the disease occurring in 1977 
(16) in Somalia (9, 11).  As such, it is still the only human infectious disease to be 
successfully eradicated (11), and only one of two infectious diseases to have been 
eradicated, with Rinderpest being the second (17-19).  Recent reports, however, have 
revealed an outbreak of the latter disease in Bulgaria (20), (21), though this outbreak 
is being caused by an ovine (sheep and goats) rinderpest virus that is closely related 
to the bovine (cattle) rinderpest virus, which was the one eradicated (21).   
Despite the eradication of Smallpox, the need to study POXVs remains.  
Molluscum Contagiosum virus (MOCV), like VARV, is an obligate human pathogen, 
though it generally only causes benign lesions in young children.  There are also other 





virus (MPXV) (22, 23), which is responsible for outbreaks in Central Africa.  Other 
POXVs, such as Vaccinia virus (VACV) and Cowpox virus (CPXV), are endemic in 
parts of Brazil (12) and Europe, respectively, and are also capable of infecting 
humans via zoonotic transmission, similar to MPXV (22-24).  The emergence and 
spread of these diseases, in combination with the fact that newer generations are not 
vaccinated against Smallpox and older generations who are protected are dying off, 
mean that the threat of POXVs as infectious agents is ever-present (8, 22).  This 
threat is enhanced in light of the potential use of Smallpox, and perhaps similar 
diseases, in bioterrorism attacks (12, 22, 23).  There have also been multiple reports 
of vaccine or VACV escapees infecting animals and establishing enzootic cycles, 
leading to epizootic infections of horses and other animals (12, 24).  Just as alarming 
is the occurrence of cases in which vaccinated individuals have transmitted the virus 
to animals (12, 23, 24).  As such, learning as much as we can about them will help 
when POXV outbreaks occur.   
POXVs have been studied for other reasons though.  For decades they have 
been used as expression vectors, which has provided a powerful tool for 
immunologists and biochemists alike (7), and as gene delivery systems for gene 
therapy, due to the relative ease with regard to formation and isolation of recombinant 
viruses, their relatively high gene expression, their wide host ranges (7), and their 
large genomes and ability to incorporate large fragments of DNA (7, 25-27).  They 
have also been considered and/or developed for use as both animal and human 
vaccines and oncolytic viruses in cancer therapy (7, 11, 23, 27-33).  POXV research 





interactions and general molecular biology (7, 34, 35).  VACV was the first animal 
virus to be seen through a microscope, grown in tissue culture, accurately titered, 
physically purified, and chemically analyzed.  Discovery of RNA-synthetic activity 
and virally-encoded proteins which affect cell growth and modulate host immune 
defense mechanisms led to discoveries of similar activities in RNA viruses and new 
insights into virus-host relationships, respectively (7).   
This work focuses on the interesting gene expression system of poxviruses, 
which is separated into three distinct phases:  early, intermediate, and late.  Each 
phase has its own stage-specific transcription factors, along with stage-specific 
promoter sequences, which allow for expression of genes at certain times (7).  
Currently, much more information is known regarding early transcription and its 
regulation compared to intermediate and late transcription.  Chapter 2 will expand on 
this disparity in knowledge as well as the differences between early and 
intermediate/late transcriptional regulation, in addition to how POXVs adapt to 
selective pressures.  Chapter 3 will detail experiments used to determine if orthologs 
of the VACV intermediate transcription factors are able to complement viruses 
deficient in these genes.  Promoter sequences are quite similar between POXVs (27, 
36-38), so we wanted to see if the transcription factors were equally interchangeable.  
Once that was determined, recombinant viruses with orthologs in place of the native 
VACV genes were generated and blindly passaged to see if mutations would arise 
that would enable these recombinants to replicate better.  Whole genome sequencing 
(WGS) discovered the presence of five distinct mutations present in the two largest 





site of the Myxoma A8 ortholog.  Experiments were then carried out which confirmed 
that these mutations were indeed responsible for the increases in fitness of the 
recombinant viruses.  The experiments in Chapter 3 were recently published.  My 
contributions to this work included generating the deletion viruses and plasmids 
containing the orthologs, performing the initial Western blots and Luciferase assays, 
generating the hybrid viruses, carrying out the blind passaging, isolating the P10 
clones, preparing and sending the viral DNA for WGS, helping with the Amplicon 
Sequencing, and carrying out the viral yield assay.  Appendix A will explore the 
preliminary experiments carried out to characterize these mutations by attempting to 






Chapter 2: Literature Review 
2.1 The Poxviridae 
2.1.1 Classification 
The family Poxviridae is distinctive thanks to their cytoplasmic sites of 
replication, large complex virion, and single, linear dsDNA genome ranging from 130 
to 300 kilobase pairs (kbp) in length, with a hairpin loop at each end (7).  They are 
placed in Group I: dsDNA of the Baltimore classification system (29).  POXVs are 
distantly related to other large DNA viruses, in particular members of the following 
virus families:  Asfaviridae, Iridoviridae, Phycodnaviridae (7), and Ascoviridae, all of 
which were discovered prior to 1983 (4).  All of these viruses are also members of the 
superclade, proposed order Megavirales (2), of viruses known as nucleocytoplasmic 
large DNA viruses (NCLDVs), all of which infect eukaryotes (4, 39).  Since 2003, 
more viruses and virus families have been discovered whose characteristics led them 
to be categorized as NCLDVs.  They are Mimiviridae, Marseilleviridae, Megaviridae, 
Pandoraviridae, Pithoviridae, and Faustovirus (4).   
POXVs themselves are divided into two subfamilies:  Chordopoxvirinae, 
which infect vertebrates, and Entomopoxvirinae, which infect insects.  
Entomopoxviruses are divided into three genera, based on the insect host of isolation:  
Alphaentomopoxvirus (7 species), Betaentomopoxvirus (13 species), and 
Gammaentomopoxvirus (6 species) (7, 40).  There are also two unassigned species 
(40).  Chordopoxviruses (ChPVs) (32) were previously divided into eight genera:  
Orthopoxvirus (9 species), Parapoxvirus (4 species), Avipoxvirus (10 species), 





Molluscipoxvirus (1 species), and Yatapoxvirus (2 species) (7, 40).  Since then, two 
more genera have been added:  Cervidopoxvirus (1 species), in addition to one 
unassigned species (40), Crocodilepox virus (41, 42).  Viruses within a genus are 
closely related genetically, and have similar host ranges and morphologies (7).  All 
ChPVs have their genes similarly arranged, have interchangeable promoters, and have 
conserved RNAP and transcription factors (TFs) (27).  Members of the Parapoxvirus 
genus have a broad host range and infect animals in the Laurasiatheria (placental 
mammals) superorder, including humans occasionally.  Viruses in the Avipoxvirus 
genus on the other hand are only able to infect birds, although abortive infections 
have been observed in other animals.  Member viruses of the Capripoxvirus genus 
infect ruminants, which include cattle, sheep, and goats.  Species of the 
Leporipoxvirus, Suipoxvirus, Molluscipoxvirus, and Cervidpoxvirus genera are each 
only capable of infecting one type of organism or species:  rabbit or leporid species, 
swine, humans, and species of deer, respectively.  Finally, Yatapoxvirus genus 
viruses infect primate species (42).  Prior to the advent of genome sequencing, it was 
often theorized that the association of poxviruses with their vertebrate hosts was quite 
ancient and thus host and parasite had co-evolved throughout the history of amniotes.  
Phylogenetic analysis in general, however, does not support this analysis and instead 
strongly hints that transfers from one host species to another have been a recurrent 
feature throughout the evolution of the Chordopoxvirinae and that, overall, host and 







Of the ChPVs, the Orthopoxviruses (OPXVs) have been the most extensively 
studied, with VACV serving as the prototypical member of the genus (7) and, as a 
result, the best characterized virus in the NCLDV superclade (4).  Viruses in this 
genus are immunologically cross-reactive and cross-protective, so infection with one 
member confers immunity against another member of this genus (8).  As a genus, 
OPXVs are believed to have diverged from the other POXV genera about 130,000 
years ago (44).  There are 10 virus species which make up the OPXV genus:  
Camelpox (CMLV), CPXV, Ectromelia (ECTV), MPXV, Raccoonpox, Skunkpox, 
Taterapox (TATV), VACV, VARV, and Volepox.  The CPXV genome contains all 
the genes found in other members of the OPXV, suggesting that it is the least 
diverged from the ancestral member of this particular genus (1, 7, 44, 45).  The 
working hypothesis is that the subsequent evolution of the OPXVs has been a gradual 
restriction of host range via mutations of genes and loss of genes/shortening of the 
genome (1, 45, 46).  As a result of having the largest genome, CPXV has the widest 
host range (1, 13, 44, 45).  Additionally, recent analyses suggest that multiple species 
of OPXV have been grouped under the CPXV species (40, 44), which can be 
separated into anywhere from three to five distinct phylogenetic clades (13, 24).  
Many strains began evolving independently from a common ancestor about 10,000 
years ago (44).  The diversity among these isolates is so great it has been proposed 
that they should be assigned to different OPXV species (1, 44).    
Genes common to VACV, VARV, CPXV, ECTV, and CMLV all have greater 





Raccoonpox, Skunkpox, and Volepox, show a much greater genetic divergence (40), 
with their progenitor virus diverging about 50,000 years ago after the New World was 
colonized (44).  Viruses in the OPXV genus have a broad host range and infect a 
wide variety of mammals, including humans.  Species of CPXV infect many 
mammals, such as cats (13), including humans (unvaccinated ones in Europe (13)), 
and even zoo animals (13),  but their natural hosts seem to be rodents.  MPXV species 
also have a wide host range, infecting non-human primates (NHPs), humans, and 
other large animals, in addition to a large variety or rodents.  As with CPXV, rodents 
may be the natural hosts for these viruses.  The species origins and natural host(s) of 
the VACV species are currently unknown (14, 24, 42), though the natural source is 
assumed to be Horsepox virus (HSPV), which can also infect rodents (1).  In 
laboratory settings, VACV species infect a wide range of animals.  This wide host 
range is highlighted by the occasional outbreaks among bovine populations in South 
America (12, 42) and the ability of the virus to readily pass from animal-to-human 
and vice versa, as mentioned above (12, 23, 24).  CMLV virus is only known to infect 
camels, while TATV virus infects gerbils.  ECTV infects mice and moles (23, 42).  
VARV, like MOCV, is a human-specific pathogen (42). 
2.1.3 Virion Chemical Composition 
The VACV mature virion (MV) is the basic and most abundant infectious 
form of the virus.  Also known as the intracellular mature virion (IMV) (47, 48), it 
has a mass of 9.5 femtograms (fg).  The main components are proteins, lipids and 
DNA, which represent 90%, 5%, and 3.2% of the dry weight, respectively.  In 





about one-third of its virion weight in the form of lipids.  The lipids in the VACV MV 
are primarily cholesterol and phospholipids (40, 49, 50), while FWPV also contains 
squalene and cholesterol esters.  Spermine and spermidine, along with trace amounts 
of RNA have also been found in the VACV MV (7), which may lend credence to the 
results published in a recent paper (51).   
2.1.4 Virion Morphology 
POXV virions are quite large for animal viruses.  They are so large that they 
are just discernible using a light microscope.  To see ultrastructure, however, electron 
microscopy (EM) is required.  This tool, along with a technique known as Cryo-
electron tomography, have provided many details about the organization and 
composition of the POXV virion.  The VACV MV possesses a barrel shape, 
dimensions of approximately 360x270x250 nanometers (nm), and an outer layer 
whose density and thickness (5-6 nm) seem consistent with one lipid bilayer 
membrane.  The complex internal structure consists of a dumbbell-shaped core and 
aggregates of heterogeneous material, known as lateral bodies, occupying the space 
between the concavities and the outer membrane.  The core wall, which has an overall 
thickness of 18-19 nm, consists of two layers:  an inner layer and an outer layer.  The 
inner layer, which appears continuous, except for a small number of channels, has a 
diameter and density consistent with a lipid membrane.  The outer layer on the other 
hand has a palisade structure, made up of T-shaped spikes (8 nm long and 5 nm wide) 
which are anchored in the putative lower membrane.  Freeze fracture and deep etch 
EM have been used to confirm both the outer membrane of the virion and the palisade 





membrane.  Cryo-electron tomography, while a powerful technique, has its limits and 
is not yet able to resolve the ultrastructure of the core.  It has been able to glean, 
however, that the core has two distinct phases:  the core wall itself and a denser layer 
underneath with a fiber-like morphology, suggesting nucleoprotein.  Cylindrical 
elements, which may take on an S-shape or more complex, flowerlike structures, have 
been visualized using other methods within POXV cores (7, 40).  These structures are 
presumed to represent nucleoprotein (7), though no viral proteins have yet been 
localized to structural features of virions (40).  A recent publication has found that 
viral transcripts are incorporated into virions, at least in the case of CPXV (51).   
2.1.5 Polypeptide Components of the Virion 
POXV virions contain many polypeptides.  From MVs alone about 30 can be 
visualized using one-dimensional polyacrylamide gel electrophoresis (PAGE), after 
being purified from infected cells and disrupted with sodium dodecyl sulfate (SDS) 
and a reducing agent (7).  About 80 can be detected using a two-dimensional gel or 
mass spectrometry, while 30 have been characterized as being near the exterior of the 
purified MVs using one or a combination of techniques, e.g. surface-specific 
labelling, sensitivity to proteases, extraction with nonionic detergents, and reactivity 
with neutralizing antibodies (40).  These surface proteins can be categorized, 
structurally, as those with or without transmembrane domains (TMs) (7), and 
functionally, as those required for attachment, entry, disulfide bond formation, 
morphogenesis, and virulence (40).  The source of the viral membrane has since been 





Treating MVs with a nonionic detergent and a reducing agent leads to the 
release of viral cores. Almost 50 polypeptides have been identified in the cores, none 
of which can be found in the membrane fraction.  Enzymes make up about 30 of 
these, and of these 30, at least half are directly involved in the biosynthesis of early 
mRNA.  The remaining non-enzymatic proteins could be involved in morphogenesis 
and structure, with A17, L4, A3, and A10 being the most abundant (7).   
Meanwhile, the VACV enveloped virion (EV), which is its other infectious 
form, contains carbohydrates as a result of its glycoproteins (7).  The EV can also be 
referred to as the cell-associated enveloped virion (CEV) or extracellular enveloped 
virion (EEV) (47, 48).  The EV possesses an additional membrane, which contains 
several glycosylated proteins unique to this extra membrane:  A33, A34, A56, B5, 
and K2, and F13, which is a non-glycosylated putative phospholipase (7).  EVs are 
also reportedly enriched with sphingomyelin and phosphatidylserine (PS) with lower 
amounts of phosphatidylinositol (PI), relative to the MV (47).  This extra membrane 
results in EVs having a lower buoyant density than MVs (40).  Of the six EV 
membrane proteins, only two, A34 and F13, have been found in all ChPVs.  While 
EVs are generally regarded as simply being MVs with an additional membrane, this 
definition is not technically accurate.  Evidence suggests that MVs possess at least 
two surface proteins that EVs do not, A25 and A26.  The existence of EVs was first 
suggested by vaccine-related studies, where it was noticed that antibodies against 
inactivated MVs failed to protect rodents as well as antibodies to live virus or 





differences between the different types of sera in their abilities to neutralize virus 
(40).   
2.1.6 Genome Organization 
All POXVs contain a linear, dsDNA genome.  These genomes can range in 
size from 133-134 kbp in Parapoxviruses and Yatapoxvirus (42) to 300 kbp in some 
Avipoxviruses (7), including almost 360 kbp in Canarypox virus , and even larger 
than that in some Entomopoxviruses (370-380 kbp) (7), and encode usually more than 
150 genes (56).  This coding potential can range, though, from 133 genes in 
Parapoxviruses and Yatapoxviruses to 328 genes in Canarypox virus (32, 42).  The 
average size of a POXV-encoded protein is about 30 kiloDaltons (kDa or kD), similar 
to eukaryotes.  Furthermore, as these viruses replicate in the cytoplasm and thus do 
not undergo mRNA splicing, the number of viral genes can be estimated to be 1 per 1 
kb of genome (56).  The genome itself is not infectious, as virally encoded enzymes 
and other factors are required for expression in the cytoplasm.  Complete genome 
sequencing has been done for two Entomopoxviruses and at least one member of each 
ChPV genus (7).  Out of all the POXV genomes that have been fully sequenced, 90 
genes are conserved in all ChPVs, which represent about half of the genes encoded by 
the ChPV subfamily (48, 50), with about half of these, 41, also present in 
Entomopoxviruses (48, 56, 57).   
The organization of POXV genomes appears to follow some general rules:  
genes for the most part do not overlap, tend to occur in blocks pointing towards the 
nearer end of the genome, and ones essential for replication, which are highly 





host interactions, which are variable and species-specific, are located on the ends of 
the genome (7) (Fig. 2.1).  A significant proportion of the variable gene products 
engage host defense mechanisms (50), while the genes in the central region are vital 
for cell entry, DNA replication, gene expression/transcription, intramolecular 
disulfide bond formation, and virion assembly (48, 50).  The arrangement of the 
central genes is similar across all ChPVs (7).  This core region of the genome makes 
up about 75% of the complete sequence (42).  One study found that both gene order 
and gene spacing are well conserved within the ChPV genomes, with the FWPV 
genome being a notable exception, as it has undergone several rearrangements (58).  
Another group found that this exception applied to other Avipoxvirus genomes as 
well, as large genome inversions were found (42).  The former study also found that, 
of the genomes it analyzed, there is seemingly no conservation of gene order between 
Entomopox genomes or between the Entomopox and ChPV genomes (58).   
All POXV genomes contain inverted terminal repeats (ITRs), which consist of 
identical yet oppositely-oriented sequences of the genome.  These regions include:  an 
AT-rich, incompletely base-paired, hairpin loop that connects the two DNA strands 
and results in their linear genome; a highly-conserved region of almost 100 base pairs 
(bp) that contains sequences required for the resolution of concatemers formed during 
genome replication; variable-length sets of short, tandemly repeated sequences (7, 59-
62); and up to several open reading frames (ORFs).  These ITRs end up being 
variable in length as a result of a combination of deletions, repetitions, and 
transpositions (7).  The ITRs vary in size between species, with some being 





genes within the ITRs are present as diploids in the viral genome.  For instance, 
within the OPXV genus, the ITRs of VARV are about 200-500 bp and contain no 
genes, while strains of VACV have ITRs that are almost 12 kbp in length and contain 
six diploid genes (42).   
2.1.7 Genome Nomenclature 
The practice of naming VACV genes or ORFs was used prior to the entire 
genome being sequenced but has since been used for the complete sequence of the 
Copenhagen strain of VACV (VACV CP).  The convention used called for the 
naming of fragments of the VACV genome generated after digestion with the HindIII 
restriction endonuclease.  Names were assigned based on the size of the fragment, 
with the largest fragment referred to as A, the second largest referred to as B, and so 
on.  Within each fragment, each ORF was given a number, from left to right, 
followed by an L or R, depending on which direction the ORF was transcribed (7, 
48).  The exception to this rule was the C fragment, which was numbered from right 
to left to avoid starting in the highly variable left end of the genome (7).  The 
polypeptides that are encoded in the genome share names with their respective ORFs, 
but the L/R designation is dropped (7, 48).  Regarding the subsequent complete 
POXV genome sequences, the ORFs were successfully numbered from one end to the 
other.  Despite this, the old letter designations are still used as common names when 
referring to homologs to avoid confusion and to provide some continuity in the 
POXV literature.  The ORF number of the Western Reserve (WR) strain of VACV is 
widely used as this strain has been used for the vast majority of biochemical and 





generating physical maps of these viruses (63), which can aid in identification and 
classification of POXV isolates as more closely related POXVs tend to give similar 
banding patterns when digested with the same enzyme, while more distantly related 












































































Figure 2.1. Scheme of OPXV genome (not to scale).  Figure 1 from Babkin, I.V. 
and Babkina, I.N. The Origin of Variola Virus. Viruses, 2015. 7: 1100-1112. (1).  





2.2 Virus Lifecycle 
2.2.1 Attachment and Entry into Cells 
There are many mysteries surrounding POXV attachment and entry into cells, 
compounded by the fact that there are two forms of infectious particles, the MV and 
EV.  The surface proteins between the two are different and evidence supports the 
idea that they have distinct binding sites.  This includes relative differences in binding 
efficiencies of the two virus types to specific cell lines, differing effects of changes in 
binding after cell surface digestion with proteases, and the effect of a monoclonal 
antibody against the cell surface on the ability of MVs to bind to it (7).  Even though 
the MV is the more abundant form of the virus, the EV is the form more adapted for 
cell-to-cell spread (40).   
2.2.2 MV Entry 
Evidence suggests MVs utilize one of two pathways for entry.  One involves 
fusing with the plasma membrane, which demonstrates a pH-neutral mode of entry.  
The second involves endosomal entry, indicating a low-pH method of entry (7, 48).  
Endosomal acidification enables entry of the viral core into the cytoplasm, following 
actin-dependent micropinocytosis or fluid uptake of the large viral particles.  
Myxoma virus (MYXV) virus also enters cells via a low-pH endocytic pathway (40).  
Which method is used may depend on the strain of virus and cell type being studied 
(7) as there is considerable variation with regard to preference for alternative entry 
pathways when it comes to strains of VACV.  This preference may be dependent on 





mechanism could explain their ability to infect most cell types. For example, VACV 
infects primary cultures of well-differentiated human airway epithelial cells via the 
basolateral surface but egress via the apical surface (40).  VACV can even enter 
Drosophila S2 cells and other insect cells, although replication is abortive (48) and 
does not proceed past DNA synthesis (65).  Dual entry pathways have also been 
observed in herpesviruses (7).  Endosomal entry is thought to be more advantageous 
as it allows for passage through the dense cell cortex.  Evidence suggests that this is 
the preferred pathway for the WR strain of VACV (48) and of OPXVs that have 
recently been isolated in nature (50).  The A25 and A26 proteins reportedly serve as 
fusion suppressors for MVs, dictating the entry pathways utilized by specific strains, 
i.e., MVs lacking these two proteins enter through the plasma membrane, while those 
containing functional versions of these proteins do not readily fuse with the plasma 
membrane and thus enter via the endocytic pathway.  The route of viral entry is also 
cell-type dependent.  For example, VACV infection of Drosophila S2 cells happens 
exclusively via the endocytic route (48).  Using fluorescence microscopy, MVs have 
been observed trafficking to early endosomes and recycling endosome compartments 
prior to fusion of the membrane, following endocytosis (50).  Despite their biological 
significance, very few studies on VACV entry have used EVs and so most of these 
studies have focused on MVs (48, 50).  The reasoning is two-fold.  From a practical 
point of view, the fusion proteins are only located on the MV membrane (50).  From a 
technical aspect, a high proportion of EVs released from cells contain partially 
disrupted outer membranes, making results obtained with these particles difficult to 





2.2.3 Attachment Proteins 
Many enveloped viruses possess one or two proteins which serve dual roles in 
attaching to and fusing with cellular membranes.  VACV is unique in that it encodes 
at least four attachment proteins and 11 entry proteins (40).  The four attachment 
proteins are A26, A27, D8, and H3.  The initial attachment appears to be facilitated 
by binding to glycosaminoglycans.  D8 can bind chondroitin sulfate, A27 and H3 
bind to heparan sulfate (7), and A26 binds laminin.  Of these attachment proteins, 
only two have a TM domain, D8 and H3.  A26 and A27 interact with each other, the 
latter of which is anchored by the A17 TM protein (40), an important component of 
the MV membrane (48) that will be discussed later.  Individually, none of these 
proteins are essential (7, 48), although deletion of A27 and H3 severely reduces 
VACV infectivity (48, 50).  The crystal structures of both A27 and H3 have been 
solved, with the former in the form of a trimer and the latter in the form of a dimer 
(50).  All four attachment proteins are multifunctional (48), having roles unrelated to 
attachment (50), but only H3 is highly conserved among POXVs.  H3 is involved in 
MV assembly, while A27 is required for wrapped virion (WV) formation.  A26 
mediates MV incorporation into structures known as A-Type cytoplasmic inclusion 
bodies (ATIs) of some OPXVs, such as CPXV and ECTV.  The VACV A25 protein 
is a truncated form of the ATI protein, but is reported to be a fusion suppressor.  A 
soluble, truncated, recombinant form of the L1 protein, which will be described in 
more detail later, can attach to cells lacking glycosaminoglycans.  This results in the 
blocking of VACV entry, suggesting it is a receptor-binding protein.  The putative 





Interestingly, heparin, which has an inhibitory effect, appears to exert a greater 
competitive effect on strains which preferentially enter via a pH-neutral mechanism 
(40).  While the viral attachment proteins are known for the MV, those associated 
with the EV have not yet been identified (48).  EM images have shown dissociation 
of the EV membrane at the cell surface though, supporting the idea that it is not 
fusogenic.  Rupture of this membrane requires the EV membrane glycoproteins A34 
and B5, along with interactions with glycosaminoglycans on the cell surface 
following virus attachment (50).   
2.2.4 Entry Proteins 
An entry-fusion complex (EFC), a group of molecules essential for viral entry, 
was identified, and it consists of at least 11 proteins:  A16, A21, A28, G3, G9, H2, J5, 
L5 (40), F9, L1 (66), and O3 (48, 67).  L1 and F9 are associated with the EFC, while 
the rest are all integral components of the complex (48).  All 11 are necessary for 
entry (48) but not for assembly of virions or attachment to cells (7, 48), as assembly 
of normal-looking virions still occurs if these proteins are repressed (40, 48).  These 
viruses, however, are unable to infect cells.  More evidence of their importance is the 
fact that all 11 proteins have been found in all POXVs analyzed to date, suggesting a 
common entry mechanism (40).  These proteins are all made after DNA replication 
(48), range in size from 4 to 43 kDa, are not glycosylated, and do not resemble the 
type 1, 2 (40, 48), or 3 (50) fusion proteins found in other viruses (40, 48, 50).  The 
lack of glycosylation and cleavable signal peptides raise questions regarding how 
these proteins are trafficked to the MV membrane (50).  All, with the exceptions of 





POXV-encoded cytoplasmic redox system, which has also been found in all POXVs 
to date (40, 48).  As no other viral proteins have yet been identified as substrates of 
the POXV redox system, the current thinking is that this system co-developed with 
the EFC proteins (48).  Three of the proteins appear to have been derived from a 
common gene early in POXV evolution:  A16, G9, and J5 (40, 48).  This seems to be 
the result of a gene duplication, which then diverged over the course of POXV 
evolution (48).  These three proteins have low sequence identities, despite their 
evolutionary relationship (50).  In that same vein, L1 and F9 are structurally related.  
Despite this, each paralog is encoded by all POXVs and each one is individually 
required for entry (48).  All 11 proteins possess a TM domain (66), with five 
possessing it in their N-terminal regions (A21, A28, G3, H2, and O3), while the 
remainder (A16, F9, G9, J5, L1, and L5) have it in their C-terminal regions (48).  The 
proteins that make up this complex are required for the membrane fusion step of entry 
of the MV (66), cell-to-cell spread of the EV, and low-pH-induced syncytia 
formation, all of which support the idea that only the MV membrane is fusogenic and 
that fusion and entry are coupled together (7).   
While some interacting partners have been identified, neither the 
stoichiometry nor the structure of the EFC has been solved (40).  This complex fails 
to come together if viral membrane formation is inhibited, which prevents its 
synthesis in heterologous systems, thus hindering its physical characterization.  The 
combined mass of the EFC and the associated proteins would be 232 kDa, operating 
under the assumption that each protein is only present in a single copy.  The EFC is 





being held together by multiple subunit interactions, some of which have been solved.  
These interactions are:  A28-H2, A16-G9, and G3-L5.  The A16-G9 complex has an 
additional function, as it can bind to the A56-K2 heterodimer of fusion regulatory 
proteins as well as A26 (48).  O3 is the smallest protein encoded by VACV, at just 35 
amino acids (aa) long.  Orthologs from other POXVs, ranging in in size from 29 – 48 
aa in length, can complement an O3 deletion mutant, despite their low degree of 
amino acid identity.  This is thanks to its N-terminal TM domain, which is essential 
but sufficient for it to associate with other EFC proteins (48, 67).  Mutagenesis 
experiments with H2 identified a highly-conserved region (a conserved LGYSG 
sequence between two cysteines (50)) that is crucial for its interaction with A28.  L1 
is myristoylated at a Glycine residue in its N-terminal region and has three 
intramolecular disulfide bonds.  Mutating this Glycine prevents the complementation 
of VACV infectivity, changes the intracellular localization of L1, and reduces the 
formation of the intramolecular disulfide bonds.  Despite all that, the mutated protein 
will still associate with the EFC and MVs.  The crystal structure of this protein has 
also been solved, revealing a fold comprised of a bundle of -helices packed against a 
pair of two-stranded -sheets, as well as a large hydrophobic cavity which would 
seem to accommodate the N-terminal myristate moiety.  Mutations within said cavity 
have no effect on myristoylation but do inhibit infectivity, leading to a model 
involving a “myristate switch”, in which the acyl chain is released from the cavity 
during entry.  Interestingly, both L1 and A28 are targets of neutralizing antibodies, 
meaning that they are both at least partly exposed on the surface of the MV.  The 





Additional proteins, including A27 and I2, have been implicated in entry (7). 
Specifically, A27, along with A17, have been implicated in membrane fusion, but no 
genetic evidence supports their requirement for entry (40, 48).  The heterologous 
expression of A17 reportedly causes the fusion of transfected cells, suggesting a 
similar role in viral entry.  Conditional lethal A17 mutants have a block in viral 
membrane formation, where fusion may play a role, making it hard to determine an 
additional entry function (48).  With regard to I2, it was found that virions lacking the 
protein are unable to enter cells, thus greatly reducing infectivity (66).  This Hyun et 
al. (66) study set out to investigate the initial report from another group regarding this 
defect in viral entry by determining which step of replication or entry was affected by 
the absence of I2.  I2 itself is a small protein, at only 72 aa long and with a mass of 
8.4 kDa.  It possesses a C-terminal TM domain, does not contain any conserved 
intramolecular disulfide bonds (48), is made after VACV DNA replication, is 
associated with purified MVs, and is conserved in all ChPVs.  What they found was 
that, while an I2 deletion mutant was unable to enter cells, the primary block was, 
unexpectedly, in virion morphogenesis, specifically after the formation of IVs, a 
process which will be discussed in more detail later.  Virions lacking I2 were 
deficient in EFC proteins, which likely prevented the entry of the aberrant particles 
into cells.  Given the findings, they concluded I2 is not an entry protein per se but has 
an indirect effect on viral entry.   
2.2.5 EV Entry 
The entry of EV particles requires at least one additional step, as the outer 





only on the MV membrane.  This additional membrane contains several proteins 
unique to it, most of which are glycosylated, A33, A34, A56, B5, and K2, and one 
which is not, F13, which is a non-glycosylated putative phospholipase. EVs appear to 
be able to shed their outer membranes at both low and neutral pHs.  The A34 and B5 
glycoproteins, plus polyanionic molecules, are required for this process at neutral pH.  
B5 has also been implicated in cell entry, thanks to neutralizing antibody studies.  
Mutations in either member of the A56 hemagglutinin-K2 glycoprotein heterodimer 
leads to fusion of adjacent infected cells without the need for a low pH trigger.  EVs 
are largely responsible for the efficient cell-to-cell spread of VACV by adhering to 
the cell surface at the ends of finger-like projections that are formed by actin 
polymerization.  Actin has also been potentially implicated in MV entry via an actin-
mediated internalization mechanism, perhaps involving macropinocytosis.  For EVs, 
deletion of the A34R, A33R, or A36R genes prevents the formation of actin tails and 
reduces virus spread efficiency and EVs lacking A34 possess low infectivity.  
Deficiencies in actin tail formation can be partly overcome using mutants or strains 
that produce more EVs.  One such example is the IHD strain of VACV, which seems 
likely to have arisen from a spontaneous mutation in the A34R gene, releases large 
amounts of EV particles and produces comet-like satellite plaques (7).  Other viruses 
which possess mutations in A33, A34, or A36 are able to overcome a deficiency in 
actin tail formation via enhanced EV production (40).   
2.2.6 Signaling Receptors 
Studies have indicated that the interaction between the MV and the cell 





with the formation of actin- and ezrin-containing protrusions that envelop the virus 
(7).  MVs are engulfed by the cell via clathrin- and caveolin-independent 
micropinocytosis or fluid phase endocytosis, both of which are dependent upon actin 
dynamics and cell signaling (48).  Additional experimental evidence suggests that 
both signaling and actin rearrangements are required for the initial fusion of the viral 
and cellular membranes (40).  Inhibitors of actin dynamics do not significantly affect 
binding but do impair membrane fusion.  It has been proposed that actin remodeling 
facilitates fusion by forcing membranes together and enlarging pores in certain 
situations, such as viral protein-induced cell-cell fusion and virus entry.  In fact, actin 
dynamics may be required for both hemifusion and pore formation.  The requirement 
for cell signaling may have been the impetus behind earlier proposals putting forth 
chemokine receptors as the receptors for POXV entry.  It has been determined, 
though, that the cellular proteins, VPEF (48), integrin B1 (50), and CD98 (48, 50), 
participate in the fluid phase uptake of MVs (48, 50).  These proteins are associated 
with lipid rafts (48).  In contrast to this, however, is EV entry, which does not appear 
to be signaling dependent (47), which may occur using either of the above routes used 
by MVs (48, 50).   
2.2.7 Cellular Lipid Composition 
The lipid composition of the cell membrane is important for entry, as virus 
penetration is inhibited by the depletion of cholesterol (7, 47).  Cellular cholesterol 
inhibition does not prevent binding but it does significantly reduce viral core entry, 
possibly suggesting a role for lipid rafts (47, 48).  MVs have reportedly been found to 





endosomal acidification and membrane blebbing resulted in the same phenotype (48).  
Specifically, this block occurred during the initial stages of virus-cell membrane 
fusion.  These experiments also supported the hypothesis of a two-step entry model 
for VACV with a hemifusion intermediate (49).  In this model of entry, the outer 
leaflets of the apposing membranes form a hemifusion intermediate, followed by 
merging of the inner leaflets, thus forming the fusion pore.  As such, lipid mixing and 
content mixing occur in a sequential order (48, 49).  The site of hemifusion, although 
yet to be directly determined, is thought to be at the plasma membrane (50).  The 
individual roles of each EFC member were investigated using conditional lethal 
inducible mutants.  All were able to attach to cells but unable to carry out even the 
initial step in the fusion process, with the exceptions of the A28, L1, and L5 mutants.  
For these three, lipid mixing occurred, but no subsequent steps took place.  These 
data further supported the two-step model of viral entry (48, 49).   
VACV infectivity can be enhanced in combination with PS and an apoptotic 
mimicry model with a role for a specific PS receptor has been put forth, based on 
reconstitution of delipidated virus (40, 49, 50).  In this model, virion-associated PS 
flags virions as apoptotic debris for cell uptake via macropinocytosis (49, 50).  The 
stereoisomer of PS and other phospholipids not known to signal apoptotic uptake are 
also capable of reconstituting infectivity however (40, 49, 50).  This means that either 
the putative receptor has broad specificity or that the phospholipids play a different 
role in enhancing infectivity (40, 68).  Regardless, the viral membrane lipid 
composition, specifically the presence of anionic phospholipids, is important for the 





membrane fusion.  Cores can be detected in the cytoplasm of infected cells in as little 
as 10 minutes (mins), when the medium is acidified and entry occurs via the plasma 
membrane.  At neutral pH, however, it takes 20-30 mins to detect cores being 
liberated from the endosome.  These determinations were done using fluorescence 
and electron microscopy.  Using a luciferase assay-expressing recombinant VACV, 
there is a delay of about 20 mins in detection of cores by EM versus detection of an 
appreciable amount of luciferase activity.  It was determined that at least 10 of the 
EFC proteins are required for core entry (50).   
Specific protein receptors required for viral entry have not been identified yet, 
though some have been proposed, such as the epidermal growth factor receptor and 
chemokine receptors (7, 48).  Neither of these theories has been supported by 
experimental results however.  Slow progress on this aspect of the POXV lifecycle is 
due, at least in part, to the fact that no cell line refractory to POXV entry has yet been 
identified.  Once such a cell line was found, a genetic screen could be performed to 
identify a receptor, as has been done with numerous other viruses (7).  It should be 
noted, however, that for VACV and most other OPXVs, it is believed that cellular 
tropism is not regulated at the level of binding and entry but rather by intracellular 
events (69), a theory which has been supported by experimental findings (48, 65, 70).   
2.2.8 Syncytia Formation 
Syncytia formation is a phenomenon in which cells fuse to one another.  It is 
dependent upon the formation and externalization of virions and on components of 
the EFC, implying that it has features related to viral entry.  This process is also 





cause this, namely A56 and K2.  These two proteins form a fusion suppressor 
complex on the plasma and EV membranes and interact with the A16-G9 subunits of 
the EFC, preventing spontaneous activation of the fusion apparatus by viral progeny.  
Both A56 and K2 are required for this function, as uninfected cells expressing both, 
but not either alone, are resistant to syncytia formation when mixed with A56R 
deletion mutant-infected cells.  Syncytia formation can also occur if cells infected 
with wild-type VACV are briefly exposed to low pH.  A similar phenotype is 
observed with A56R and K2L mutants at neutral pH.  This process is also referred to 
as fusion from within, even though it too is dependent upon virions being present on 
the cell surface.  Fusion from without, on the other hand, can occur when cells 
infected by a high multiplicity of MVs are exposed to low pH.  The A26 protein also 
reportedly binds to the A16-G9 subunit complex of the EFC.  This association is 
weakened in low pH and A26 deletion mutants are capable of inducing fusion from 
without at a neutral pH (48, 50).   
2.2.9 Superinfection Inhibition 
Superinfection exclusion (SIE) is a phenomenon which prevents EVs from 
infecting cells which express the A33 and A36 proteins, both of which are made by 
early genes (48), on the surface of their membranes (40, 50).  This repulsion 
mechanism likely enhances the spread of EVs to uninfected cells.  Another 
mechanism POXVs use to prevent superinfection, specific to MVs, is the interaction 
between the A56-K2 heterodimer and the A16-G9 subunit complex of the EFC, an 
interaction which also serves to prevent syncytia formation, as mentioned above (40, 





virus at late times, seemingly in addition to the already reduced superinfection 
exclusion.  These two proteins alone are sufficient for superinfection exclusion, as 
uninfected cells stably expressing both are resistant to infection (48).  Thus, this viral 
protein complex has roles as a fusion suppressor for both viral entry and syncytia 
formation (50).  Yet another way POXVs prevent superinfection is at the membrane 
lipid-mixing, or hemifusion, step of viral entry.  This mechanism requires the primary 
virus to undergo early mRNA and protein synthesis, but not DNA synthesis.  Thus, 
the secondary, or superinfecting, virus binds to the cell but is unable to release its 
core into the cytoplasm and initiate early gene expression.  This mechanism differs 
from the A56/K2-mediated block, which takes place after membrane fusion occurs 
(40, 49, 50).  As such, it is necessary to distinguish between SIE of the secondary 
virus and superinfection resistance induced by the primary virus, which act on 
different steps of viral entry and via distinct mechanisms (40, 71).  Regardless of 
which mechanism is used, SIE operates between virus adsorption and early gene 
expression, nearing completion by 6 hours post-infection (hpi) (48).   
2.3 Genome Replication 
POXVs, as mentioned before, replicate in the cytoplasm of infected cells, and 
are even able to replicate in enucleated cells.  The specific sites or foci of replication 
are referred to as viral factories.  Each infectious particle is capable of generating its 
own viral factory (7), though factories are capable of merging over the course of an 
infection (40).  DNA replication begins 1-2 hpi and generates about 10,000 copies of 
the VACV genome, about half of which end up being packaged into progeny virions 





can be affected by the multiplicity of infection (MOI) and cell type (40).  One recent 
study (72) found that, in a confluent A549 cell monolayer, about 500 VACV genomes 
per cell had accumulated by 6 hpi.  This same paper used digital droplet PCR 
(ddPCR) to determine the rate of replication.  The rate of synthesis was calculated to 
be 86 bp/second (s) from 3.5 to 4 hours (h) and 130 bp/s from 4 to 5 h, which was the 
maximal rate observed.  This rate was several times faster than what has been 
calculated for herpes simplex virus (HSV) DNA replication.  Using these numbers, it 
was estimated that it would take between 25 and 35 mins to replicate a full-length 
VACV genome.  These calculations were done under the assumption that there is 
only one replicon per genome.  If multiple origins of replication existed, however, the 
rate of synthesis would be lower (72).  There is evidence which suggests replicating 
DNA may be associated with ER membranes, (40) as the ER is actively recruited as 
the viral factory expands due to macromolecular synthesis (72).  Senkevich et al. (72), 
however, did not find evidence that VACV DNA synthesis takes place in close 
association with recognizable ER membranes.  They proposed that the ER 
surrounding the factories is passively pushed out from the interior, in addition to other 
cellular organelles, as the factory expands.   
2.3.1 Uncoating and DNA Synthesis 
While it is obvious that uncoating of the viral core is a necessary event prior 
to DNA replication, more and more evidence has now shown that uncoating and 
DNA synthesis are deeply intertwined, with a significant role being played by the 
ubiquitin-proteasome system.  The interconnectedness and complexity of these two 





three different proteins were all found to function redundantly in both uncoating and 
DNA synthesis.  How exactly this system facilitates either of these two processes, 
however, is not yet understood.   
2.3.2 Origin of Replication 
Until recently, no origin(s) of replication had been found.  It had been 
theorized that POXVs perhaps do not need specific origin sequences, unlike nuclear 
DNA viruses (7).  What was known, however, is that in cells infected with Shope 
fibroma virus (SFV) or VACV, any circular DNA molecule got replicated.  
Additionally, origin-independent plasmid replication takes place in viral factories and 
requires every protein necessary for genome replication, confirming the specificity of 
this activity.  In experiments studying linear DNA molecules containing VACV 
hairpin ends, the presence of the terminal 200 bp resulted in enhanced replication.  
This terminal region contains the concatemer resolution sequence, but the mechanism 
of this enhancement is currently unknown (40).  A recent paper, by Senkevich et al. 
(74), shed some light on this process by finding that origins possessing a prominent 
initiation point mapped to a sequence within only one of the isomeric hairpin loops at 
the end of a mature genome.  Interestingly, this same sequence was also located 
within all the concatemeric junctions of replication intermediates.  Given that these 
two sequences are identical, the group was unable to discriminate between the two.  
What they did find, however, was that their analysis was consistent with VACV DNA 
synthesis starting at a replication fork at an origin found within the terminal hairpin of 
a mature monomeric genome following infection, during the initial round of 





replication intermediates that form during VACV DNA replication.  What may 
represent the main start site of VACV DNA replication corresponds to a spot 35 nt 
from the apex of the hairpin.  Additionally, several potential minor start sites were 
also detected in both directions.  The finding of one prominent start site led to the 
conclusion that VACV DNA replication starts primarily on one end or is asymmetric.  
Also, its location within the hairpin loop is not surprising given that early experiments 
suggested the genome ends were the sites of initiation and that the loop is the most 
AT-rich region of the viral genome (74).   
2.3.3 DNA Replication Model 
Two possible models have been proposed for how POXVs replicate their 
genomes:  one like the rolling hairpin strand displacement mechanism proposed as the 
method of replication for single-stranded Parvoviruses; or one involving RNA 
priming and semi-discontinuous DNA synthesis at replication forks, which is more 
conventional than the former model.  The first model is supported by the fact that the 
POXV genome has a unique terminal structure and a high molecular weight, along 
with the presence of junction fragments and evidence suggesting that nicking and 
initiation occur near the end of the molecule.  For this model to work, a hypothetical 
nick is placed at one or both ends of the genome, providing a free 3’-end for priming 
replication.  The replicated DNA strand then folds back on itself and the replication 
complex copies the rest of the genome.  Concatemer junctions form after the complex 
goes through the hairpin.  Very large, branched concatemers arise when new rounds 
of replication are initiated before these structures are resolved.  Once late-stage 





progeny and the incompletely base-paired terminal hairpins are regenerated, with 
inverted and complementary sequences intact.  This model has not been supported yet 
as neither the nicking site nor the essential nicking enzyme needed to begin DNA 
replication has been identified (40).  The alternative discontinuous model was 
supported by early reports of VACV DNA covalently linked to RNA and the chasing 
of DNA into larger molecules, pointing to lagging strand synthesis as the mechanism 
(40, 74).  The problem with this model is that, until recently, a virally-encoded RNA 
primase had not been discovered and the virally-encoded DNA ligase was not 
essential for viral replication.  This model is now supported by the recent discovery of 
the long-sought viral RNA primase (75) and by the fact that the host DNA ligase can 
be substituted for the viral ligase when it is absent (76).  More support for this model 
was gained after a group used deep sequencing to map the origins of replication.  
These findings were consistent with the early EM and biochemical studies looking at 
VACV DNA replication, along with the need for primase and ligase activities (74).  
The presence of branched DNA molecules in this model can be explained by what has 
been seen in phage T4, in which recombination-dependent DNA replication involves 
invasion of duplex DNA by the 3’ OH of ssDNA.  It is also entirely possible that 
POXVs use multiple mechanisms to successfully replicate their large genomes, as 
these mechanisms are not mutually exclusive (40), although this scenario seems far 
less likely now due to recent findings (74).   
2.3.4 Enzymes Involved in DNA Precursor Metabolism 
Some poxviruses encode the enzymes involved in DNA precursor 





suboptimal precursor pools.  These enzymes include a thymidine kinase (TK), 
thymidylate kinase, ribonucleotide reductase (7, 77), dUTPase, and an incomplete 
guanylate kinase (7), all of which are found in OPXVs.  The incomplete guanylate 
kinase may indicate that an intact one exists in some other POXVs.  Leporipoxviruses 
lack genes encoding the large subunit of ribonucleotide reductase, thymidylate kinase, 
and remnants of the guanylate kinase.  MOCV lacks all these genes, which may 
contribute to its limited host range.  FWPV encodes a protein related to human 
deoxycytidine kinase, which has yet to be found in any other Poxvirus.  
Entemopoxvirus Melanoplus sanguinipes does not encode any of these genes, but it 
does have a thymidylate synthetase homolog.  A homologous TK gene has been 
found in other Entemopoxviruses however (40).  The TKs encoded by POXVs are all 
20-25 kDa in size and have 35-70% amino acid identity with their corresponding 
eukaryotic enzymes.  Interestingly, they are not related in sequence to the pyrimidine 
kinase of herpesviruses.  The VACV TK is, however, quite similar in structure to the 
human TK.  The differences between the two relate to their associations with dTTP 
and are subtle enough that this enzyme could be a potential target for antivirals.  The 
TK gene possesses an early promoter, while the enzyme exists as a tetramer, has 
adenosine triphosphate (ATP) and Mg2+ binding domains, and is susceptible to 
feedback inhibition by dTDP or dTTP.  Even though TK is not essential for virus 
growth in cell culture, deletion mutants are severely attenuated in animal models (40).   
The thymidylate kinase encoded by VACV is 23 kDa and can complement 
Saccharomyces cerevisiae mutants deficient in the homologous enzyme.  This kinase 





promoter and is not required for replication in cell culture.  The VACV thymidylate 
kinase has 42% sequence identity with its human homolog, but differs in substantial 
ways, such as having broader substrate specificity (40).   
The ribonucleotide reductase is made shortly after VACV infects a new cell.  
This enzyme converts ribonucleoside diphosphates into deoxyribonucleoside 
diphosphates.  It exists as a heterodimer, with the small subunit containing the 
catalytic domain and the large subunit being the regulatory subunit.  Each subunit 
closely resembles its eukaryotic counterpart in terms of function and structure (70-
80% identity).  The enzyme’s catalytic activity is inhibited by hydroxyurea 
preventing DNA replication.  Interestingly, drug-resistant mutants generate direct 
tandem repeats of the gene coding for the catalytic (small) subunit.  Mutating the 
regulatory (large) subunit prevents induced enzyme activity which does not affect 
replication in cell culture but mildly attenuates the virus in a mouse model.  This 
virally-encoded heterodimer is only present in OPXVs, as many ChPVs only have the 
large subunit, which then must form a complex with the host small subunit in order to 
form an active enzyme (40).   
The VACV dUTPase hydrolyzes dUTP into dUMP, which is an intermediate 
in the biosynthesis of TTP.  Its activity may also minimize dUTP incorporation into 
DNA.  Like the previous three enzymes, the dUTPase is made during the early phase 
of gene expression and is not required for the virus to replicate, in dividing cells at 
least.  Its absence or mutation is felt more in quiescent cells, especially if the viral 
uracil DNA glycosylase is missing.  Like the viral TK, the VACV dUTPase closely 





differences exist between the two, allowing for the possibility that this enzyme could 
be exploited as an antiviral target (40).   
2.3.5 Viral Proteins Involved in DNA Replication 
VACV encodes its own DNA polymerase (DNAP) (E9), complete with 3` 
exonuclease activity, a nucleic-acid-independent nucleoside triphosphatase (NTPase) 
(D5), a serine/threonine protein kinase (B1), a uracil DNA glycosylase (UDG) (D4), a 
DNA processivity factor (A20), and a functional ATP-dependent DNA ligase.  The 
DNAP, serine/threonine protein kinase, UDG, NTPase, and DNA processivity factor 
are all essential for VACV DNA replication (7).  The 117-kDa viral DNA polymerase 
(78) is homologous to other eukaryotic and viral DNAPs (40).  Information regarding 
the active site has been gathered from codon substitutions at certain residues which 
confer resistance to inhibitors of DNA synthesis (40).  This enzyme has been one of 
many viral proteins viewed as a potential antiviral target.  One such compound, 
Cidofovir, even made it to the clinical stage of testing.  This acyclic nucleoside 
analog, and its oral derivatives (78), get incorporated into the growing DNA strand, 
inhibiting the 5`-to-3` chain extension and 3`-to-5` exonuclease activities of the viral 
DNAP (40, 78).   
The B1 kinase is a 35-kDa enzyme which is expressed early in infection, 
packaged in virions, and is required for VACV DNA replication.  A host cytoplasmic 
protein known as barrier to autointegration factor, or BAF, is a potent inhibitor of 
POXV DNA replication.  It has now been shown that B1-mediated phosphorylation 
of BAF blocks its DNA-binding activity.  A ts VACV mutant defective in B1 kinase 





substrates that are involved in immune defense activities (40) and translation of viral 
transcripts (5).  Another known substrate for B1 is the early protein H5.  Direct 
interactions between these two proteins were demonstrated via the yeast two-hybrid 
(Y2H) system.  H5 seems to be a versatile protein as it reportedly has roles in DNA 
replication, transcription, mRNA processing, and morphogenesis (40).   
D4, encodes a functional UDG, similar to the one found in SFV.  These 
enzymes are involved in DNA repair, removing uracil residues that have been 
introduced into the DNA through either misincorporation of dUTP or cytosine 
deamination.  VACV mutants with an enzymatically inactive UDG show attenuation 
in a mouse model, demonstrating that the repair function is beneficial for replication 
and virulence.  This benefit is highlighted by the fact that the catalytic site is 
conserved in all POXV orthologs.  Outside of POXVs, the POXV UDG only has 
about 20% sequence identity with non-POXV homologs, in addition to possessing 
different secondary and tertiary structures (40). D4 also plays a role as a processivity 
subunit of the viral DNAP, a function which does not require its enzymatic activity 
(79).   
The D5R gene encodes a 90-kDa enzyme with both NTPase and primase 
activities.  Mutations in the active site of either region are unable to complement a 
conditional lethal temperature-sensitive (ts) mutant. D5 is needed for viral replication, 
though it seems this is independent of its glycosylase activity (40).  The requirement 
for D5 in DNA synthesis is emphasized by the fact that it is conserved across all 
POXVs, with more diverged orthologs found in members of all other families of the 





primase superfamily (40, 75).  The discovery of a virally-encoded primase has 
important implications regarding the mechanism of genome replication and also 
provides an additional potential therapeutic target (75).  One trait that sets D5 apart 
from the other viral DNA synthesis proteins is that it is currently the only one 
involved in uncoating of the viral core (73).   
Another protein involved in DNA replication is the A20 protein, which has no 
non-POXV homologs.  The role of A20 was first hinted at thanks to Y2H analysis, 
which showed an interaction between it and the viral DNA replication proteins D4, 
D5, and H5.  Additional Y2H studies demonstrated that non-overlapping regions of 
A20 were responsible for these separate interactions, implying that these four proteins 
can interact simultaneously to form a multicomponent complex.  These interactions 
were then confirmed via co-immunoprecipitation.  Targeted mutagenesis showed that 
A20 was involved in VACV DNA replication, specifically regarding processivity 
when A20 is complexed with D4 and the DNAP.  Another protein, which was found 
to be essential for VACV replication, is the 34-kDa phosphoprotein encoded by the 
I3L gene.  This protein forms octameric complexes on ssDNA and is found in 
punctate cytoplasmic inclusions containing parental VACV DNA.  All five of these 
proteins are expressed early in infection and were identified using complementation 
groups of ts/conditional lethal mutants that were impaired with regard to DNA 
synthesis (40), thus defining them as being essential for DNA replication (72, 75).   
VACV encodes its own functional ATP-dependent DNA ligase (A50).  It was 
initially found to be non-essential for replication in cell culture.  It was then 





ligase deletion mutants.  This means that some ligase activity is required for VACV 
replication.  The viral ligase still has a significant role though, as its absence imparts 
sensitivity to DNA damaging agents and is important for virulence.  Furthermore, 
encoding its own ligase allows VACV to enhance its replication in resting cells by 
boosting DNA synthesis.  This is especially evident when ligase-deficient mutants are 
used to infect resting primary cells.  Replication is greatly reduced and delayed, 
which correlates with low initial levels of cellular ligase I and subsequent viral 
induction and localization of the host ligase in viral factories (40, 76).  Photolyases 
also play an important role in DNA replication by protecting DNA from ultraviolet 
(UV) radiation via excision of cyclobutane pyrimidine dimers.  These are found in 
Avipoxviruses, Leporipoxviruses, and Entomopoxviruses and are likely important for 
POXVs which are transmitted through the environment versus from animal-to-animal 
(40).   
2.3.6 Concatemer Resolution 
During replication, POXV genomes form multimeric structures called 
concatemers, which must be resolved to generate unit-length genome molecules to be 
successfully packaged.  The concatemer junctions consist of a precise duplex copy of 
the hairpin loop present at the ends of the mature DNA genome.  The minimum 
sequence requirement needed for resolution to occur is two copies of T6-N7-9T/C-
A3-T/A.  This must be present in an inverted repeat orientation on either side of an 
extended double stranded copy of the hairpin loop (7).  As mentioned above, this 
sequence also contains what is believed to be the main start site of VACV DNA 





as a bidirectional origin.  Intriguingly, the minimum resolution sequence contains a 
functional late promoter, suggesting a link between concatemer resolution and 
transcription (40).  Not surprisingly, the 35-nt start site located within this sequence is 
situated close to this well-characterized, strong late promoter.  The transcript made by 
this promoter does not contain an extended ORF and its role, if any, in VACV 
replication is unclear.  One theory is that the interaction of the vRNAP with this 
promoter helps to unwind the DNA duplex during initiation of replication (74).  The 
sequence of the intervening region that is destined to form the hairpin loop, while not 
highly conserved, must be palindromic (59-61) and no more than 200 bp long (40, 
62).   
Concatemer resolution occurs quickly and independently of virion assembly, 
as junctions only accumulate if post-replicative gene expression is inhibited (40), 
specifically late gene expression (80).  Junctions contain an inverted repetition, 
which, in supercoiled plasmids, makes a cruciform structure resembling a four-way 
Holliday junction (HJ).  This led to the conclusion that the putative concatemer 
resolving enzyme would be an HJ resolvase.  This was confirmed when the motifs 
and structural elements critical for the activity of the E. coli RuvC HJ resolvase were 
discovered in ORFs conserved in all POXV genomes.  When this homolog, A22R in 
VACV, was expressed as a recombinant protein in E. coli, it was found to specifically 
resolve HJs, experimentally confirming what the bioinformatic analysis revealed.  
Similar to RuvC, A22 exists as a dimer in solution and when bound to HJ structures, 
but it possesses a lower degree of sequence specificity with regard to cleavage (81).  





genomes with hairpin ends under non-permissive conditions, leading to the 
conclusion that the enzyme is required for resolution, though additional proteins may 
assist in determining site specificity (40, 82).  This mutant displayed reduced late-
stage DNA replication and inhibited concatemer junction cleavage.  As such, most of 
the newly-replicated DNA remained in a branched or concatemeric form.  It also had 
a block in virion morphogenesis at an early step in the process, yet protein synthesis 
was not affected (82).  The requirement for late gene expression to occur in order for 
concatemer resolution to happen (80, 81) made sense when it was determined that the 
HJ resolvase is expressed late in infection.  This enzyme also happens to be packaged 
into virus particles (82).  A similar phenotype was observed in a paper published by 
Katsafanas et al. (77).  What this paper found was that by depleting the pyrimidine 
nucleotide pool, they could reduce VACV replication by 3 logs.  Specifically, even 
though viral DNA accumulation was only reduced by 60%, very little of it ended up 
being converted into genome-length molecules.  They also noticed a drastic decrease 
in post-replicative gene expression (77), which would explain the DNA processing 
phenotype since the HJ resolvase is expressed after DNA replication takes place (82).   
Type I DNA topoisomerases are another class of enzymes capable of 
resolving certain DNA structures.  They form covalent links with DNA and relieve 
supercoils during replication, transcription, and recombination.  POXVs encode their 
own topoisomerase.  The POXV version of this enzyme has an unusual trait, 
however, in that it exhibits some sequence specificity.  While its roles in vivo still 
need to be fully illuminated, it has been characterized in vitro to carry out a multitude 





and ligation of a variety of DNA structures, one of which is a HJ.  Mutants in which 
this gene is knocked out are still able to undergo DNA synthesis and concatemer 
resolution.  There is evidence, however, that this enzyme plays an important role in 
transcription.  This makes sense upon realizing that the gene is regulated by a late 
promoter, which is more in line with the enzyme having a role in transcription or 
DNA processing rather than replication (40, 83).   
2.3.7 Homologous Recombination 
Recombination occurs quite often within POXV-infected cells.  Such frequent 
occurrence, specifically between the terminal sequences of POXV DNA, may explain 
the variation in the number of tandem repeats found in addition to translocations and 
mirror image deletions.  Recombination can have much more significant impacts on 
POXVs though.  For instance, it has apparently taken place naturally between 
individual Capripoxviruses and between SFV, which produces benign fibromas in 
rabbits, and MYXV, the agent of Myxomatosis, to form malignant rabbit fibroma 
virus.  Perhaps even more extraordinary is the fact that both field and vaccine strains 
of FWPV carry a near full-length and seemingly infectious integrated avian retrovirus 
genome.  Even though the precise mechanism of recombination is not fully 
understood, what is known is that the process does not require post-replicative gene 
products and there seems to be a strong connection between recombination and 
replication.  Evidence suggests that the DNA polymerase is directly involved in 
recombination and that the 3` exonuclease and DNA joining activities are both 





G5, an early protein conserved in all POXVs, belongs to the FEN1 family of 
exo/endonucleases.  G5 deletion mutants are severely impaired and there is a 100-fold 
reduction in infectious virus yield.  The virions produced seemingly contain the 
normal complement of proteins but have a spherical shape, instead of the 
characteristic brick shape, and contain little to no DNA (40, 84).  Similarly-shaped 
virions have been observed with A32, an ATPase (85), and I6, a telomere-binding 
protein, mutants, both of which are required for DNA packaging.  G5 itself may also 
be required, as it is normally present in viral cores (84).  Additionally, even though 
the amount of viral DNA produced by these mutants is similar to that made by the 
wild-type virus, the mean size is about one-fourth the full-length genome (40, 84), 
suggesting a role in full-size genome formation (72).  Most of the DNA made in G5 
deletion-infected cells is not packaged, even though HJs were resolved, forming 
mature termini.  Senkevich et al.  postulated that there may be a length requirement 
for packaging DNA into virions or that mature termini are required on both ends of 
the genome (84).  Experiments using transfected plasmids have shown that G5 is 
required for double-strand break repair via homologous recombination, which led to 
the assumption that it played a similar role in VACV genome replication (40, 84).  
This kind of DNA damage commonly occurs at replication forks, which further 
supports the semi-discontinuous model of POXV DNA replication (40).   
Recombination can also occur between viral genomic DNA and transfected 
subgenomic DNA fragments, a fact which has been exploited to map and construct 
mutations as well as insert genes for expression.  The viral genomes rapidly eliminate 





Both single- and double-crossover products resulting from recombination between 
transfected plasmids and viral genomes, as well as both intra- and intermolecular 
plasmid or bacteriophage DNA recombinants have been detected in POXV-infected 
cells.  All ChPVs except Avipoxviruses encode homologs of serine recombinases.  
Only the Crocodilepox virus (CRV) homolog, however, contains all the amino acids 
which make up the active site, and deletion of the VACV homolog, F16 (79), has no 
effect on replication in cell culture (40).  In fact, the role of F16 in virus reproduction 
is unclear, although it was found to unexpectedly localize to the nucleoli of infected 
cells (79).   
2.3.8 Viral DNA-Associated Proteins 
In total, there are currently 10 viral proteins known to be involved in DNA 
replication, with another 4 involved in precursor metabolism, and 2 more involved in 
packaging DNA into newly formed viral particles.  The viral proteins required for 
DNA replication, as mentioned above, are the DNAP (E9), a processivity factor 
(A20), a UDG (D4), a multifunctional scaffold protein (H5), and an NTPase 
(primase/helicase) (D5).  The additional viral proteins involved in this process are the 
ssDNA binding protein (I3), the DNA ligase (A50), the serine-threonine protein 
kinase (B1), a FEN-1 homologous nuclease (G5), and an HJ resolvase (A22).  These 
are all early proteins, made before DNA synthesis occurs, with the lone exception 
being the resolvase.  It is not required for DNA synthesis, as it is needed to process 
concatemeric replicative intermediates into unit-length genomes with hairpin ends.  
While this list would lead one to believe that VACV does not require additional 





be involved somehow, perhaps by enhancing replication or providing some missing 
functions.  Studies have found evidence for roles of the cellular topoisomerases IIA 
and IIB (TOP2A and TOP2B), DNA ligase I (76) and DNA damage response 
proteins, the ssDNA binding protein RPA, and the DNA clamp protein proliferating 
cell nuclear antigen (PCNA).  Additionally, there are host defense molecules which 
act in opposition to VACV infection, particularly DNA replication.  These are BAF1, 
which acts as a negative regulator of VACV genome replication, and DNA-PK, 
which is a sensor of cytoplasmic DNA.  While some of these host proteins have been 
demonstrated to localize in viral factories, direct association with the VACV genome 
in vivo has yet to be observed (72).   
To this end, Senkevich et al. (72) undertook a study to address these gaps in 
knowledge regarding the VACV DNA replication machinery.  What they found was 
the complete set of viral replication proteins associated with the nascent DNA.  This 
included the seven proteins necessary for DNA synthesis (E9, A20, D4, H5, D5, I3 
and A50), plus G5, I1, and B1.  Some of these interactions may have been direct, 
while others may have been mediated by another protein.  For instance, D4 can bind 
DNA and forms a holoenzyme complex with A20, which has not demonstrated DNA-
binding activity, and E9.  H5 is also able to bind DNA and interacts with A20 as well, 
and B1.  The three most abundant viral proteins detected were H5, the I1 telomere-
binding protein, which is required for morphogenesis instead of DNA replication, and 
I3, which is consistent with their abilities to directly bind DNA, as well as their 





Host proteins found associated with the nascent DNA include TOP2A and 
TOP2B, PCNA, several additional host DNA replication/repair proteins like 
HMGA1, TOP1, PARP1, and RUVBL2, and DDX3X.  The topoisomerases were 
only recovered from cells infected with wild-type virus, and not from cells infected 
with the ligase-deficient virus, supporting the findings of another group.  Despite this 
though, the VACV DNA ligase mutant was still capable of replicating, calling into 
question what role(s) the type II topoisomerases play in VACV DNA replication.  
PCNA increases the processivity of the DNA polymerase in eukaryotic DNA 
replication.  VACV, however, already encodes two proteins which serve a similar 
function, D4 and A20.  Other studies have provided evidence for a role of PCNA, 
though.  One report found that two human PCNA-associated proteins were inhibitors 
of a host range mutant (86) while another reported that T2AA, a PCNA-specific 
inhibitor, and siRNAs specific for PCNA both inhibited VACV DNA synthesis (72).  
In light of these reports, Senkevich et al. (72) found that T2AA did indeed inhibit 
VACV DNA replication in a concentration-dependent manner.   Such results will 
likely lead to more studies regarding the role of PCNA in VACV DNA replication.  
DDX3X is a DEAD box helicase, which has been reported to be a target of the 
VACV K7 protein and an activator of IRF3.  The specificity of its association with 
the nascent DNA is questionable though. There is no evidence yet to support the 
remaining host proteins detected having essential roles in VACV DNA replication.   
Surprisingly, the cellular DNA ligase I was not detected in this study with the 
viral ligase-deficient mutant.  This host protein in essential for VACV DNA 





viral factories.  Studies that have implicated DNA damage response proteins (ATR, 
CHK1, Rhino, INTS7, and TOPBP1) and the DNA replication protein RPA were not 
supported by this study, as none of these proteins were detected.  It had been 
proposed by another group that RPA served as the replicative ssDNA binding protein, 
not I3 (72).  This proposal was not supported by the findings of Senkevich et al. (72), 
as I3 was one of the most abundant proteins detected and none of the RPA subunits 
were detected (72). 
2.4 Virion Morphogenesis, Maturation, and Egress 
Virion assembly begins in structures known as the viral factories, which are 
circumscribed, granular, electron-dense areas of the cytoplasm.  The first distinct 
morphological structures that can be visualized are crescents and immature virions 
(IVs).  The latter structures contain a membrane with spicules on the convex surface 
and granular material in the concavity.  Deep-etch EM revealed the spicule layer to be 
a honeycomb lattice viewed on edge.  The mechanism of IV formation and the source 
of its membranes remained a conundrum for many years, with many hypotheses 
being put forth.  Some evidence suggested that the viral membrane formed de novo, 
while another proposed that it was derived from a cellular organelle.  There was 
evidence suggesting that the intermediate compartment between endoplasmic 
reticulum and Golgi apparatus (ERGIC) was not the source of the IV membrane.  
Additionally, no ER or ERGIC protein had been found to co-localize with the IV 
membrane and no viral proteins identified as being incorporated into purified MVs 
possessed any signature of ER translocation, such as signal peptide cleavage or 





being consistent with the MV membrane originating from the intermediate 
compartment or cis-Golgi network (47).  It had been found that a heterologous signal 
peptide fused to the N-terminal region of a VACV membrane protein was cleaved.  
The truncated protein then localized in IVs and MVs, providing evidence for at least a 
functional pathway between the ER and viral membranes (40).  In the intervening 
years, however, it has since been determined that the ER is indeed the source of the 
viral membranes, through the use of deletion viruses missing proteins critical for viral 
membrane assembly (6, 53-55, 87, 88).     
2.4.1 Crescent and IV Formation 
Viral proteins required for IV formation, F10 kinase, H5, G5, A11 (7), H7, L2 
(40), and I2 (66) have been identified through the use of conditional lethal VACV 
mutants (7) and deletion mutants in conjunction with a complementing cell line (53, 
66).  Interestingly enough, none of these proteins make up the IV membrane (7).  
Both H5 and G5 have other roles in viral replication, so they may have indirect roles 
in crescent formation (40).  In addition to being required for IV formation, F10, A11, 
H7, and L2, along with A17, A14, and A6, are all essential for crescent formation.  
Without even one of these proteins, dense masses of viroplasm along with vesicles 
and tubules often accumulate in the cytoplasm instead of the characteristic crescents 
and IVs  (6, 54, 87, 88).   
A6 is a 43-kDa protein that is conserved in all ChPVs.  It has no predicted TM 
domain, is expressed post-replicatively, is packaged to a minor extent in MV cores, 
and has been shown to associate with the A11 protein.  H7 also has no predicted TM 





highly-purified MVs, and is not strongly retained in viral factories following 
synthesis (87).   
L2, unlike the other proteins needed for IV formation, is made during the 
early phase of infection, contains a TM domain, associates predominantly with the 
ER throughout the cytoplasm (54), and can be found near the growing edge of 
crescents (40, 52).  All these characteristics set it apart from other proteins involved 
in this process (54).  Regarding its topology, the N-terminal end faces the cytoplasmic 
side of the ER while the C-terminal end faces the luminal side (89).  L2 is conserved 
across all ChPVs (90), hinting at how essential it is for VACV and consistent with its 
important role in virion morphogenesis.  This made characterizing the protein 
difficult, requiring either the construction of an inducible mutant (90) or a deletion 
mutant, which could only be isolated with the help of a complementing cell line (53).  
When L2 expression is blocked, proteolytic cleavage of the major core proteins and 
A17, an essential component of the IV membrane, fails to occur.  Such a phenotype 
suggests that the block in virion morphogenesis happens early in the process.  
Repression of both A11 and A17 yield similar phenotypes (52).  Additionally, 
repression of any of these three proteins drastically decreases the stability, and thus 
the amount, of a certain subset of viral proteins (52), 25 to be exact (53), including 
members of the EFC complex (52, 53).  As such, it appears the role of L2 is two-fold.  
It is required for the formation or elongation of crescent membranes (90), which it 
does by recruiting ER and modulating its transformation into viral membranes in the 





subset of viral proteins which are entirely dependent on viral membranes for stability 
(52, 53, 87).   
A11 is made during the post-replicative phase of viral gene expression, like 
other virion morphogenesis proteins, localizes in cytoplasmic viral factories, self-
associates to form dimers or higher-order structures, is phosphorylated independent of 
the F10 kinase, and is absent or not found in significant amounts with purified MVs.  
This last trait it shares with both H7 and L2.  In fact, A11 shares many features with 
L2.  Both are present at the edges of crescent viral membranes, over the course of a 
normal infection, and are found on or near aberrant membranes in mutant virus-
infected cells.  Both proteins are tail-anchored and associate, post-translationally, 
with microsomal membranes, which was demonstrated by in vitro transcription and 
translation experiments.  Despite these similarities, A11 possesses some features 
which distinguish it from L2.  For instance, A11 co-localizes with the ER, but only in 
viral factories.  This contrasts with L2, which also co-localizes with the ER, but 
throughout the cytoplasm.  In uninfected cells, L2 still co-localizes with the ER and 
was found to associate with membranes.  On the other hand, A11 does not, even when 
L2, A6, or H7 are co-expressed.  When A11 expression is knocked down, large, 
dense bodies formed, like what is seen when working with H7 and A6 mutants.  IV-
like (IV-L) structures are also observed trapped in the ER when A11 expression is 
blocked.  This phenotype had only been previously seen with an L2-deletion mutant, 
highlighting yet another common feature shared by these two proteins (54, 87).   
A previously uncharacterized protein was also found to be vital for virion 





the genome sequences of many POXVs, even though ORFs corresponding to the 
same location have been found in representatives of all ChPVs.  The lack of 
annotation may be due to its small size, at just 42 aa in length (55).  Its well-
conserved nature, however, would imply that it is important in the virus lifecycle.  
A30.5 was found to interact with L2, associate with the ER, participate in biogenesis 
of the ER, and be required for replication (55, 87).  Despite its association with L2, its 
topology differs from that of its interaction partner.  It was discovered that both the 
N- and C- termini face the cytoplasm (89).  The study, by Maruri-Avidal et al. (55), 
characterizing this protein also found evidence of direct formation of the crescent 
membranes from the ER, in addition to finding that D13 localized to the luminal side 
of the ER membrane.  This led to the conclusion that the outer surface of the MV is in 
fact derived from the luminal side of the ER.  The report that crescent membranes 
were directly connected had been confirmed by transmission electron microscopy 
(TEM), but not by electron tomography (ET), until recently, when the continuity 
between these two structures was unambiguously demonstrated (6).   
2.4.2 VMAPs 
Using null mutants, multiple proteins were found to be involved in a similar or 
the same step of virion morphogenesis as L2.  This group of proteins has been dubbed 
VMAPs, or viral membrane assembly proteins.  The proteins designated as such are 
L2, A30.5, A11, H7, and A6 (6, 55, 66, 87, 88).  These five proteins are scarcely 
found or completely absent from MVs, despite their importance for IV formation.  If 
expression of any of the VMAPs is blocked or drastically inhibited, electron-dense 





in the phenotypes of VMAP-knockout mutants.  The structures seen with L2 and 
A30.5 deletion viruses are virtually identical, which was not surprising given that the 
two proteins form a heterodimer.  Surprisingly, the A6 deletion mutant also formed 
identical structures, perhaps hinting at functional and physical associations with L2 
and A30.5.  While indistinguishable structures were also seen with the H7 deletion 
virus, there were differences present.  In these infected cells, there was more 
extensive ER wrapping plus additional particles which looked like hooks and double-
wrapped IVs.  Such structures were also observed in cells infected with an A11 
deletion virus.  ET revealed, however, that these also represented incomplete 
spherical or crescent structures which had connections to the ER.  As such, all five 
VMAPs share a common feature:  deletion of any results in continuity between the 
viral and ER membranes.  It is currently unknown, though, whether higher-order 
structures with all five VMAPs exist.  This study, by Weisberg et al. (6), also 
demonstrated that A17 and D13, which are known interaction partners, both have 
membrane-remodeling properties.  Taken together, these data were used to propose a 






























 Figure 2.2.  Model of viral membrane formation from ER. The first step (I) 
consists of modification of the ER by insertion of the A17 transmembrane 
protein, represented by green spheres. In the presence of all five VMAPs, 
represented by red rectangles, membrane scission occurs, and the edges of 
the sheets are stabilized, as shown on the Left (II). D13, represented by blue 
shapes, associates with the N terminus of A17 to increase curvature-forming 
crescent structures (III), which extend around core proteins (purple) to form 
the spherical IVs (IV). VMAPs missing one component (ΔVMAP), 
represented by red triangles, are unable to induce membrane scissions, the 
crescents remain attached to the ER, and empty IV-L particles bud into the 
lumen, as shown on the Right. The core proteins form dense inclusion 
aggregates (purple) outside of the ER.  Figure 6 from Weisberg, A.S., et al. 
Enigmatic origin of the poxvirus membrane from the endoplasmic reticulum 
shown by 3D imaging of vaccinia virus assembly mutants. Proc Natl Acad 
Sci USA, 2017. 114(51): p E11001-E11009. (6).  Reprinted with 





In this model, the ER is first modified via insertion of A17.  The ER 
membrane is then broken up and its loose ends stabilized by the VMAPs in 
conjunction with other viral proteins or perhaps even cellular proteins.  D13 then 
binds to A17, providing additional curvature of the viral structures.  These crescents 
then extend around core proteins to form spherical IVs.  In the absence of even one 
VMAP, ER membrane scission does not take place.  This results in the crescents 
remaining attached to the ER and the budding of empty IV-L particles into the lumen.  
The core proteins then form dense inclusion aggregates outside of the ER (6, 87, 88).   
As stated earlier, I2 is a small protein, at only 72 aa long and with a mass of 
8.4 kDa.  It possesses a C-terminal TM domain, is made after VACV DNA 
replication, is associated with purified MVs, and is conserved in all ChPVs. It was 
found that virions lacking I2 are unable to enter cells, thus greatly reducing infectivity 
(66).  The Hyun et al. (66) study set out to investigate the initial report from another 
group regarding this defect in viral entry by determining which step of replication or 
entry was affected by the absence of I2.  What they found was that, while an I2 
deletion mutant was unable to enter cells, the primary block was, unexpectedly, in 
virion morphogenesis, specifically after the formation of IVs.  This resulted in an 
accumulation of dense, spherical particles with poorly formed cores instead of the 
characteristic brick-shaped MVs with well-defined core structures.  The IVs that 
formed appeared normal and contained normal amounts of most core and membrane 
proteins.  However, during maturation, the incomplete MVs that formed had a drastic 
reduction in the amounts of the EFC proteins, had more D13 remaining, and greater 





scaffold was a phenotype that had previously been observed when I7 expression was 
inhibited.  I7 is the protease responsible for cleaving A17, in addition to several core 
proteins.  Another intriguing find was that there were reduced amounts of I7 found in 
cytoplasmic extracts of non-complementing cells infected with the I2 deletion virus, 
perhaps hinting at a relationship between I2 and I7.  The failure to remove the D13 
scaffold prevents the insertion of the EFC proteins into viral membranes and their 
hydrophobicity causes them to be unstable without the membranes, thus leading to 
their enhanced degradation.  They concluded that I2 was required for virion 
morphogenesis, release of the D13 scaffold, and the association the EFC proteins with 
viral membranes.  This overall phenotype, involving a block in morphogenesis, 
inability to form and accumulation of membranes free of D13, and a drastic reduction 
of EFC proteins, is also seen in VMAP mutants as it turns out.  The difference 
though, is that the VMAP mutants encounter their blocks earlier in morphogenesis, 
prior to the formation of IVs, whereas I2 mutants actually progress to the IV stage of 
virion maturation (66).   
2.4.3 Core Protein Association with IVs 
Work with conditional lethal VACV mutants also revealed that seven core 
proteins are each required for the association of crescent membranes with the granular 
viroplasm.  These core proteins are:  A15, A30, D2, D3, G7, J1, and the F10 kinase.  
These seven proteins form a complex, presumably linked to one or more membrane 
proteins which have not yet been identified (7).  Similar phenotypes are observed 
when expression of the core proteins A10 (7), E6, and F17 (also called F18) are 





because it phosphorylates A14 and A17, which are IV membrane proteins, and its 
kinase activity is critical for its function in morphogenesis (40).  A14 and A17, the 
latter of which is a cellular reticulon-like protein (91), are vital for morphogenesis 
because when the synthesis of either protein is repressed, crescent membrane 
formation is reduced or abrogated and small vesicles accumulate.  The fact that 
similar phenotypes are obtained with either one or the other supports evidence of 
interactions between these two proteins (40, 87), an interaction which has since been 
confirmed, although it is still not known whether it is a direct interaction (87).   
2.4.4 D13 Scaffold and Rifampicin 
The antibiotic rifampicin was discovered to negatively impact assembly, as its 
presence during infection leads to the accumulation of irregular viral membranes 
lacking the honeycomb lattice.  Within minutes of the drug’s removal, the single 
membrane bilayer becomes coated by the protein responsible for forming the 
honeycomb lattice, resulting in crescents being formed.  This process occurs even in 
the presence of RNA or protein synthesis inhibitors, which led to the conclusion that 
rifampicin directly interferes with assembly.  The protein responsible for forming the 
lattice and rifampicin resistance was found to be D13, which, when repressed, 
resulted in a similar morphological phenotype as when assembly is attempted in the 
presence of rifampicin (7).  D13 forms trimers which come together to form the 
honeycomb lattice scaffold, leading to the spherical shape of VACV IVs.  D13 
interacts with the A17 N-terminal region to form the scaffold (7, 87).  Duplication or 
overexpression of A17 confers rifampicin resistance to VACV (87).  The existence of 





containing viruses suggests that the developmental stages of POXVs reflect evolution 
from an ancestor with an icosahedral capsid (7) into what is the present MV form.  
POXV retention of a capsid-like structure around the IV supports this by 
demonstrating that, like embryogenesis, morphogenesis recapitulates evolution.  The 
predicted similarity of D13 with the capsids of other viruses and phage has been 
supported by structural studies (40, 87).   
2.4.5 Genome Packaging 
The next step in morphogenesis involves a dense mass of nucleoprotein 
entering the immature envelope, before being completely sealed.  When assembly is 
interrupted prior to the formation of IVs, viral DNA concatemers are still processed 
normally and mature DNA accumulates in large crystalloid structures.  It was also 
determined that, while concatemer resolution can take place in the absence of viral 
morphogenesis, DNA processing is required for morphogenesis to occur (7, 82).  As 
mentioned earlier, when expression of the viral HJ resolvase is blocked, virion 
morphogenesis is blocked at an immature stage during this process (82).  One protein 
found to play a crucial role in DNA packaging is A32, whose repression leads to a 
block in VACV genome packaging (7, 85).  This activity was predicted based on its 
sequence similarity to the gene I of filamentous single-strand DNA bacteriophages 
and to the Iva2 gene of adenovirus, which are both ATPases involved in DNA 
packaging (7).  A32 mutants do not go on to form mature particles with defined core 
structures, even though normal-looking crescents and IV particles can be seen 
beforehand.  Very few of the particles have nucleoids and the result is an electron-





activity.  Infection with these mutant viruses also led to the formation of large 
cytoplasmic DNA crystalloids, similar to what is seen when VACV infection is 
carried out in the presence of rifampicin (85).   
Two other proteins which play important roles in genome packaging are I6 
and A13, which are telomere-binding and viral membrane proteins, respectively.  
DNA packaging fails to occur under non-permissive conditions in cells infected with 
an I6 mutant, while conditional lethal A13 mutants display a defect in genome 
packaging and lead to the accumulation of DNA crystalloids associated with 
membrane.  Mutation of I1, another telomere-binding protein, unlike results seen with 
I6 mutants, causes a defect at a later step in morphogenesis.  It is not currently known 
how A32, I6, and A13 enable entry (7).   
2.4.6 Packaging of the Transcriptional Complex 
Components needed for early transcription must also be packaged into virions.  
These include RNA-associated protein of 94 kD (RAP94), VACV early transcription 
factor (VETF), the vRNAP, poly(A) polymerase, capping enzyme, topoisomerase, 
nucleoside triphosphate phosphohydrolase (NPH) I, and NPH II (7).  A recent paper 
working with a panel of RAP94 mutants found that progeny virions produced by 
these viruses lacked nucleocapsids and had aberrant morphologies, which could be 
described as empty or collapsed in appearance (92).  The mutant progeny contained 
wild-type levels of DNA but were selectively deficient in several transcriptional 
enzymes and thus had a reduced capacity to catalyze in vitro early transcription and 
reduced infectivity.  These findings support the idea that the nucleocapsid is made up 





proteins.  Going one step further, the authors present the idea that the vRNAP and the 
associated transcriptional enzymes are in fact a structural component of the 
nucleocapsid, meaning that when these proteins fail to be encapsidated, the structural 
integrity of the nucleocapsid becomes compromised (92).  Repressing the synthesis of 
VETF leads to accumulation of IVs (7).  A32 mutants contain representative amounts 
of the vRNAP, VETF and several other enzymes, in addition to membrane proteins 
and cleaved and uncleaved core proteins.  These findings suggested that the 
incorporation of these components is not tightly coupled with DNA packaging (85).   
2.4.7 MV Formation 
Once these previous stages have occurred, the spherical IV loses its lattice 
scaffold, D13, resulting in its conversion to a barrel-shaped particle, the MV.  
Disassembly of D13 is correlated with processing of A17 by the I7 protease.  When 
I7 expression is blocked, D13 is retained on aberrant virus particles (40, 66).  This 
transition process also involves the association of additional membrane proteins, and 
the processing and reorganization of core components.  The transition from IVs to 
MVs is impaired when expression of A9, L1, H3 (7), or A6 (40) are knocked down.  
Defective-looking MVs are produced when some core proteins are mutated or their 
expression is blocked altogether (7).  A recent study by Sivan et al. (93) found that 
knockdown of nuclear pore genes greatly inhibited VACV spread.  There was no 
effect on viral entry, with only modest effects on early and late viral gene expression 
and viral DNA replication.  The screen found that production of infectious virus was 
severely reduced, specifically beyond the IV stage of the virion morphogenesis 





cells.  The likely reason for the defect found in this study is perturbations of nuclear 
transport.  Whether or not disruption of this nuclear transport results in the inability of 
necessary cellular molecules to exit the nucleus or viral defense proteins to enter the 
nucleus is currently unknown, although the latter scenario seems more plausible.   
2.4.8 Intramolecular Disulfide Bonds 
Some of the MV membrane proteins contain intramolecular disulfide bonds in 
their cytoplasmic domains.  Normally, disulfide bonds form in the ER.  This oddity of 
the MV membrane proteins raised the possibility that POXVs encode novel 
oxidoreductases.  This bore out upon confirmation that a unique cytoplasmic disulfide 
bond pathway was formed by three virally-encoded proteins:  E10, A2.5, and G4.  
Repressing any of these three proteins blocks virion maturation (7).  The structure of 
G4 has since been solved.  It crystallized as a dimer, burying the Cys-X-X-Cys active 
site which may protect the reactive disulfides from being reduced in the cytoplasm 
(40).  So far, nine viral membrane proteins have been identified containing 
intramolecular disulfides formed by this cytoplasmic redox system:  L1, F9, and 
seven of the eight entry-fusion proteins.  As of yet, no evidence suggests that this 
system forms the disulfide bonds of other membrane proteins or core proteins (40).  
This redox system is the only virally-encoded one discovered so far, in addition to 
being the only one known to operate on the cytoplasmic side of a membrane in any 
system.  An ortholog of each protein involved in this redox system is found in every 
known POXV, emphasizing its ancient origin and requirement for POXV replication 
(7).  The fact that the entry proteins have also been found in all known POXVs 





2.4.9 Proteolytic Processing 
Several VACV proteins undergo proteolytic processing during 
morphogenesis.  These include A17, a membrane protein, and A3, A10, A12, L4, and 
G7, which are all core proteins.  A17 processing is dependent upon the formation of 
the membrane component of the IV, while core protein processing will fail to occur if 
a later step in morphogenesis is blocked (40).  Cleavage occurs at a consensus 
sequence in each case:  AG_X.  The protease mostly likely responsible for these 
cleavage events is I7, based on the observed phenotypes seen when studying I7 
mutants and mutagenesis of the conserved cysteine protease active site.  Another 
candidate is G1, which contains a motif found in some metalloproteases, HXXEH.  
Indeed, conditional lethal G1 mutants are blocked in morphogenesis, but the 
processing of the known membrane and core proteins is unaffected.  Additionally, 
mutating the putative active site renders G1 incapable of rescuing a null mutant.  
Interestingly, G1 appears to undergo proteolytic processing, leading to the theory that 
it mediates self-cleavage (7).   
2.4.10 MV Occlusion 
The MVs of some ChPVs, such as CPXV, ECTV, Raccoonpox virus, FWPV 
(7), and Volepox virus (94), become occluded in a dense protein matrix within the 
cytoplasm, referred to as A-type cytoplasmic inclusion bodies or ATIs.  They are 
distinct from the sites of viral replication and assembly, which are sometimes referred 
to as B-type inclusions (7).  Some OPXVs such as VARV, VACV, HSPV and MPXV 
do not form ATIs but still retain a disrupted form of the gene, which may have 





environment following degeneration of infected cells (7), which protects the enclosed 
MVs from environmental stresses (40), such as UV radiation, thus prolonging 
infectivity.  For those POXVs that do not form these structures during infection, it 
seems they rely instead on the inherent stability of the MVs in the environment or 
direct animal-to-animal spread (94).  The CPXV ATI protein is 160-kDa and may 
account for up to 4% of the total protein at late points of infection.  Some VACV 
strains do encode a truncated version of a homologous protein, even though VACV 
does not form ATIs.  The inclusion proteins of both CPXV and VACV are 
myristylated.  Some CPXV mutants can form inclusions without virions, indicating a 
role for a protein specific to the MV known as 4C.  The VACV homolog is A26.  
This protein acts as a bridge between the ATI protein and A27, which is tethered to 
MVs via A17.  In the VACV strains that do encode the ATI homolog, it is also 
associated with A26.  EVs do not contain either A26 or A25 (40).  Entomopoxvirus 
virions also undergo occlusion where, following ingestion by a larval host, infectious 
particles may be released in the alkaline pH of the gut.  Several Entomopoxviruses 
have these occlusion proteins, called spheroidin or spherulin.  These homologs are all 
cysteine-rich, about 100 kDa in size, and lack homology to fusolin, the abundant 50-
kDa spindle-body protein of Entomopoxviruses, the ATIs of ChPVs, and the 
polyhedrin protein of baculoviruses (7).  Unlike MVs, neither the crescent nor IV 
membrane has been extensively purified and characterized, so their respective lipid 
compositions are currently unknown but they are assumed to be similar to that of the 





2.4.11 EV Formation 
The other infectious form of the POXV virion, the EV, consists of an MV 
wrapped in an additional membrane.  This extra membrane can be generated in one of 
two ways:  an intracellular MV wrapping process, followed by exocytosis, or direct 
budding of the MV from the plasma membrane.  FPXV on the other hand, exits from 
the cell primarily by budding (40).  The former mechanism has been studied more 
extensively.   
2.4.12 Wrapping of EVs 
Some MVs are wrapped by two additional membranes, forming wrapped 
virions or WVs, which are also referred to as intracellular enveloped virions (IEVs) 
(47, 48), both of which are derived from virus-modified trans-Golgi or endosomal 
cisternae (7).  With one exception, the phospholipid components of the WV are 2-3 
times higher than in the MV (47).  These extra membranes contain at least 8 viral 
proteins, A33, A34, A36, A56 hemagglutinin, B5, F12, F13 (7), and E2 (40), all of 
which contain a TM domain, with the exceptions of F12, F13, and E2.  Of these eight 
proteins, A36 and F12 are exclusive to the outermost membrane, which is lost during 
exocytosis, and thus are not retained on the EV.  The palmitoylation of cysteines 185 
and 186 are essential for F13’s association with the wrapping membrane (7), while 
F12 reportedly associates with E2 and A36 (40, 79).  Deletion of any of the above 
genes results in a small plaque phenotype.  The only exception is an A56 deletion 
mutant, which yields a syncytial phenotype (7) that may be due to its inability to bind 
to the EFC (40).  The composition of the EV membrane is determined by complex 





that could be responsible for interactions with other viral or cellular proteins (40).  
Studies done with VACV mutants have shown that several proteins are required for 
efficient wrapping.  The most severe effects are seen when the A27 MV protein, the 
F13 protein, and the B5 glycoprotein are either repressed or deleted.  F13 is needed 
for the Golgi membrane localization of B5, in addition to having a putative 
phospholipase motif that is required for its role in wrapping and induction of post-
Golgi vesicles (7).  Another recent study by Sivan et al. (95) provided more insight 
into the wrapping process and viral egress, determining that F13 was transported to 
the sites of wrapping via retrograde transport.  This is in contrast with B5, which is 
transported via the secretory, or anterograde, pathway.  This novel use of retrograde 
transport, and the use of two different pathways, while seemingly inefficient, ensures 
that virions are not wrapped prematurely.   
2.4.13 Intracellular Movement and Exocytosis 
Within cells, WVs rely on microtubules for long-range movement, and not on 
actin polymerization as had been originally thought.  The process of moving MVs 
from the sites of virion assembly to the sites of wrapping is dependent on 
microtubules, but the viral attachment protein is not currently known.  There is 
thought that A27 is required for movement and wrapping, but this debate has not been 
conclusively settled.  It has been demonstrated that the A36 protein interacts with the 
cargo-binding domain of the light chain of kinesin, a microtubule motor protein (7), 
which F12 reportedly had structural similarity to (40).  This shared, functionally-
relevant similarity between F12 and the tetratricropeptide repeats (TPR) of kinesin 





revealed that the ChPV F12 protein is a derived family B DNAP in which the 
activities of both the polymerase and exonuclease domains have been abrogated due 
to mutational replacement of catalytic amino acid residues.  Their analysis found no 
similarity to TPRs.  Additionally, the presence of all-alpha TPRs is inconsistent with 
both the predicted structure of F12 and the alpha-beta nature of the DNAP domains.  
This paper also states that no quantitative evidence has been presented in support of 
this TPR similarity.  Furthermore, TPRs have also been reported in both E2 and A36, 
both of which reportedly interact with F12.  Yutin et al. (79) found no presence of this 
region in either ChPV protein.  All three reportedly contribute to IEV maturation and 
intracellular motility (79).  F12 also has a motor-binding motif vital for virion export 
(40, 79), via the recruitment of kinesin-1, which allows for movement of the IEVs 
along microtubules and that deletion of the purported TPRs in F12 abrogated kinesin 
binding (79).  Yutin et al. (79) found that while their results do not necessarily 
conflict with those experimental observations, they do suggest that the interaction 
between kinesin and F12 is mediated by the derived DNAP domains.   
When WVs reach the periphery of the cell, the outermost membrane fuses 
with the plasma membrane, liberating the EV, which now only has one more 
membrane than an MV (7).  The migration of WVs through the dense cortical actin is 
mediated via the F11 protein prevention of RhoA signaling (40).  The majority of 
EVs adhere to the cell’s surface, while only a fraction of virions is found in the 
medium.  The ratio of cell-associated to free virions is dependent on which VACV 
strain is being used (7, 48).  This difference, at least in one case, appears to largely be 





the A34 membrane protein (7, 48).  Mutations in A33R and B5R have also been 
found to enhance release.  The host Abl-family tyrosine kinases and phosphoinositide 
5-phosphatase SHIP2 have also been implicated (40).  EVs are important for virus 
dissemination, with cell-associated EVs being responsible for efficient cell-to-cell 
spread and plaque formation, in the context of a cell monolayer, and EVs in the 
medium providing long-range dissemination (7).  While MVs are quite stable and are 
believed to be responsible for transmission between hosts, EVs, with their fragile 
outer membrane, are well-adapted to exiting an intact cell and spreading within a host 
(48).   
2.4.14 Actin Tail Formation 
Adherent EVs rely on their location at the tip of motile, actin-containing 
microvilli in order to efficiently spread from cell to cell (7, 48).  When A33, A34, or 
A36 are not expressed, these actin-containing microvilli are not formed, yielding 
viruses that form small plaques.  The nucleation of the actin tails is dependent on 
tyrosine phosphorylation of the A36 protein of OPXVs and the functional homologs 
found in other POXVs by Src- or Abl-family kinases (40).  The phosphorylated form 
of A36 then interacts with the adaptor protein Nck, which leads to the recruitment of 
the Ena/VASP family member N-WASP to the site of actin assembly (7).  This 
process of viral egress is one potential target for antiviral development, with one 
compound, ST-246, making it to clinical testing (40).  This novel small molecule is 
an OPXV egress inhibitor, developed by SIGA Technologies (96), and blocks the 





2.5 Poxvirus Gene Expression and Transcriptional Regulation 
POXV genes are expressed in a manner known as a cascade mechanism, i.e., 
the products of the preceding stage regulate the next stage.  Specifically, POXVs have 
three stages of gene expression:  early, intermediate, and late.  Nearly all the enzymes 
needed for carrying out this cascade are encoded by the virus, including a vRNAP 
and stage-specific TFs.  The core of the virion contains a complete early transcription 
system which allows for synthesis of early mRNA shortly after infection.  This also 
provides an explanation for why purified POXV DNA is not infectious.  Early mRNA 
encodes for enzymes and factors needed for synthesizing viral DNA and transcribing 
intermediate genes.  These intermediate transcripts are translated into enzymes and 
factors needed for late gene expression.  Late genes include structural proteins, used 
for making progeny virions, and the early transcription factors, which are packaged 
into these progeny virions along with the vRNAP.  Thus far, all POXV genes consist 
of a continuous ORF and there has been no evidence to suggest that RNA splicing 
occurs (7).   
VACV has 118 early genes (3, 97, 98) (Fig. 2.3), although some included in 
this number have both early and intermediate or early and late promoters, and so may 
be classified as early genes for the sake of simplicity (97, 98).  A study also found 
that, at 4h in VACV-infected HeLa cells, 25-55% of the mRNAs were viral and by 7h 
80-90% of the RNA hybridized to VACV DNA.  The overall amount of 
polyadenylated RNA stays fairly constant, meaning that the change in proportion is 
due to the simultaneous degradation of host RNA and robust synthesis of viral RNA.  





effect.  There is a total of 93 post-replicative genes (3, 97, 98).  Similar to the early 
genes, some post-replicative genes have been categorized as intermediate even 





















































Figure 2.3.  VACV transcriptome map. VACV WR ORFs are shown as 
colored arrows indicating the direction of transcription. When applicable, 
the common (Copenhagen) HindIII fragment letter/number name was used 
to identify ORFs; otherwise the VACV WR name was provided. The 
numbers from 1 to 194711 indicate the nucleotide positions on the VACV 
genome. Note that each ORF has been assigned the stage at which its 
earliest expression can be detected and that the presence of additional 
promoter elements that potentially contribute to later stages of gene 
expression are not indicated.  Figure 8 from Yang, Z., et al. Expression 
Profiling of the Intermediate and Late Stages of Poxvirus Replication. J 





2.5.1 Regulation of Early Transcription 
As mentioned above, a complete early transcription system is contained 
within the core of an infectious viral particle.  This system produces mRNA that is 
capped, methylated, and polyadenylated, even in vitro.  Shortly after entering a cell, 
the virus core is transported on microtubules to the site of transcription, where mRNA 
synthesis is detectable within 20 mins.  RNA/DNA hybridization studies done with 
VACV have shown that about half of the genome is transcribed prior to DNA 
replication, meaning that about half of the genes are early genes (7).  These findings 
have been supported by genome tiling and deep RNA sequencing experiments (40, 
97).  As mentioned above, these genes are involved in DNA replication and 
intermediate gene expression, but also include genes that encode for growth factors 
and immune defense molecules (7).  Early transcripts can actually be divided into two 
groups, based on their kinetic cluster analysis.  Both groups are expressed in the 
presence of protein synthesis inhibitors and are thus classified as immediate early 
genes (40, 97).  The paper, by Yang et al. (97), named the two groups E1.1 and E1.2.  
There was no distinction between the two regarding their functional class.  Both are 
involved in transcription, DNA replication, and host interactions, and are distributed 
throughout the genome.  One observed difference, however, was in the promoter 
sequences, as the E1.1 promoter more closely resembled the consensus sequence than 
E1.2.  The authors postulated that the different kinetics may be due to higher-affinity 
TF binding sites for the E1.1 promoters, other DNA-protein interactions, and DNA 





Early gene expression terminates upon uncoating, the disruption of the virus 
core.  This latter process is dependent upon RNA and protein synthesis occurring.  If 
protein synthesis inhibitors are used to block uncoating, early mRNA synthesis is 
both increased and prolonged.  In contrast, the use of DNA replication inhibitors does 
not block uncoating and only prolongs early transcription to a limited extent.  These 
findings suggest that, under normal conditions, disassembly of the core results in the 
disruption of the early transcription complex, which EM images suggest occurs via 
the nucleoprotein complex passing through breaches in the core wall (7).  As 
mentioned earlier, the viral type I DNA topoisomerase plays a role in transcription, 
specifically early transcription.  While it is not essential for replication in cell culture, 
a deletion mutant was found to have a reduction in infectivity of about a log.  These 
mutant particles were able to able to go through all the initial steps of infection but 
had a severe defect in early gene transcription and a delay in DNA replication.  This 
defect, however, could be overcome by increasing the amount of virus used by 10-
fold.  These findings were quite surprising, especially given the usual and expected 
functions of a topoisomerase, i.e., in DNA replication.  It seems that the primary and 
possibly the only role for the viral topoisomerase is to aid in early gene expression 
(83).   
The first step in uncoating begins almost immediately after infection, 
consisting of the removal of the lipoprotein envelope and liberation of the cores into 
the cytoplasm.  This step obviously requires fusion of the viral envelope or membrane 
with that of the host plasma or endosomal membrane.  The second step of uncoating, 





and liberation of the genome, which allows for the subsequent process of DNA 
replication (73) and signals the end of early transcription.  It is this second step which 
requires RNA and protein synthesis (7, 73).  One uncoating protein has been 
identified, D5, which is also the viral primase/helicase, meaning it is also involved in 
viral DNA synthesis (73).   
Early transcription peaks around 1-1.5 hpi but declines rapidly after that.  The 
decline is so rapid that it cannot solely be explained simply by the cessation of 
transcription and is consistent with an increase in mRNA degradation after virus 
infection (7).  This enhanced mRNA degradation was at first only speculative (97) but 
has since been confirmed.  It is carried out by the D9 and D10 viral decapping 
enzymes, leading to the generation of uncapped mRNAs (99, 100), which are 
presumably rapidly destroyed by host 5` exonuclease activity (40), in the form of 
Xrn1 (93, 101, 102).  This increased rate of mRNA degradation applies to all classes 
of mRNA (7, 99-102) and it is thought that this rapid turnover serves as a mechanism 
for eliminating both host and viral mRNA at the end of early and intermediate stages 
(40, 99, 101).  These enzymes would also seem to help emphasize the cutoffs 
between the early, intermediate, and late phases of gene expression (101).  
Degradation of host mRNAs would contribute to the observed global host protein 
shutoff seen in VACV-infected cells, allowing the virus to first have preferential and 
then exclusive access to translational machinery and macromolecular building blocks 
(99, 100, 103-105).  A paper by Katsafanas and Moss (105) put forth an additional 





the translation initiation factors within the viral factories, where viral transcription 
and translation take place.   
Despite the global host shutoff, a subset of host mRNAs was actually found to 
be increased at 2 hpi (97).  These mRNAs were found to be involved in apoptosis, 
ligand-mediated signaling, the NF-kB cascade, and signal transduction, likely 
representing the host response to infection.  At 4 hpi, the only increase in cellular 
mRNAs was seen for those involved in chromatin packaging and assembly (97).  Two 
recent papers explored this topic in more depth (103, 104).  The first, by Dai et al. 
(103), found that host mRNA depletion was predominantly responsible for host 
protein synthesis shutdown but that despite this, a subset of host mRNAs experienced 
a significant increase in their translation efficiency.  These mRNAs were transcribed 
from genes involved in oxidative phosphorylation, which generates energy for the 
cell.  This is important because viruses are unable to produce energy on their own and 
require the cell to survive long enough for them to complete their lifecycle.  Their 
results showed that the short 5` untranslated region (UTR) of the oxidative 
phosphorylation mRNAs contributed to this observed translational upregulation.  
Even more telling was that the protein levels and activities of these gene products 
increased due to VACV infection, in addition to oxygen consumption.  Not 
surprisingly, inhibition of this process greatly reduced viral replication (103).  This 
mechanism contrasts with that of Influenza A Virus (IAV), which protects oxidative 
phosphorylation simply by maintaining the levels of the appropriate mRNAs and 





The viral decapping enzymes also contribute to virulence (100, 101) directly, 
by reducing synthesis of immunomodulatory proteins (99) and accelerating host 
mRNA decay, especially of innate (97, 101) and adaptive immune responses (100), 
and indirectly, by preventing or reducing the formation and accelerating the 
degradation of viral double-stranded RNA (dsRNA) (101, 102).  dsRNA formation, 
which is an issue particularly during intermediate and late transcription, is a hallmark 
pathogen-associated molecular pattern (PAMP) and thus a potent inducer of the host 
innate antiviral immune response (101, 102, 106).  The last benefit of these enzymes 
is that they eliminate inhibitory capped RNA degradation products or abortive 
transcripts, which are responsible for translational defects.  These molecules can 
severely hinder viral protein synthesis by competing with viral mRNA for association 
with ribosomes and/or sequestering translation factors (102).   
2.5.2 Early-Stage Promoters and Termination Signal 
The promoter for early genes is an A/T-rich region located upstream of the 
RNA start site.  A critical core region was defined from -13 to -27 (15 nucleotides 
(nt) (107)), relative to the RNA start site, which is denoted as +1.  The consensus core 
sequence was determined to be AAAAAATGAAAAAA/TA, with initiation of 
transcription occurring with a purine predominantly found 12-17 nt downstream of 
the core region.  This consensus sequence is close to the optimal one, as defined by 
saturation mutagenesis experiments (7).  Interestingly, this core motif is present in 
several locations throughout the genome and seems to be required but not sufficient, 
on its own, for the initiation of transcription.  Perhaps even more intriguing though is 





annotated ORFs.  This brings up the possibility that the virus may have the capacity 
to generate new proteins over the course of its evolution (40, 107).  Most of these 
putative or anomalous TSSs lack an upstream core motif, however.  Most mapped to 
the positive-sense ORFs.  Those that were found associated with a highly conserved 
core promoter motif (about 5%), though, were capable of being translated into shorter 
protein isoforms (107).  The DNA that lies between the core and the RNA start site 
appears to play a spacer role (7) and is 10 nt in length.  This region may facilitate 
DNA unwinding, which would form the open complex needed for transcription 
initiation (107).  Additional studies have revealed that a high AT content in this 
spacer region is correlated with active transcription (107).  There is also no evidence 
suggesting the presence of transcriptional enhancer elements (7, 97), as has been 
found in nuclear DNA viruses (7).  The distance between the 5` boundaries of early 
mRNA and the first AUG codon varies considerably but has a mean of about 40 nt.  
Due to the lack of enhancer elements, it was hypothesized that perhaps both the level 
and timing of early gene expression is regulated by the promoter sequence (97).  
Promoter regions are conserved between different POXV genera (36-38), which 
provided an explanation for an old phenomenon referred to as non-genetic 
reactivation.  In this scenario, a heat-inactivated POXV is rescued via coinfection 
with another POXV from a different genus, with the heat-killed virus providing the 
template while the other POXV provides the enzymes needed for transcription (7).   
VACV early mRNA transcription terminates between 20 and 50 bp 
downstream of the RNA sequence UUUUUNU (TTTTTNT in the DNA).  This 





When it is not present, the mRNA tail may extend over into the next downstream 
early gene (40).  Experimental evidence suggests that the termination efficiency is 
about 80%, although it is less in some cases due to the RNA secondary structure (7).  
This 80% termination efficiency applies to genes with a single termination motif, 
which most early genes have.  Some, however, have multiple termination signals, 
while others have none.  Still, in others, the signal is unrecognized because of the 
secondary structure.  As such, the RNAP may continue to transcribe downstream 
ORFs until encountering functional termination sequences.  This scenario would 
potentially lead to gene misclassification, as mentioned above.  If the two adjacent 
genes were both early, read-through would not affect gene classification.  If an early 
gene, however, overlapped with an adjacent intermediate or late gene, then the latter 
would be wrongly categorized as early (97).  This termination signal has also been 
found near the ends of putative early genes in other POXV genera, suggesting it plays 
a similar role in termination in other POXVs besides VACV (7).  A genome-wide 
analysis of the 3’ ends of VACV early mRNAs revealed that only about two-thirds 
actually contained the termination sequence, raising the possibility that an additional 
termination mechanism may exist.  The mechanism in question may have been 
revealed when the existence of a pyrimidine-rich sequence in the coding strand up to 
position -25, relative to the polyadenylation site (PAS), was found.  This sequence 
was found regardless of the termination sequence being present, suggesting that it 
may facilitate termination (40, 107).  Specifically, this mechanism may involve the 
viral protein NPH II.  This protein has RNA helicase activity and efficiently unwinds 





the fact that virions lacking NPH II synthesize RNA molecules that are abnormally 
long and inefficiently released from the viral core.  Thus, the observed enrichment of 
pyrimidines in the coding strand, which corresponds to purines in the tracking strand, 
upstream of the PAS may facilitate termination.  The first PAS was usually around 40 
nt after the termination sequence for most early transcripts.  Additional PASs can be 
found downstream of the initial one.  These other ones may provide backup 
termination or serve to terminate anomalous transcripts.  They may even represent re-
polyadenylation of processed RNAs (107).   
2.5.3 Enzymes and Factors for Early-Stage Transcription 
Many virally encoded enzymes and factors are packaged into the virus 
particle, as evidence by the fact that a soluble extract of VACV virions can transcribe 
an early promoter template in vitro and produce properly initiated and terminated 
mRNA.  Some of these packaged enzymes and factors include the multisubunit DNA-
dependent RNA polymerase (MSDdRP), RAP94, VACV early transcription factor 
(VETF), capping and methylating enzymes, the poly(A) polymerase, NPH I, and 
topoisomerase, all of which are directly involved in the synthesis and/or modification 
of mRNA.  Additional packaged enzymes have various other roles in processes such 
as virion assembly, protein processing, and DNA packaging (82).  The vRNAP 
resembles those found in eukaryotes regarding their size and complexity.  It is 
encoded by at least eight viral genes, and the subunits range in size from 7 to 147 
kDa.  While it is known that at least one copy of each large subunit is present in the 
complex, the stoichiometry of the small subunits is still unknown (7), although if each 





kDa (108).  Multiple subunits resemble their counterparts in eukaryotic cells.  For 
instance, RNA polymerase subunit (RPO) 147 (J6) and RPO132 (A24) have 20-30% 
sequence identity with the corresponding large subunits of cellular RNA polymerases, 
RPO30 (E4) is about 23% identical to eukaryotic transcription factor SII (TFIIS), and 
RPO7 is homologous (about 23% amino acid sequence identity) to the smallest 
eukaryotic RNA polymerase subunit.  In fact, all of the subunits, with the exceptions 
of RPO30 and RPO35 (A29), are homologous to cellular RNA polymerases, 
suggesting they perform similar duties for the virus (40).   
RAP94, encoded by the H4L gene, is associated with about half of the RNAP 
molecules in VACV virions.  This protein is specifically required for transcribing 
from early promoter templates, along with VETF.  RNAP is still able to transcribe 
without RAP94, but that transcriptional activity is limited to single-stranded DNA 
nonspecifically or double-stranded intermediate and late promoter templates with the 
appropriate transcription factors.  RAP94 is made only during the late phase of 
expression, which aligns well with its exclusive role as a virion-associated early TF.  
This aspect sets it apart from the other core RNAP subunits, which all have early 
promoters, as they are needed for intermediate and late transcription (40).  It seems 
likely though that de novo synthesis of RNAP occurs prior to both intermediate and 
late gene transcription, especially given that RNAP in complex with RAP94 is 
specific for early gene transcription (108).   
VETF, as with RAP94, is made only during the late phase of expression.  
VETF is a heterodimer, formed by the 82- and 70-kDa proteins expressed by the A7L 





dual binding sites, one in the core region of early promoters and the other in DNA 
downstream of the RNA start site (40, 109).  This downstream region of DNA need 
not have a specific sequence, as it seems to simply aid in stabilizing the 
transcriptional complex.  This dual interaction seems to be the responsibility of only 
one molecule of VETF (109).  Mutations in the core region that decrease transcription 
also negatively affect VETF’s ability to bind the DNA, leading to the conclusion that 
it binds this stretch of DNA in a sequence-specific manner (40, 109).  It was also 
determined that the small subunit of VETF possesses DNA-dependent ATPase 
activity that is essential for transcription, but not for promoter binding.  The 
mechanism for this essential function may be via promoter clearance.  RNAP, 
RAP94, and VETF are sufficient for transcriptional activity in vitro.  Complexes of 
VETF and RNAP have been found, raising the possibility that VETF recruits RNAP 
to the promoter.  It also seemed likely that there was a direct interaction between 
VETF and RAP94, a theory that has since born out to be true (40, 110).  This study 
by Yang and Moss (110) yielded many findings:  VETF associates only with RPO 
containing RAP94 (both in vitro and in vivo); the association between RAP94 and 
VETF requires both subunits of VETF; neither viral DNA nor other virus-encoded 
late proteins are required for the interaction of RAP94 with VETF and core RPO 
subunits; different domains of RAP94 bind VETF and core subunits of RPO; and 
VETF and NPH I bind independently, and possibly simultaneously, to the N-terminus 
of RAP94.  As such, they concluded that RAP94 serves as the bridge connecting RPO 





Once transcription has been initiated, the process of elongation of the 
transcript occurs.  The elongation complex possesses 3` RNase activity which allows 
a stalled polymerase to resume transcribing.  It has been noted that such activity 
resembles that exhibited by eukaryotic RNA polymerase II in the presence of TFIIS, 
which the VACV RPO30 subunit happens to be a homolog of (7).  A complex 
consisting of RNAP, RAP94, VETF, capping enzyme (alternatively referred to as 
vaccinia termination factor or VTF (111) with regard to its role in termination (40)), 
and NPH I is able to both initiate and accurately terminate transcription on DNA 
templates containing an early promoter and the TTTTTNT termination signal.  While 
RNAP and VETF are sufficient for reconstitution of transcriptional initiation and 
elongation, capping enzyme and NPH I, a DNA-dependent ATPase, are required for 
the release of nascent mRNA with the UUUUUNU termination sequence from the 
transcriptional complex.  This transcript release process requires ATP.  It has also 
been demonstrated that NPH I interacts with RAP94, which may provide an 
explanation for the specificity of this termination complex for early transcripts (7).  
NPH I is capable of releasing transcripts independent of VTF and the termination 
sequences, as long as the vRNAP is not actively undergoing transcription elongation.  
If the vRNAP is actively elongating, however, then both VTF and the termination 
sequence are required (111).  A recent paper (111) found that VTF, in the presence of 
the termination signal, enhances pausing of the vRNAP, thus inhibiting elongation 
and facilitating NPH I-mediated transcript release.  The authors of this paper also put 
forth an alternative hypothesis with regard to pyrimidine-rich sequences possibly 





structures of most early mRNAs alone may not be enough to induce transcriptional 
pausing and termination.  These transcripts would then require VTF and the 
termination signal.  For those few that do not contain the termination signal, however, 
the RNA secondary structure may be sufficient to cause termination on their own, 
with VTF functioning to stabilize these weak RNA structures (111).  An additional 
role NPH I plays is that of an elongation factor for the polymerase to facilitate read-
through of intrinsic pause sites (7).   
Early transcripts, whether made in vitro or in vivo, are capped and 
polyadenylated such that they resemble, structurally and functionally, eukaryotic 
mRNA.  These transcripts possess a cap I structure, which consists of a terminal 7-
methylguanosine connected to a 2`-O-methylribonucleoside via a triphosphate bridge.  
While the role of the ribose methylation has yet to be determined (112), the N7-
methylguanosine portion of the cap is essential for the stability of the mRNA and for 
the binding of the viral mRNA to ribosomes.  Capping takes place co-
transcriptionally, when the nascent RNA transcripts reach about 30 nt in length.  The 
capping enzyme is a heterodimer, consisting of the D1R and D12L gene products, 
and it carries out the first three steps of cap formation.  The 97-kDa (D1R) large 
subunit forms a covalent lysyl-GMP intermediate in addition to possessing both the 
RNA triphosphatase and guanylyltransferase activities in its N-terminal region.  The 
N7-methyltransferase activity, on the other hand, is formed by the C-terminal region 
of the large subunit and the 33-kDa small subunit.  Cap formation occurs as follows:  
first, the removal of the terminal phosphate of the triphosphate end of the nascent 





G(5`)ppp(5`)N-; then, transfer of a methyl group from S-adenosylmethionine to 
produce m7G(5`)ppp(5`)N-; and finally, transfer of a second methyl group to form 
m7G(5`)ppp(5`)Nm.  This final step is actually carried out by a separate viral protein, 
VP39, which is the gene product of J3R.  Viral mRNAs made in vivo possess 
additional base and ribose methylations catalyzed by cellular enzymes (7).  
Phenotypic analysis studies carried out with a ts mutant of the capping enzyme large 
subunit support its multifunctional roles (40).   
Interestingly, VP39, which is a nucleoside 2`-methyltransferase, exists in two 
forms:  as a monomer and as the small subunit of the poly(A) polymerase, which 
itself exists as a heterodimer, consisting of VP39 and VP55 (E1L).  VP55 is 
responsible for binding to uridylate sequences near the end of the RNA transcript and 
catalyzing the processive addition of 30-35 adenylate residues before switching over 
to a slow, non-processive mechanism.  VP39’s role as part of this heterodimer is to 
bind poly(A) and stimulate VP55 to semi-processively add additional adenylate 
residues.  Thanks to its dual function as a methyltransferase and as a processivity 
factor for the poly(A) polymerase, VP39 is expressed in excess, compared to VP55, 
in infected cells.  Interestingly enough, the two functions of VP39 are independent of 
each other, as studies found that mutations in VP39 that abolished its 
methyltransferase activity had no effect on its adenyltransferase stimulatory activity.  
The revelation that the capping enzyme/termination factor activities and the ribose 
methyltransferase/poly(A) polymerase processivity factor activities are housed within 
the same enzymes is quite fascinating.  These seemingly disparate functions operate 





peculiar pairings may provide a specific advantage to the virus or simply represent an 
economical use of its proteins.  Genetic and biochemical studies had implicated VP39 
playing a role in intermediate and late transcription elongation (7), which has since 
been confirmed (72).   
The minimal complex for synthesis of correctly initiated, capped, terminated, 
and polyadenylated early mRNAs was determined using in vitro reconstitution 
assays.  There are, however, additional proteins required within the viral core.  They 
are:  the H6 DNA topoisomerase I, the I8 NPH II, and H1 serine/tyrosine 
phosphatase, and L4 DNA-RNA binding protein, and the L3 and E8 proteins, which 
have no known functions as of yet (7, 40).   
2.5.4 Regulation of Intermediate Transcription 
Intermediate gene expression cannot take place until DNA replication occurs.  
This requirement may stem from the fact that the genome is inaccessible to the newly 
synthesized transcription factors prior to uncoating and replication.  This potential 
inaccessibility may be due to specific repressor proteins, which is less likely, or 
nonspecific due to remaining virion proteins.  This inaccessibility is supported by 
transfection experiments demonstrating that DNA isolated from purified virions can 
serve as a template for intermediate and late transcription without DNA replication 
occurring (7).  Additional support for this idea is the fact that a transfected 
intermediate gene can get transcribed prior to DNA replicating taking place, even in 
the presence of a DNA synthesis inhibitor like hydroxyurea, whereas that same gene 
in the viral genome does not get transcribed under the same conditions (113, 114).  In 





to proceed normally (108).  Intermediate gene expression can be detected around 100 
mins after infection (3), peaks around 2 hpi, but rapidly declines from there, similar to 
the decline observed for early gene expression.  The rapid decline seen for 
intermediate mRNA, as with early transcription, is a combination of two factors:  
termination of transcription and rapid mRNA turnover.  Initially, only five VACV 
intermediate genes had been characterized:  the late transcription factors A1, A2, and 
G8 (7), (115), the I8 RNA helicase NPH II (7), and the I3 single-stranded DNA 
binding protein, which interacts with ribonucleotide reductase and is regulated by 
both early and intermediate promoters (7, 113).  Since then, the list of intermediate 
genes has been expanded to 53 (3, 40), although some of these are expressed late as 
well (3).  Gel electrophoresis analysis of intermediate mRNA shows diffuse bands 
equal to and longer than the coding regions, suggesting that the preferred sites of 3`-
end formation that do not correlate with the TTTTTNT, the early transcription 
termination sequence (7).   
2.5.5 Intermediate-Stage Promoters 
The core region of intermediate promoters resembles that of early promoters 
in terms of A/T richness, but they differ with regard to the specific sequence.  
Another similarity between the two is that there is no evidence of enhancer elements.  
Intermediate promoters possess two important regions, as determined by mutagenesis 
experiments:  a 14-bp core element separated by 10 or 11 bp from a 4-bp initiator 
element, TAAA.  Intermediate-stage mRNAs are initiated within the AAA, but these 





mechanism (7).  A consensus sequence was derived from analysis looking at all the 
sequences preceding the 53 intermediate ORFs that have been identified (40).   
2.5.6 Enzymes and Factors for Intermediate-Stage Transcription 
Both viral and cellular proteins are involved in intermediate transcription as 
intermediate promoter templates can be transcribed using VACV-infected cell 
extracts in the presence of a DNA replication inhibitor.  The viral proteins involved 
include:  the vRNAP; the viral capping enzyme, which in addition to capping the 
mRNAs (7) acts as a transcription initiation factor (116); VACV intermediate 
transcription factor (VITF) -1, which is RPO30; and VITF-3, a heterodimer formed 
by the 45-kDa A23 and 34-kDa A8 proteins (7, 117).  A8 and A23 are essential for 
the virus.  Without them, intermediate and late gene expression and resolution of 
concatemers do not occur, but early gene expression and DNA replication still take 
place.  As a result, deletion mutants must be studied using a complementing cell line 
(118).  It has also been reported that protein phosphorylation is involved in 
intermediate transcription, via the B1 kinase.  B1 mutants were found to be defective 
in intermediate transcription but not late transcription.  The substrate(s) that may 
require phosphorylation to function during this process have not been determined 
(108).  Unlike VETF, neither VITF-1 nor VITF-3 exhibit ATPase activities or 
sequence-specific DNA binding (7).  Both VITFs have early promoters (7) and are 
thus synthesized during early protein synthesis, prior to DNA replication (113).  This 
means they can begin aiding in transcribing intermediate stage genes once the viral 
DNA has been sufficiently copied.  VITF-2 was determined to come from the host, as 





be distributed throughout the nuclear and cytoplasmic fractions of VACV-infected 
cells.  Two different proteins, which form a complex together, were found to serve 
the role of VITF-2 in an in vitro complementation assay:  G3BP, the Ras-GTPase-
activating protein SH3 domain-binding protein, and p137/Caprin-1, the cytoplasmic 
activation/proliferation-associated protein (7, 119).  These proteins have been 
observed to accumulate at sites of transcription in viral factories, though an essential 
role in vivo has yet to be confirmed (105).  One interesting theory for the role of 
VITF-2 is that it may act as a gatekeeper between the pre- and post-replicative phases 
of the virus lifecycle by signaling that a quiescent cell has been activated, which 
would allow for optimal viral replication (7, 119).  Additional studies have revealed 
that the cellular TATA-binding protein positively affects VACV intermediate and late 
gene expression, while the eukaryotic transcription factor YY1 negatively affects 
post-replicative gene expression (40).  In the case of the latter, it was found that YY1 
binds, in vitro, to the promoter of the I1L gene, which was initially thought to possess 
a late promoter but has since been categorized as having an intermediate promoter. 
Searching through the VACV genome revealed numerous other promoters containing 
the YY1 binding site, TAAATGG.  Furthermore, YY1 was found to localize to the 
cytoplasm of infected cells (7).  Such a reliance on the host is a bit surprising given 
that POXVs encode their own RNA polymerases and other transcription factors (40).   
Multiple genetic studies have supported the idea that positive and negative 
regulators of intermediate and/or late transcription exist.  One example involves 
VACV A18 RNA helicase mutants, which have an indistinguishable phenotype, with 





the antiviral drug isatin-B-thiosemicarbazone (IBT) (7, 120).  Specifically, what is 
observed is an increase in the steady state concentrations of late mRNA, activation of 
the cellular ribonucleolytic 2-5A pathway, which results in cleavage of viral mRNA 
and host rRNA and premature cessation of late protein synthesis (120).  Mutations 
which conferred resistance to the drug mapped to RPO132 (A24R) (7, 120, 121), 
while drug-dependent mutations mapped to the G2 protein (7, 120), which has since 
been determined to be a positive transcription elongation factor (72).  The IBT 
resistant mutant that was isolated (120) did have to endure a fitness trade-off though, 
as it was discovered that this mutant was defective in transcription elongation, with 
the mutant complex pausing longer and more frequently than the wt complex (121).  
Since then, additional drug-resistant mutants have been mapped to RPO147 (J6R) 
(122).  Adding another wrinkle to this story is the fact that while mutations in A18 
resulted in increased transcriptional read-through, mutations in G2 resulted in 
decreased mRNA length.  Furthermore, G2 mutants can rescue A18 mutants.  
Physical interactions have been demonstrated to take place between G2, A18, and H5, 
one of the late transcription factors (7, 123).  A18 has also been implicated as a 
transcript release factor, working in conjunction with a yet unidentified cellular 
protein.  It was also determined that J3R also had a role as a transcription elongation 
factor, in addition to serving as the cap 2`-O-methyltransferase and as a subunit of the 
poly(A) polymerase  (7).  Additional IBT-dependent mutants have been mapped to 
the J3R gene.  These mutants, along with the drug-dependent mutants mapped to 
G2R, produce intermediate and late transcripts, in vivo, which are shorter than wt 





2.5.7 Regulation of Late Transcription 
Late gene transcription can be detected around 140 mins after infection (3), 
peaks around 4 hpi, and continues for the remainder of the viral lifecycle.  The need 
for such continuous mRNA synthesis is emphasized by the fact that late mRNAs have 
an estimated half-life of about 30 mins or less.  This high level of transcription leads 
to the accumulation of large amounts of late proteins, which include VETF, RAP94, 
and the major virion components (7).  The late genes, although spread through the 
genome, tend to cluster in the central region.  A study which was undertaken to 
distinguish between intermediate and late genes identified 38 total that belonged to 
the latter phase of gene expression (3, 40).   
2.5.8 Late-Stage Promoters 
The late promoter can be broken down into three regions:  a core sequence of 
about 20 bp with some consecutive T or A residues, which is separated from a highly 
conserved TAAAT element in which transcription initiates, by a 6-bp region.  
Mutations of the TAAAT region severely decrease transcription, while a synthetic 
promoter consisting entirely of Ts in the core region proved stronger than any natural 
late promoter that was tested (7).  The consensus promoter sequence that was derived 
from analysis of 38 late ORF upstream sequences corroborated the conclusions from 
the mutational analysis (40).  This region is usually followed immediately by a G and 
sometimes an A.  The former scenario results in a transcription initiation sequence of 
TAAATG, which results in an overlap with the translation initiation codon, ATG.  
The apparent lack of an untranslated RNA leader in this situation was a source of 





length poly(A) leader sequences formed from slippage of the RNAP.  The poly(A) 
leaders have also been observed on certain early mRNAs with a TAAAT initiation 
site and on intermediate mRNA.  These findings seem to indicate that slippage on the 
complement of the AAA sequence is an intrinsic property of the vRNAP (7).   
2.5.9 5` Poly(A) Leaders of Post-Replicative Genes 
One possible benefit of the structure and nature of post-replicative genes is 
that the 5` poly(A) leader could compensate for the complementary RNA by 
providing a single-stranded binding site for the 40S ribosomal subunit and initiation 
factors, which would then move by antisense RNA, unimpeded, to the first AUG, 
where ribosome assembly and translation would take place (7).  The 5` poly(A) 
leaders, which are present on all post-replicative mRNAs but only a few early 
mRNAs, may reduce the need for certain translation initiation factors (102).  These 5` 
poly(A) leaders may also facilitate translation and stability (40).  These hypotheses 
were put to the test in a recent paper (124).  What this group found was that the 5` 
poly(A) leaders of post-replicative genes did indeed confer a translational advantage 
during infection.  While a constitutive and uninterrupted leader 12 residues long was 
optimal, the most frequent lengths were between 8 and 12 residues, supporting 
findings from another study (125).  The consistency of the length of the leader led the 
authors to conclude that this process has been optimized over the course of POXV 
evolution in order to maximize protein synthesis, and not simply an accident due to 
the vRNAP (5, 124).  This advantage was even seen in infected cells with impaired 





Furthermore, this paper raised the possibility that the 5` poly(A) leaders may 
allow for cap-independent translation, although it does not seem to serve as an IRES.  
Such a requirement would be necessary, since intermediate and late genes are made 
after host protein synthesis has been shut down.  This shutdown would include cap-
dependent translation initiation factors.  Additionally, cap-independent translation 
would ensure efficient translation of viral mRNA under other physiological 
conditions, like cell mitosis and cellular stress, during which cap-dependent 
translation is suppressed.  This would allow VACV to switch between the two forms 
of translation depending on the availability of translation initiation factors and the 
status of the cellular environment, which has also been observed to happen with 
cellular mRNAs (124).  This capacity for utilizing two modes of initiation probably 
maximizes how well viral mRNAs compete for ribosomes or allows them to undergo 
initiation in spite of the viral decapping enzymes, which do their job indiscriminately 
































Figure 2.4. Translation control in uninfected and VACV-infected cells.  In 
uninfected cells (top), the 40S ribosomal subunit is recruited to the mRNA 
m-7-GTP cap through the combined actions of eIF4F and eIF3.  The 
ribosome then scans (blue arrow) the 5` UTR in search of a start codon, at 
which point the 60S ribosomal subunit joins to initiate translation. 
Ribosomes slide (red arrows) on polyA stretches, and 50 polyA leaders do 
not act as enhancers in mammalian cells.  In VacV-infected cells (bottom), 
the vRNAP slips on intermediate and late promoters, reiterating adenosine 
residues to create randomly sized polyA leaders. Viral enzymes control 
mRNA capping and decapping in infected cells, where polyA leaders enable 
either cap-dependent or cap-independent translation of viral mRNAs; 
whether cap-independent translation occurs on viral mRNAs that have been 
decapped or were never capped remains unknown (?). Modification of 
RACK1 by the viral B1 kinase contributes to the ability of polyA leaders to 
function in infected cells. eIF, eukaryotic initiation factor; m-7-GTP, 7-
Methylguanosine-5`-triphosphate; RACK1, receptor for activated C kinase 
1; UTR, untranslated region; VacV, vaccinia virus; vRNAP, viral RNA 
polymerase.  Adapted from Figure 1 from Walsh, D. Poxviruses:  Slipping 
and sliding through transcription and translation. PLoS Pathog, 2017. 
13(11): e1006634. (5).  Reprinted with permission under the Creative 





It is also possible that the high abundance of viral mRNAs contributes 
somewhat to the apparent eIF4F-independent phenotype (5).  The group, however, 
did not rule out the possibility of a minimal amount of cap-binding translation 
initiation factor eIF4E being required, which would be an alternative cap-dependent 
translation mechanism (124).  It had already been shown that VACV sequesters 
crucial translation initiation factors within the viral factories (105).  It should be 
noted, however, that once a ribosome has been recruited to a viral transcript, these 5` 
poly(A) leaders may become a liability.  Runs of 11 or more As cause bidirectional 
sliding of ribosomes in a process known as phase-less wandering.  Adding another 
wrinkle to this story is the recent discovery that the B1 kinase acts upon residues in a 
flexible loop in the small ribosomal subunit protein, receptor for activated C kinase 1 
(RACK1).  This phosphorylation appears to slow initiation rates to facilitate leader 
activity, which may compensate for sliding and/or allowing cap-independent viral 
transcripts to dominate (Fig 2.4).  Thus, VACV relies on slippage during both 
transcription and translation, in a peculiar coupled strategy (5).  Dhungel et al. also 
found that the 5` poly(A) leader could be used to increase foreign gene expression in 
conjunction with POXV-based vectors (124), such as the bacteriophage T7 promoter-
based expression system with VACV (27, 126, 127) that was used in this study.  
Taking a broader view, this paper also brings up the possibility that their findings 
could point to a novel cellular translational mechanism (124).   
2.5.10 RNA Processing Signal 
As with intermediate transcription, the early transcription termination signal is 





coding sequence.  Because of this, most late mRNAs are long, heterogeneous, and 
lack defined 3`-ends.  This terminal heterogeneity, coupled with concurrent 
transcription from both strands of DNA, commonly causes overlapping of transcripts.  
This leads to self-annealing of the late transcripts or annealing with early transcripts, 
which result in ribonuclease-resistant hybrids (7).  In fact, at 4 hpi, observations have 
been made of RNA sequences covering both DNA strands in their entirety, which is 
consistent with the annealing of late RNA forming long duplex structures (97).  These 
structures may be resolved or the deleterious effects may be inhibited by the virally-
encoded dsRNA binding protein, E3 (101, 102), the K3 protein, the K1 protein, (101), 
the D9 and D10 decapping enzymes (101, 102), or the RNA helicase (7).  Possessing 
many ways to deal with the production of dsRNA is important since it activates the 
host’s innate immune response.  dsRNA is made during the replication of most RNA 
and DNA viruses (101), making it a signature feature of viral infection,.  In the case 
of VACV, about 15% of the polyadenylated RNA made during intermediate and late 
gene expression can anneal, forming long intermolecular duplexes with single-
stranded RNA tails (101, 102).  
There are at least two known exceptions to the general 3` heterogeneity of late 
mRNAs.  In CPXV, the late mRNA encoding the ATI protein has a 3`-end 
corresponding to a specific site in the DNA template.  The DNA sequence at this site 
encodes an RNA cis-acting signal for RNA 3`-end formation, which functions 
independently of either the nature of the promoter or the RNAP responsible for 
generating the primary RNA.  Evidence supports the idea that a specific endonuclease 





transcript of VACV is generated via cleavage as well (7).  Endonuclease activity 
attributed to the H5R gene product is capable of cleaving the F17 RNA, which is then 
polyadenylated (40).  It is unclear how many other late mRNAs are processed 
similarly.  This means that POXVs have two different mechanisms for generating the 
3`-ends of RNA transcripts:  a sequence-specific manner, in the form of an RNA 
signal, which is used during the early phase of infection; and a site-specific manner, 
involving cleavage, used during the late phase of infection (7).   
2.5.11 Enzymes and Factors for Late-Stage Transcription 
There are four confirmed VACV late transcription factors (VLTFs):  G8, A1, 
A2, and H5, which are referred to as VLTF-1, -2, -3, and -4, respectively.  The first 
three all have intermediate promoters (7), meaning they are only transcribed from 
replicated or transfected viral DNA.  These three TFs were also found to be both 
necessary and sufficient to overcome a block in late promoter expression (115).  H5, 
on the other hand, has an early promoter (7).  A1, A2, and G8 are all essential for 
viral replication, so deletion mutants must be characterized using a complementing 
cell line (98), similar to the VITF-3 subunits A8 and A23 (118).  A1 and A2 can both 
bind zinc (7, 115), while yeast two-hybrid (Y2H) studies provide evidence of 
interactions between G8 and A1 and G8 with itself (7, 128).  Additional interactions 
were seen A1 and itself and G8 and A2 (128).  Computational analysis has suggested 
that G8 possesses a PCNA-like sliding clamp motif (40).  Additionally, other studies 
have reported interactions between H5 and the other late transcription factors (7, 
128), specifically A2 and G8 (128).  H5 may also play a role in transcript elongation 





the vRNAP, and other additional transcription factors (123).  H5 reportedly also 
interacts with itself (128).  In vitro transcription assays have demonstrated that H5 
increases late transcription several-fold, while also hinting at the involvement of a 
host factor, dubbed VLTF-X, consisting of the heterogeneous nuclear 
ribonucleoproteins (hnRNPs) A2/B1 and RBM3 (7), both of which were found to 
bind to A2.  Additionally, hnRNP A2 was observed to interact with itself (128).  
Similar to intermediate transcription, evidence suggests that the cellular TATA-
binding protein and YY1 play positive and negative regulatory roles, respectively, 
during late transcription (40).   
2.5.12 Intermediate and Late Gene Comparison 
Initial attempts to distinguish between the two classes of post-replicative 
genes were thwarted for a variety of reasons.  The promoters are similar, so it was 
difficult to identify them based on sequence.  Even techniques such as RNA-seq and 
genomic tiling were unable to make distinctions between intermediate and late genes.  
This was due to the close spacing of the ORFs themselves, the extensive read-through 
of transcripts, and the small differences in temporal expression levels.  However, 
genes regulated by intermediate and late promoters can be distinguished by 
transfecting plasmids into cells in the presence of a DNA replication inhibitor, as only 
the intermediate genes will be expressed (3).  One study, by Yang et al. (98), found 
that, of the 53 intermediate promoters, 26 had detectable late activity.  This study 
used a cutoff of 5% activity in relation to the strong F17R promoter.  This paper also 
found that there were two statistically significant features for late activity, neither of 





at +4 in the initiator region and T residues between -12 and -8 in the core region of 
the coding DNA strand.  Meanwhile, the frequency of A residues between -22 and -
14 was correlated with intermediate transcription activity, but not late activity.  The 
importance of these regions was demonstrated via transformation of a strict 
intermediate promoter into a late promoter, and vice versa.  It had also been noted by 
a previous study that interconversion of intermediate and late promoters with TAAAT 
initiator sequences could be accomplished, at least to some extent, by altering the 
space between the core and initiator sequences (98).   
2.5.13 Post-Replicative Gene Initiation and 3` End Formation 
Similar to what was found for early genes (107), pervasive initiation and 3` 
end formation have been observed for both intermediate and late mRNAs.  
Anomalous TSSs were found were located throughout the genome, within both the 
coding and non-coding strands.  Again, like the early genes, some were downstream 
of functional promoter sequences and can generate truncated isoforms of proteins.  
The 5` poly(A) leaders for intermediate and late genes were found to be at least 5 nt 
long for the vast majority of transcripts.  The median lengths were 8 and 11 nt for 
intermediate and late transcripts, respectively.  The poly(A) leaders for anomalous 
TSSs were shorter in general, perhaps hinting at the fact that they might not be 
optimal for translation.  Interestingly, pyrimidine-rich sequences were found 
immediately upstream of the PASs, suggesting that NPH-II-mediated termination 
may occur for both early and post-replicative transcripts (125).  Perhaps this reliance 
on pyrimidine-rich sequences is related to the Katsafanas et al. (77) study in which 





on the DNA synthesis and processing was mentioned earlier, it was also found that 
transcription and translation were affected.  The levels of intermediate and late 
transcripts were drastically reduced, while the effect on early transcripts was less cut 
and dry.  For at least one example of each, shorter early transcripts (500 nt) saw a 
two-fold increase, while longer early transcripts (4300 nt) saw a two- to three-fold 
decrease.  The authors postulated that longer mRNAs, or at least ones with long 
pyrimidine tracts, may be more affected than the shorter mRNAs.  They also 
observed prolonged synthesis of some early proteins and a severe reduction in late 
proteins.   
2.5.14 Viral DNA-Associated Transcription Proteins 
VACV encodes an impressive complement of transcription proteins, including 
an MSDdRP, stage-specific TFs, a type I topoisomerase, an elongation factor, 
capping and methylating enzymes, a poly(A) polymerase, and transcription 
termination factors.  Despite this repertoire, there are questions as to whether 
additional proteins are involved in these steps of the viral lifecycle (72).  While the 
notion that POXVs perform functions seemingly independent of their hosts has 
prevailed for years, it has become increasingly obvious that host proteins are needed 
for both intermediate and late transcription, in contrast to early transcription.  The 
rationale behind this would seem to be two-fold:  location and timing.  Early 
transcription occurs entirely within the confines of the viral core, whereas 
intermediate and late transcription occur in the cytoplasm, which is a much more 
open environment.  The timing of intermediate and late transcription, after DNA 





be more beneficial for the virus to postpone recruitment of host proteins to the viral 
factories until sufficient amounts of DNA have accumulated in the cytoplasm (108).  
For instance, as mentioned above, roles for host proteins have been observed, 
including cellular heterogeneous nuclear ribonucleoproteins A2/B1, G3BP and p137 
(or caprin I), TATA binding protein, and YY1 (7).   
To provide some answers to these open questions, Senkevich et al. (72) 
performed experiments to try and confirm known and perhaps identify new members 
of the VACV transcription machinery.  They were able to identify viral proteins 
known to have roles in intermediate and late transcription, which indicated that the 
pool of replicating DNA was being transcribed.  The four largest subunits of the 
vRNAP (RPO 147, 132, 35, and 30) were detected, but the remaining four were not.  
Both subunits of the capping enzyme (D1 and D12) and cap 2` O-methyltransferase 
(J3) were also recovered, in addition to a positive transcription elongation factor, G2.  
As mentioned before, J3 is also the noncatalytic/small subunit of the poly(A) 
polymerase and a positive transcription elongation factor.  Perhaps the most 
intriguing result, however, was that the intermediate and late transcription factor 
complexes were both recovered.  This was interesting because none have been shown 
to directly interact with either DNA or the RNAP.  H5, which plays, a role in DNA 
replication, is also involved in transcription.  It also interacts with G2.  Host proteins 
previously reported to be involved in VACV transcription were also detected.  These 
included G3BP1, Caprin-1, and HNRPA2B1.  G3BP1 and Caprin-1 form a 
heterodimer have been demonstrated to co-localize with viral mRNA in virus 





intermediate transcription (72, 105).  The RNA-binding proteins HNRPA2B1 and 
RBM3 have been found to stimulate late gene transcription, as mentioned previously, 
and the former was detected in this study as being associated with nascent DNA (72).   
The large/catalytic subunit (E1) of the poly(A) polymerase was not detected in 
this study, consistent with its posttranscriptional activity and its association with 
mRNA instead of DNA.  Additional host proteins with suggested roles in 
transcription that were not found associated with the nascent DNA include RBM3, 
the TATA binding protein, and YY1.  The TATA binding protein and YY1, as 
mentioned above, reportedly upregulate and downregulate intermediate and late 
transcription, respectively, via promoter binding, so not detecting them casts some 
doubt on their biological relevance (72).   
 2.5.15 Translation and Annotation of Viral ORFs and Transcripts 
One consistent theme for POXV gene expression is that proteins which 
interact with each other are frequently made at the same time.  One such example is 
the partnering of the EFC and the redox proteins.  Most members of the EFC have 
intramolecular disulfide bonds, which are formed by the viral redox proteins.  Both 
sets of proteins are made late in infection.  In contrast, the proteins used for the MV 
membrane and the EV membrane are made at different times, supporting the idea of 
independent pathways of membrane morphogenesis.  It is conceivable that 
synthesizing some proteins at the wrong time could have a deleterious effect on the 
virus (3).   
As mentioned previously, pervasive initiation and 3`-end formation have been 





genes, alternate TSSs are capable of producing shortened isoforms of proteins (107, 
125).  Subsequent work has since corroborated these findings.  RNA-seq in 
combination with ribosome profiling has uncovered novel putative translation 
initiation sites throughout the genome (129), approximately 600 to be exact (130).  
These sites could have arisen thanks to the ribosome scanning past earlier start 
codons or from shorter mRNAs, which is where the observed pervasive transcription 
initiation (107, 125) could come into play.  Many of these new sites were located 
within larger ORFs. Thanks to the compact nature of the viral genome, only a few of 
these putative translation initiation sites were found within intergenic regions.  Some 
were also found in untranslated leader sequences and on the antisense strand.  The 
predominant start codon was still predicted to be AUG, although other near-cognate 
start codons were found, particularly for post-replicative genes.  The short nature of 
these additional ORFs did raise questions regarding their biological importance 
though.  Furthermore, questions still remain with regard to the synthesis and stability 
of the peptides encoded by these ORFs (129).  On the other hand, these newly 
identified ORFs have the potential to play important structural or regulatory roles in 
VACV replication (130).  Regardless, it is evident that POXVs seem capable of 
encoding more proteins that previously thought.  Pervasive transcription and 
translation initiation serve to increase the coding capacity and expand the functional 
repertoire by allowing for the generation of extra RNAs and proteins.  These findings 
are not unique to VACV and POXVs.  Ribosome profiling has also revealed short 
ORFs and alternative start codons in studies with cytomegalovirus (CMV), Kaposi’s 





eukaryotic cells (129, 130).  Given that POXVs have acquired cellular genes over the 
course of their evolution as a result horizontal gene transfer (79, 131, 132), 
presumably via reverse transcription since introns are missing (130), pervasive 
transcription and translation initiation may provide an explanation for how these 
novel ORFs were initially expressed (129, 130), since they would have been 
randomly inserted into the genome.  Then, natural selection should result in 
enhancement of promoter and translation sites which would allow optimal expression 
(129).  Such genomic plasticity would allow POXVs to adapt to changes in their 
environments.  These newly discovered putative gene products may impact the 
differences in host range and pathogenicity observed between POXVs, which in turn 
contribute to the efficacy and specificity of POXVs being used for oncolytic 
virotherapy and as vaccine vectors (130).   
2.6 Poxvirus Evolution 
Debates regarding the origins and evolution of viruses have gone on for many 
years, with many theories being put forth to explain the existence of viruses, which 
are the most abundant biological entities on the planet and outnumber cells by at least 
an order of magnitude (133-135).  Two of the more common theories are the cell 
degeneration model of virus origin and the escaped-genes model.  Other models do 
exist though, including:  the origin of viruses from a primordial gene pool; an ancient 
lineage of viruses spanning the three domains of cellular life, based on the presence 
of a jelly-roll capsid (JRC) protein in various groups of DNA viruses; and at least 
three ancient RNA virus lineages giving rise to independent DNA viruses lineages, 





133, 135, 136).  The ability to accurately and quickly sequence genomes has made it 
easier to find similarities and trace lineages of organisms and individual genes.  A 
paper by Koonin et al. (133) suggested that the first two models are not supported by 
comparisons of viral genomes and leaned towards the primordial gene pool model as 
the most likely origin of the major virus lineages (133, 137).  Starting with 
prokaryotic viruses, this scenario would involve extensive mixing and matching of 
diverse genetic elements. The next major event proposed by the paper would be the 
emergence of eukaryotic viruses, in which the newly-emerged eukaryotic cell would 
serve as a site for extensive mixing and matching of viral and cellular genes (133, 
135).  The existence of viral genes with no known cellular homologs, such as the 
superfamily 3 helicase, provides evidence for an ancient pre-cellular virus world (43, 
133, 137).  This idea has since been explored in more depth and supported by other 
phylogenetic and comparative-genomic studies (138-144).  These findings also do not 
support another popular theory regarding viruses making up, or originating from a 
now-extinct, fourth domain of life (140, 145).   
Another important point of the 2006 Koonin et al. paper (133) is that it puts 
forth the idea that viral and cellular evolution are uniquely interconnected (133), 
outside of the oft-cited “arms race” or Red Queen hypothesis of how viruses and cells 
drive the evolution of their responses to each other  (134, 146).  Another level of this 
interconnectedness is evident when it was realized, not surprisingly, that viruses have 
acquired, and sometimes repurposed, genes from their respective hosts via a process 
called lateral or horizontal gene transfer (LGT or HGT) (43, 79, 131-134, 136, 143, 





cellular hosts have been known to recruit viral genes for a range of functions (134, 
149, 154, 155).  In fact, the transfer of genes may be a bit more one-sided than 
commonly believed, and not in the direction that would be expected, i.e. cell-to-virus.  
Viruses may have played a major role in the evolution of cells, with cells being the 
main recipient of new genetic material (154).  Adding another layer onto this is the 
fact that cellular hosts are not the only source of new genes for viruses and can 
include bacteriophage (79, 135, 144, 152, 153) and other viruses (141, 144, 156), 
bacteria (136, 144, 152, 153, 157) and other prokaryotes (144), other eukaryotic 
organisms besides their respective hosts, in the case of eukaryotic viruses (144),  
diverse families of mobile genetic elements (131, 143, 144, 150, 157-159), and even 
sources with ambiguous genetic phylogenies (144).  For example, some POXVs 
contain homologs of vertebrate host immune system genes, including multiple 
members of the interleukin-10 (IL-10) family, which also includes human ILs-19, -
20, and -24 (43), (151), while some POXVs contain homologs of the vertebrate 
vascular endothelial growth factor A (VEGFA) (43).  The proteins encoded by the 
members of the Chordopoxvirinae subfamily generally show greater similarity to 
eukaryotic proteins than to viral proteins from non-POXVs (160), such as in the case 
of the viral DNA ligase (152).  Evolution can also occur at the species level when a 
new environment or host is encountered.  This can drive and/or be driven by changes 
at the molecular level.  POXVs are no exception to these two phenomena.   
2.6.1 Poxvirus Phylogeny 
POXV phylogeny is an interesting story, both at the species/strain level and at 





2001 (2, 43).  Since then, a new name for the order containing these viruses has been 
proposed, Megavirales, given their large genomes and viral particles (2).  The original 
members of this superclade were the Poxviridae, Asfaviridae, Iridoviridae, 
Ascoviridae, and Phycodnaviridae families.  Since 2003, the number of virus family 
members has more than doubled (Table 2.4), with the discoveries of the Mimiviridae, 
Marseilleviridae, Megaviridae, Pandoraviridae, Pithoviridae, and Faustovirus families 
(2, 4, 161).  This extremely broad range of viruses infects hosts across seemingly the 
entire range of eukaryotic cells.  Two of the five currently recognized supergroups of 
eukaryotes (Rhizaria and Excavata) have not yet been studied in enough detail to 
determine if they too are infected by NCLDVs.  The perceived ancient origin of the 



























Family Yr discovered Host(s) Replication 
site 
Assembly site Genome (kb) 
Poxviridae 1798? Vertebrates, 
insects 
Cytoplasm Cytoplasm Linear (130–
380)c 
Asfarviridae 1921 Pigs, 
warthogs, 
insects 
Cytoplasm Cytoplasm Linear (170–
190)c 
Iridoviridae 1966 Fish, frogs, 
snakes, 
insects 
Nucleus Cytoplasm Linear (102–
212)d 
Ascoviridae 1983 Insects, 
moths 
Nucleus Cytoplasm Circular (157–
186) 
Phycodnaviridae 1981 Algae Nucleus Cytoplasm Linear (100–
560) 
Mimiviridae 2003 Amoebae, 
zooplankton 
Cytoplasm Cytoplasm Linear 
(~1,200) 
Marseilleviridae 2009 Amoebae Cytoplasm Cytoplasm Circular (368) 
Megaviridae 2010 Amoebae Cytoplasm Cytoplasm Linear 
(1,208–1,259) 
Pandoraviridae 2013 Amoebae Cytoplasm Cytoplasm Linear 
(1,900–2,500) 
Pithoviridae 2014 Amoebae Cytoplasm Cytoplasm Linear (610)d 
Faustovirus 2015 Vermamoeba 
vermiformisb 





TABLE 2.1 Current families within the NCLDV superclade (proposed order 
Megavirales (2))a 
aThose families considered to be giant viruses, discovered starting in 2003, are 
shown in bold. Classification and tree topology are still developing, with, for 
example, the recently discovered Dinodinavirus, Faustovirus, Cedratvirus, 
Kaumoembavirus, and Mollivirus also being considered members of the NCLDV 
superclade. 
bA protist. 
cHas covalently cross-linked ends and inverted terminal repeats. 
dCircularly permuted and terminally redundant. The upper size limit is 303 kb if 
redundancy is included. 
eEight out of nine Faustovirus genomes were circular (129, 130).  Adapted Table 1 
from Mirzakhanyan, Y. and P. D. Gershon. Multisubunit DNA-dependent RNA 
polymerases from vaccinia virus and other nucleocytoplasmic large-DNA viruses:  
impressions from the age of structure. Microbiol Mol Biol Rev, 2017. 81: e00010-
17. (4).  Reprinted with permission under the Creative Commons Attribution 





All NCLDVs have:  representatives of a set of 47 genes, more or less (2, 143, 
144, 162), needed for key viral functions, presumably conserved from the ancestral 
virus; a common virion architecture; and common major biological features, 
specifically replication within cytoplasmic factories.  All the NCLDVs share five core 
genes, encoding:  the major capsid protein (POXV D13 gene), a helicase-primase 
(D5), the DNA polymerase elongation subunit family B (E9), a DNA-packaging 
ATPase (A32), and the viral late transcription factor (A2).  All the NCLDVs form 
large, icosahedral capsids which consist of a single, homologous double B barrel jelly 
roll protein.  The only exceptions are POXVs, which form a unique brick-shaped 
virion, and Ascoviruses, which have allantoid capsids.  It should be noted, however, 
that POXV IVs resemble the icosahedral shape of the other members of this group.  
All NCLDVs replicate either entirely in the cytoplasm of infected cells or start in the 
nucleus and end up in the cytoplasm (2).  The viruses that do the latter are the 
Iridoviridae, Ascoviridae, and Phycodnaviridae families.  All the others found and 
classified so far are cytoplasm-only (4), although, in the case of the Mimivirus at 
least, it is not clear if the nucleus is involved in genome replication (163).   
Members of this superclade also temporally regulate their gene expression, 
with distinct phases separating each one for those that have multiple.  These phases 
are generally broken down into three classes: (immediate/delayed) early genes, 
intermediate genes, and late genes.  Such regulation is possible using distinct 
promoter regions for each class of genes, which differ from one another but exhibit a 
pattern of conservation within the same group.  This control over gene expression 





selected to ensure each gene is transcribed when, where, and at the level required.  
Also of note is that the promoter regions tend to be AT-rich, even in genomes with a 
high GC content, suggesting that the ancestral virus likely had an AT-promoter 
sequence (161).  Such conservation of the promoter sequences seems to support 
previous studies which found that, in viruses, sites outside coding regions tend to be 
more constrained than synonymous sites within the coding regions, due to the role the 
former has in regulating gene expression (43).  Most members of this superclade 
encode their own MSDdRPs, which tend to resemble their cellular counterparts.  The 
viral versions, however, generally appear to be stripped of their higher-order cellular 
control and honed for speed and processivity (4).  Different studies seem to point to 
the fact that POXVs are more closely related to Asfavirus (ASFV) than any of the 
other NCLDVs, as they use similar transcriptional strategies (161) and have their own 
unique virion structures (2, 138).  As a result, when phylogenetic trees of the 
NCLDVs are constructed, even though each family forms its own clade, the tree has 
two obvious branches:  with POXVs and ASFV on one and the rest of the NCLDVs 
on the other (2, 138, 164), suggesting a more recent common ancestor of the two 
families (161, 164).   
2.6.2 History of VARV 
Many groups have tried to determine the origin and history of VARV for 
academic purposes but also to understand how and why viruses move and change 
over time, perhaps enabling them to come away with lessons that can be used for 
present-day viruses, especially other POXVs  (1, 8, 9, 15).  Fortunately for POXV 





historical medical records documenting cases, providing some evidence to help chart 
the movement of the disease as it spread across the globe (1, 8, 9, 15).  The earliest 
and most reliable description of the disease dates back to the 4th century AD in China 
(1, 9, 15, 43) , then India in the 7th century, and in Southwest Asia and the 
Mediterranean in the 10th century (9).  The advent of high-throughput sequencing and 
the generation of complete sequences for entire POXV genomes has aided a great 
deal in the phylogenetic analysis of VARV lineage (9).   
It is believed that the etiological agent of smallpox occurred no earlier than 
10,000 years ago (46), with VARV having a relatively recent origin of about 3300 
years ago (1, 8, 44-46), This timeline coincides with the split of VARV, CMLV, and 
TATV from a common ancestor (43-45), presumably a CPXV-like virus (1) that 
infected rodents (8, 46) but had a broad host range (1, 44).  All of these viruses are 
closely related, only infect one particular host (1, 46), and VARV and CMLV have 
high mortality rates (1, 44).  Such an occurrence could only have taken place when 
this ancestral virus encountered new, susceptible hosts in the same area and at a 
sufficient density and size to support the spread of the virus(es) (8), (44), (1), (45).  
Once this happened, the disease could then persist in the population by infecting 
people in surrounding areas and then return to a previous area once a large enough 
new crop of susceptible individuals has been introduced (1, 8).  One event in 
particular was keyed in on by Babkin and Babkina (1):  the Santorini Eruption, which 
was one of the largest volcanic events in recorded history and caused considerable 
changes in the climate (1).  This event would have driven camels and naked sole 





Horn of Africa no earlier than 4000 years ago, consistent with phylogenetic analysis 
regarding the emergence of these viruses (1, 44).  The specific event believed to have 
triggered this divergence was the introduction of the camel, which represented a new 
potential host with a unique antibody structure and a change to which the ancestral 
virus had to adapt (1, 44).   
Along with climate change (1, 44), the most widely-accepted drivers of 
pathogen emergence are destruction of the environment of potential hosts, 
introduction of the pathogen into a new area, spread of the pathogen to other 
populations of hosts, and interactions of the pathogen with the host immune system.  
The authors were cautious though and acknowledged that just because this 
cataclysmic event correlates with the emergence of these viruses does not mean it 
caused it (1).   
Another factor that probably coincided with and may have helped this 
speciation was the disruption of the ATI gene in VARV.  Deletion of this gene in 
CPXV enhances OPXV respiratory infection, which is the primary method of spread 
for VARV in humans and MPXV in rodents, which also has a disrupted ATI gene.  
Such an occurrence would seem to provide a selective advantage for these viruses.  In 
fact, retention of a functional copy of this gene may have negatively affected the 
abilities of these viruses to spread, as ATIs would seem to be more beneficial if the 
host population is sparse or spread is inefficient or indirect (94).  A breakthrough in 
charting the molecular evolution of VARV was achieved when restriction fragment 
length polymorphism (RFLP) analysis revealed that the West African and South 





organization when compared to other VARV geographical variants.  Even more 
intriguing is the fact that these two strains within this subtype form two distinct 
phylogenetic groups, suggesting that they had evolved independent of each other (1, 
46).  The divergence of the West African strain happened about 570 years ago (1, 46).  
It then evolved into the South American strain about 350 years after it was imported 
to the continent (8, 46) as a result of the slave trade (46).  Over the course of this 
evolution, the case fatality rate (CFR) dropped from 8-12% to less than 1% (1, 44).   
Parallels have been drawn between VARV, MYXV (1, 44, 45), and ECTV 
(45), which infect European rabbits and mice, respectively as their non-natural hosts.  
The mortality rates can approach 100% in both of these cases (45).  Such high 
lethality rates are indicative of viruses which have only recently adapted to new hosts 
(1, 44), prior to genetic changes attenuating the virus (45), and this property provides 
further evidence of the fairly recent emergence of VARV (1, 44).  After introduction 
into a new host, viruses usually undergo evolutionary changes which reduce the CFR, 
as has been witnessed with MYXV in Australia (1, 45), and with MPXV, between the 
West African and Central African strains, where the former strain lost the 
complement binding protein, resulting in a reduction in the CFR compared to the 
latter strain (1, 44).  The region of West Africa provides a fascinating example of how 
geography can influence the emergence of a pathogen.  The emergence of West 
African VARV and MPXV mostly likely occurred due to the geographical isolation 
of the region from the rest of the continent due to the presence of the rain forest.  This 
region is also separated from Central Africa and South Africa by the Adamawa 





distinct separation of virus families into geographical subtypes is not limited to 
POXVs.  Examples of viruses specific to West Africa have been found in subtypes of 
Ebola virus, human immunodeficiency virus (HIV) -2, simian immunodeficiency 
virus (SIV), and hepatitis C virus (HCV) genotype 2 (46).  Parallels have also been 
made between VARV and Measles, which is also specific to humans in terms of 
pathogenicity (1).  Measles, which is theorized to have evolved from a rinderpest 
virus 1000-1500 years ago (45), requires a population of about 200-300 thousand 
people in order for a sufficient number of susceptible children to be introduced 
regularly so that it can be maintained in the population (1).   
2.6.3 History of VACV 
The history of VACV is more convoluted, as has been mentioned before.  
This has been due to multiple passages of viruses in different animals and the use of 
both cows and horses as the source material for protection against smallpox  (13, 16, 
24).  In fact, prior to the start of the smallpox eradication campaign in 1967, smallpox 
vaccines from multiple sources were used.  Once the global effort began, however, 
the WHO standardized four VACV strains for use as vaccines (14, 24).  For nearly a 
century and a half, however, it was assumed that CPXV was the virus used as the 
vaccine against smallpox, but it was not until 1939 that a British researcher named 
Allan Downie demonstrated that VACV and CPXV, though related, were not the 
same virus (14), (13, 16, 24, 43).  Furthermore, VACV is neither an attenuated strain 
of VARV nor a recombinant of CPXV and VARV (24).  It has also been shown that 





A HSPV-like virus is now assumed to be the origin of VACV (1), though this 
is unclear.  Recent evidence however supports the idea that at least early smallpox 
vaccines were based on a HSPV-like virus, as a recently-found 1902 vaccine was 
closely related to HSPV (13, 14).  HSPV, which was not present in the Americas and 
was only found in Europe (13, 14, 24), is believed to have diverged from its ancestor 
only about 3000 years ago (44).  VACV and HSPV are closely related and HSPV is 
now believed to possibly be the ancestor or at least related to the ancestor of the 
VACV lineage (13, 14, 16, 24), including the Brazilian vaccine strain known as 
VACV IOC and the two feral or field strains, CTGV and Serro 2 (12, 16).  Horsepox 
as a disease is rare and is now believed to be extinct in nature, at least in Europe (13, 
16, 24), with the only strain currently known being isolated from Mongolian horses in 
1976 (13, 16, 23, 24).  Interestingly, the genome contains genes that are fragmented 
in some VACV strains but has gene fragments of genes that are intact in other VACV 
strains, suggesting that multiple HSPV strains may have been the ancestors of 
different VACV lineages (13, 23).  A recent paper, however, detailed the generation 
of live synthetic chimeric horsepox virus (165), raising the possibility of studying the 
virus and others like it while also raising serious ethical and biosecurity concerns to 
some in the field (166-173).  This history of unintentional evolution of the vaccine 
strains has created pools of highly diverse quasispecies.  On a phylogenetic tree 
though, three obvious clusters form:  the American or Dryvax cluster, the South 
American cluster, and the Eurasian cluster , all of which are separate from both 





using multiple clustering methods, indicating how closely related these strains are and 
lending credence to the idea that HSPV may be the ancestor of VACV (12, 16).   
 
2.6.4 Accordion Model, Poxvirus Adaptation, and Experimental Evolution 
In the field of virology, it was generally believed that the polymerases of RNA 
viruses are more error-prone than those of DNA viruses.  The two sets of enzymes 
actually have similar fidelities.  What sets them apart is that the polymerases of DNA 
viruses have proofreading functions, so fewer mutations accumulate (174, 175).  
Additionally, some DNA viruses, like Herpesviruses and POXVs encode proteins 
involved in DNA repair (175).  This means that DNA viruses mutate and thus tend to 
evolve on a slower scale than their RNA counterparts (46, 160), with the ssRNA 
viruses having a mutation rate of 10-2 – 10-4 substitutions/site/year (46) and HIV-1 
having a spontaneous mutation rate of about 2 x 10-5 mutations/bp/replication.  In 
general, RNA viruses tend to have higher rates of mutations (43) and thus higher 
genetic variability (160).  What is becoming clearer though is that DNA viruses 
possess other ways of adapting to changing environments than simply relying on the 
mistakes of their polymerases.  Even among DNA viruses though, POXVs have not 
gotten much attention in this regard until recently.  For instance, more effort had been 
devoted to estimating the substitution rates of herpesviruses (43).  That said, it has 
now been calculated that OPXVs have a mutation rate of about 10-8 substitutions per 
nt per replication cycle (175).  This is in line with the calculated mutation rates of 
DNA viruses, on the order of 10-7 to 10-9 mutations per site per round of replication, 





Viruses make great models for studying evolutionary processes and evolution 
at the population level, due to their short generation times and high mutation rates, 
especially in the case of RNA viruses.  Genome sequencing advances and reductions 
in the cost of the process, in combination with short viral genomes, have made it 
easier to examine viral responses to both natural and artificial selection pressures.  
POXVs, due to their being DNA viruses and having fairly large genomes, have not 
been extensively used for population studies (43), although this has been changing 
(69, 122, 146, 174, 175).   
2.6.5 Genome Accordion Model 
POXVs, along with the other members of the Megavirales order, or the Giant 
Viruses (GVs) as they are also called (144) , are believed to have obtained their large 
genomes through successive steps of genome expansions, in the form of gene 
duplications and gene transfers, balanced by genome reductions, in the form of gene 
deletions (42, 56, 58, 143, 144, 151), with additional supplementation through the 
movement and amplification of diverse genetic mobile elements (143).  This 
multistep process is referred to as the accordion model of genome evolution.  In 
general, there does not seem to be a trend toward either genome expansion or genome 
contraction, as each expansion is balanced out by a reduction, at least for certain 
families of GVs (144).  Many pieces of evidence support this model of genome 
evolution for these viruses (69, 143, 144, 146, 174).  Additionally, it is possible that 
this process is not unique to the NCLDVs and may extend to all large DNA viruses 
and phages (143).  These findings also support the theory that genome gigantism 





different GV lineages (144).  It should be noted again, however, that all the current 
members of the OPXV genus appear to be an exception to this rule regarding the 
overall balance of genome size and/or content.  None have acquired or generated a 
gene not found in CPXV, with the lone exception being the short interspersed element 
(SINE) found in TATV (176), supporting the idea that CPXV most closely resembles 
the last common ancestor of this genus.  This finding also suggests that the members 
of this genus have undergone genome reductions, via amino acid changes and gene 
fragmentations and deletions, since that divergence, as they adapted to new hosts and 
environments (7, 42, 56, 176, 177).   
2.6.6 Nucleotide Composition and Codon Usage 
POXVs also have complex evolutionary processes acting upon their 
nucleotide composition and codon usage.  The nucleotide composition of POXVs 
seems to influence their codon preferences.  Interestingly enough, the codon usage of 
POXVs seems to be genus-specific, adding yet another layer to how evolution can act 
upon these viruses.  Specifically, the OPXV genus virus members analyzed in the 
2011 study by  RoyChoudhury et al. (177) all have AT-rich genomes.  Viruses with 
AT-rich genomes show an overall preference for A and T in the first two codon 
positions but a much stronger preference for A and T at the third codon position.  The 
POXVs with GC-rich genomes on the other hand preferred GC at the first codon 
position, AT at the second codon position, but strongly preferred GC at the third 
codon position.  This supported the finding that there was a strong and significant 
correlation between overall nucleotide composition and the nucleotide composition of 





phylogenetically close to each other, particularly those within the same genus, share 
similar nucleotide compositions.  These findings are interesting since the three 
positions are subjected to different evolutionary forces.  The first two positions are 
determined by selective constraints, while the third position is supposedly primarily 
determined by mutational pressures.  As such, it appears the third position may have 
greatly influenced the codon usage in POXVs, regardless of the overall nucleotide 
composition of the genome in question.  The authors also felt that this begged the 
question of whether mutational bias might have superseded the forces of translational 
selection during the evolution of codon bias in the Poxviridae family.  The third 
codon position preference led the authors to conclude that GC-rich POXVs probably 
evolved under much greater mutational pressures than AT-rich POXVs (177).   
All these evolutionary forces combined to largely determine the existing set of 
preferred codons for each GC- and AT-rich genus and may have ultimately led to a 
path for optimal fitness for the POXV genetic machinery.  Other factors such as gene 
length and expression level also appeared to affect codon usage patterns to some 
degree.  Sequence length directly affected the codon usage bias of all GC-rich genera 
and a few AT-rich genera, a group which does not include the OPXV genus.  In 
general, though, GC-rich POXVs have longer genes with higher codon bias, while the 
opposite is true for AT-rich POXVs.  The expression levels of genes showed a similar 
trend, in that genes with higher levels of expression in the GC-rich genera exhibited 
more codon usage bias while genes with lower levels of expression in the AT-rich 
genera showed more codon usage bias.  Not surprisingly these trends carryover to 





TA/AT and AA/TT and underrepresented in GC-rich viruses.  The opposite is true for 
GC-rich viruses, with GG being an exception to the rule.  Again, not surprisingly, 
AT-rich genera viruses preferred codons only which ended in A or U, while viruses 
from GC-rich genera only used codons with either a G or C at the third synonymous 
position (177).   
2.6.7 Gene Content 
Nucleotide changes have also been examined with regard to their effects on 
genome evolution and gene content, especially in the context of the OPXV genus.  
Specifically, the reductive evolution observed in this genus was found to be the result 
of single nucleotide polymorphisms (SNPs) and insertions/deletions (indels).  The 
accumulation of such mutations led to individual missense mutations and gene 
truncation and fragmentation via the introduction of early stop mutations (ESMs).  
These ESMs would obviously result in the loss of function of the protein in question 
and possibly the eventual elimination of that particular ORF.  Perhaps 
counterintuitively, this study by Hatcher et al. (176) found that out of all isolates 
tested, those with the shortest genomes contained the greatest number of deleted 
genes, deteriorating genes, and highest concentration of ESMs.  This may be because 
of a change in the selective pressures acting on the virus, such as when it encounters a 
new host.  Proteins that are no longer required for replication in a new host will be 
subjected to the accumulation of numerous mutations.  In fact, if a once-required 
protein becomes deleterious to the virus in its new setting, it will be selected against 
and gradually degraded until it is removed from the genome.  This will also save the 





proposed to be an important step in narrowing the host range of a virus, such as in the 
cases of VARV, ECTV, and MOCV.  Similar phenomena have been witnessed in 
symbiotic and obligate parasitic bacteria, which have smaller genomes than their free-
living counterparts.  From a research standpoint, such occurrences aid in determining 
when selection pressures are lost, as this mutation rate approaches the error rate of the 
viral DNA polymerase in the absence of selection pressure.  Despite the truncation 
and fragmentation of certain genes, it has been shown that many of them are still 
transcribed because promoters are often untouched or only minimally changed in 
genes that are in the beginning stages of degradation.  The authors point out, 
however, that this does not mean these transcripts are necessarily translated.  Even if 
they were, these proteins may not be functional.  The loss of its full repertoire of 
genes may provide a virus with the potential to maximize its replication in one or a 
few hosts, but it also runs the risk of encountering an evolutionary dead end.  In 
contrast, a virus such as CPXV that maintains a full complement of genes can 
maintain its ability to infect a more diverse range of hosts.  That being said, the 
authors warn that recombination between closely related OPXVs could occur and 
thus provide the genetic diversity needed to escape a potential evolutionary dead end, 
leading to the creation of novel host-specific pathogens (176).   
2.6.8 Adaptive Molecular Evolution 
Any genes and proteins still needed by the virus will more than likely 
continually be under selective pressures, with some genes/proteins experiencing 
greater selection than others.  As mentioned before, POXVs have a linear genome 





conserved across the entire POXV family (7, 178), both in terms of gene content and 
sequence (178).  The arrangement of these core genes is similar in ChPVs (7) and in 
OPXVs these genes form a continuous block in the middle of the genome (178).  
Genes on the terminal ends, however, are much more variable and diverse, as they 
tend to be involved in host interactions (7), (178).  Many of these are host species 
specific, meaning they have adapted to that particular host’s immune response.  Such 
genes include immune evasion genes that block apoptosis, inhibit cytokines, or inhibit 
the interferon (IFN) response.  A lot of these genes tend to be non-essential for the 
virus to replicate in cell/tissue culture, but virulence factors required for mediating 
interactions within its natural host.  Because of this, many of these genes are highly 
specialized and thus differ between different genera, between species within a genus, 
and even between different strains within the same species (178).  There are three 
types of selection that can occur regarding the ratio of non-synonymous to 
synonymous mutation fixation rates:  purifying selection, neutral selection, and 
diversifying selection.  In purifying selection, there is a higher rate of synonymous 
mutations compared to non-synonymous mutations, implying that there are stringent 
functional and/or structural constraints on a particular amino acid.  The highly-
conserved nature of the core region of the POXV genome would suggest that this 
region is under purifying selection, as non-synonymous mutations are more likely to 
have deleterious effects on the virus.  In neutral selection, the two mutation rates are 
equal and a change to a different amino acid at a certain residue has neither a positive 
nor a negative effect on the protein.  In diversifying selection, otherwise known as 





population at a greater rate than synonymous mutations.  Genes at the termini of the 
POXV genome, which would be involved in host-pathogen interactions are more 
likely to be under this kind of selection as they would be more amenable to change 
and thus possess greater sequence diversity than the central region (178).   
A paper by Esteban and Hutchinson (178) set out to investigate the selective 
pressures that act on the different regions of the POXV genome and see what role 
adaptive molecular evolution has played in the evolutionary history of POXV genes.  
They reasoned that the process of adaptive molecular evolution is a key mechanism 
for species divergence to take place and that finding proteins and/or specific residues 
under this kind of selection may aid in understanding gene function, identifying 
essential functional regions in genes of either known or unknown function, and 
categorizing genes of unknown function as ones involved in host interactions.  Using 
the CPXV-BR (Brighton Red) strain as a model, what they found was that, out of the 
175 gene families examined, 79 were found to be under diversifying selection, with 
20 of these having an as-of-yet unknown function.  Many of these 79 genes were, not 
surprisingly, found on the terminal ends of the genome and were modifiers of the host 
response to infection.  What was a bit surprising though was that genes involved in 
viral replication and virion structure were also demonstrated to be under diversifying 
selection.  The authors theorized that this may be due to these protein products being 
packaged into the virus particle.  Some of these proteins included A4, a major core 
protein and the most abundant protein in the virion (by weight), and A7, D8, and B5.  
This finding implicated a greater role for diversifying selection in host-interacting 





encompasses genes whose products interact with the host, such as major antigens 
(178).   
Furthermore, their analysis found that multiple POXV genes in the central 
region of the genome were also experiencing diversifying selection, which was not 
expected, as these genes are not typically considered when determining virulence.  
Some of these same gene products are packaged in the virion and thus may encounter 
the host antibody response, suggesting that non-immunomodulatory proteins may also 
contribute to virulence and that interactions with the host serve as the basis for 
adaptive molecular evolution.  Therefore, going forward, they felt it may be prudent 
to take adaptive molecular evolution into account in well-conserved genes in addition 
to major genomic differences when attempting to explain differences in virulence 
between strains of POXVs.  Such considerations may also prove useful when 
examining the potential for POXVs to adapt to new hosts, such as MPXV in humans.  
They concluded that diversifying selection plays an overall important role in POXV 
evolution and plays a more important role in the ends of the genome versus the 
center, though the latter should not be discounted.  Additionally, they felt their 
findings of residues under diversifying selection would provide groundwork for 
future mutagenesis studies related to determining if these sites are important for host-
specific interactions, like protein-protein contacts or immune epitopes.  This would be 
particularly useful when dealing with genes that have unknown or poorly-defined 
functions, as these data would provide a jumping-off point for characterizing these 





highlighting highly-conserved functional or diverse host-specific residues that would 
be of special interest (178).   
2.6.9 Experimental Evolution 
Up until now, all the methods discussed regarding POXV evolution have been 
primarily in the context of natural selective pressures.  These mechanisms all function 
in laboratory settings, under artificial selection, in a technique known as experimental 
evolution.  This allows researchers to study evolution in a controlled environment, so 
they can monitor when viral fitness begins to improve in a given scenario and under 
what conditions.  The advent of high-throughput sequencing, coupled with its 
decreasing cost, makes it easier to follow said changes in near real-time.  This has 
made it much more feasible to test the genome accordion model of POXV evolution 
(143, 144) under carefully regulated conditions (69, 146, 174, 175).  The first study, 
by Elde et al. (146), utilized a mutant VACV with the E3L gene deleted.  E3 is an 
antagonist of protein kinase R (PKR), one of the most potent innate defense sensors, 
which becomes activated upon detection of dsRNA in the cytoplasm.  This placed 
tremendous selection pressure on the VACV K3L gene, another antagonist of PKR.  
What they saw was that over the course of the experiment, multiple copies of the K3L 
locus were made and the genome expanded but that by the end only one copy 
remained.  This retained copy, however, had a mutation in it, H47R, which allowed 
K3 to better combat PKR and thus increase viral fitness (146).  Adaptive mutations 
don’t have to necessarily arise in the amplified locus, however, as Brennan et al. (69) 
showed in their paper.  Their study also looked at PKR and its antagonists.  The 





cytomegalovirus, in a VACV which had neither E3L or K3L.  Their findings revealed 
adaptive mutations in the A24R and A35R loci, neither of which had previously been 
implicated in PKR antagonism.    A24 is the catalytic subunit of the vRNAP, while 
less is known about A35.  What is known about A35 is that it is highly conserved in 
the OPXV genus and reportedly involved in modulation of the adaptive immune 
response.   These adaptive mutations arose at the same time the then-amplified 
rhtrs1locus was collapsing back into a single copy (69).  Similar results were obtained 
by Cone et al. (174).  In their experiments, they also used a VACV E3L deletion 
mutant, thus exerting great selection pressure on the K3L gene, just like Elde et al. 
(146).  This also resulted in a genome expansion involving the K3L locus (174).  
Unlike the results of the Elde et al. study, however, Cone et al. found adaptive 
mutations outside of K3, similar to Brennan et al. (69).  Unlike the Brennan et al. 
study though, the adaptive mutations found by Cone et al. were only located in the 
A24R locus.   
Such localized genome expansions allow viruses that have lower mutation 
rates, such as POXVs, to sample mutational space while allowing for temporary 
enhancement of gene expression (69, 146, 174).  Higher levels of expression are 
particularly useful in the case of a host-range gene such as K3L (69, 146, 174), and 
would confer a fitness advantage early in infection in which selection pressures are 
introduced, such as when a virus encounters a new host.  Once beneficial mutations 
arise, the subsequent contraction reduces the burden on the virus to replicate a larger 
genome.  In fact, during later stages of infection, viruses with expanded genomes may 





mutation (69, 146, 179).  Thus, this fairly straightforward mechanism of 
recombination-driven genomic expansions and contractions allows for more rapid 
viral evolution and adaptation than if said viral populations had to rely solely on their 
relatively low mutation rates (146).  Experimental evolution enables researchers to 
catch these transient genome expansions, which can be selected against in a 
population once it is no longer beneficial, and thus never discovered (146, 174).  This 
can be crucial since gene amplification and collapse is reportedly a dynamic process, 
at least in bacteria (69).  These studies highlight the fact that gene amplification or 
gene copy number variation (CNV), otherwise known as structural variation (174, 
175), plays an important role in adaptation of viruses with low mutation rates (69, 
146, 174).  This strategy of using CNV coupled with nucleotide substitution may also 
be utilized by other viruses with low mutation rates and somewhat limited restrictions 
on genome size, such as other large DNA viruses and phage (143, 146, 179).  Gene 
amplification followed by subfunctionalization or neofunctionalization of the gene 
copies is highlighted by the existence of families of paralogous genes in numerous 
DNA virus families (146, 179), via a process known as lineage-specific gene 
expansion (143).  Transient CNV can accelerate the fixation of mutations that provide 
a modest fitness advantage or even a potential fitness trade-off.  Thus, CNV can 
enable POXV adaptation, and virus evolution as a whole, through both direct and/or 
indirect means (174, 179).  Gene amplification is not just limited to viruses, however, 
and has been reported as a mechanism common to prokaryotes, archaea, and 
eukaryotes (69, 179).  Researchers can take advantage of this strategy, especially 





the case of adaptations within the amplified locus (146), and to identify potential 
novel host-range determinants and virulence factors, in the case of adaptations 
occurring outside of the amplified locus (69, 174).   
CNV is not the only mechanism by which POXV can adapt however.  As 
beneficial as it might be, it has yet to be identified in strains isolated out in the field, 
probably due to its transient nature (146, 175), and so far has only been confirmed in 
laboratory settings using cell culture and high selection pressures.  In fact, studies 
looking at POXV evolution have focused exclusively on changes at the genomic 
level.  One study set to examine POXV adaptation at the level of the proteome using 
CPXV as their model.  This study, by Grossegesse et al. (175), found that, overall, the 
genome was relatively stable during passaging.  While they found minor genomic 
variants, only one increased in frequency in both cell lines used.  This change was 
found in the A25R gene (A24R in VACV) and its increase in frequency correlated 
with the observed increase in viral fitness.  What they did find was that most of these 
variants mapped to the tandem repeats, or microsatellites.  These are found 
throughout the POXV genome and can account for about ¼ of the sequence.  ESMs 
have been found to accumulate in ChPV microsatellites, leading to the theory that 
microsatellite hypervariability is a major source of POXV genome variability, and 
thus, a source of POXV adaptation.  The authors felt their data supported the idea that 
microsatellite hypervariability is a mechanism by which CPXV adapts, at least in cell 
culture.  Their primary finding, however, was increased amounts of certain viral 
proteins over the course of the experiment.  They did admit though that this could be 





both.  The proteins identified could be functionally categorized in one of three ways:  
membrane-associated, immune evasion, and diverse enzymatic activities.  All the 
genomic variants were in genes involved in transcription, leading the authors to 
conclude that the proteomic changes were regulated at the level of transcription.  
Their findings implicate proteomic changes as a novel mechanism for POXV 
adaptation, which may also apply to other NCLDVs.  The authors did caution 
however that their study was only descriptive in nature and that the association 
between the observed proteomic changes in the presence of viral fitness changes was 






Chapter 3: RNA polymerase mutations selected during 
experimental evolution enhance replication of a hybrid vaccinia 
virus with an intermediate transcription factor subunit replaced 
by the myxoma virus ortholog1 
 
3.1 Summary 
High-throughput DNA sequencing enables the study of experimental 
evolution in near real time. Until now, mutants with deletions of nonessential host 
range genes were used in experimental evolution of vaccinia virus (VACV). Here, we 
guided the selection of adaptive mutations that enhanced the fitness of a hybrid virus 
in which an essential gene had been replaced with an ortholog from another 
poxvirus genus. Poxviruses encode a complete system for transcription, including 
RNA polymerase and stage-specific transcription factors. The abilities of orthologous 
intermediate transcription factors from other poxviruses to substitute for those 
of VACV, as determined by transfection assays, corresponded with the degree of 
amino acid identity. VACV in which the A8 or A23 intermediate transcription factor 
subunit gene was replaced by the myxoma (MYX) virus ortholog exhibited decreased 
replication. During three parallel serial passages of the hybrid virus with the 
MYXA8 gene, plaque sizes and virus yields increased. DNA sequencing of virus 
populations at passage 10 revealed high frequencies of five different single nucleotide 
mutations in the two largest RNA polymerase subunits, RPO147 and RPO132, and 
                                                 
1 Adapted from:  Stuart, C.A. et al.  2018. RNA polymerase mutations selected during experimental 
evolution enhance replication of a hybrid vaccinia virus with an intermediate transcription factor 
subunit replaced by the myxoma virus ortholog. J Virol 92(20): e01089-18. doi: 10.1128/JVI.01089-18 





two different Kozak consensus sequence mutations predicted to increase translation 
of the MYXA8 mRNA. Surprisingly, there were no mutations within either 
intermediate transcription factor subunit. Based on homology with Saccharomyces 
cerevisiae RNA polymerase, the VACV mutations were predicted to be buried within 
the internal structure of the enzyme. By directly introducing single nucleotide 
substitutions into the genome of the original hybrid virus, we demonstrated that both 
RNA polymerase and translation-enhancing mutations increased virus replication 
independently.   
3.2 Introduction 
The Poxviridae comprise a large family of viruses that infect vertebrates and 
invertebrates (40). During their evolution, chordopoxviruses segregated into 11 
recognized genera as well as additional unassigned species. Analysis of the genomes 
of representatives of the various genera showed that approximately 90 genes 
encoding proteins for essential functions, including entry, transcription, genome 
replication, disulfide bond formation, and virion assembly, have been preserved (57). 
A similar number of less well conserved genes are unnecessary for replication in cell 
culture; many of these genes are involved in host interactions and are present in only 
a subset of poxvirus genera (180). The diversity of the latter genes is likely related to 
their acquisition and adaptive modification during the long period of poxvirus 
evolution and speciation in various hosts (181). In some cases, these viral proteins 
counteract cellular innate immune responses, whereas others have roles that are 





In contrast to the relatively low rate of natural evolution within a single host 
species, propagation of vaccinia virus (VACV) as the smallpox vaccine in unnatural 
hosts such as calf skin and cell culture over the past 200 years has promoted rapid 
changes (183). A striking example of this is modified VACV Ankara (MVA), which 
lost approximately 15% of the genome and suffered a severe host restriction during 
>500 passages in chicken embryo fibroblasts (184). Presently, high-throughput 
sequencing methods enable investigation of the experimental evolution of poxviruses 
in near real time. Thus far, such studies have been limited to VACV host range 
mutants with deletions of genes involved in evasion of the PKR/eukaryotic initiation 
factor 2α (eIF2α) antiviral pathway (69, 146, 174, 185).  The genetic changes 
comprised both copy number amplification and point mutation of individual viral 
genes. We are seeking to extend experimental evolution to essential genes encoding 
proteins that have coadapted with other viral proteins during natural selection. Our 
approach is to swap orthologous genes from distantly related poxviruses, thereby 
encouraging the selection of adaptive mutations that enhance replication. In principle, 
the results could provide insights into protein interactions and pathways. In this first 
effort to apply orthologous gene swapping for experimental evolution of poxviruses, 
we targeted the transcription system.   
Poxviruses have three stages of gene expression: early, intermediate, and late 
(186).  An eight-subunit DNA-dependent RNA polymerase (Pol) that is homologous 
to the polymerases of archaea and eukaryotes (132, 187) acts in conjunction with 
stage-specific transcription factors and promoters. The VACV early transcription 





binds to the core region of early promoters and DNA downstream of the RNA start 
site, thereby altering the DNA conformation (188-190), and to the RNA Pol-
associated protein RAP94 (110, 191).  The intermediate factor is a heterodimer of 34- 
and 45-kDa proteins (117), and the late factor is comprised of 17-, 26-, and 30-kDa 
proteins (115). The intermediate and late transcription factors have no known 
catalytic activities, nor is there evidence of direct association with DNA or RNA Pol.   
The likelihood that chordopoxviruses use a common mechanism for mRNA 
synthesis can be inferred from the conservation of their transcription apparatus and 
from the sequence similarity and functional interchangeability of their promoters (70, 
192-194).  However, the compatibility of orthologous transcription factors has yet to 
be investigated.  Transient expression experiments described here indicated that 
orthologous intermediate transcription factors exhibit a range of compatibilities with 
VACV. Using this information, we constructed hybrid viruses in which the genes 
encoding the VACV 34-kDa (A8) or 45-kDa (A23) intermediate transcription factor 
subunit were individually replaced with the myxoma virus (MYXV) ortholog 
(abbreviated MYXA8 and MYXA23, respectively) and then carried out serial 
passaging of the poorly replicating viruses to allow experimental evolution and 
adaptive selection. Substantial increases in replicative abilities of the MYXA8 VACV 
were associated with mutations in RNA Pol subunits and sequence changes around 








3.3.1 Transient expression assays   
To initiate this study, we compared the A8 and A23 intermediate transcription 
factor orthologs of Chordopoxvirus genera. For diversity, we selected the genes from 
Myxoma virus (MYXV), Canarypox virus (CNPV), Nile Crocodilepox virus (CRV), 
and Salmon Gill poxvirus (SGPV), which encode proteins that vary in amino acid 
identity from 65% to 23% relative to VACV sequences (Table 3.1). The order of 
similarity to VACV was MYXV > CNPV > CRV > SGPV, consistent with their 

















































Table 3.1 Comparison of intermediate transcription factor orthologs 
Virus A8 
% amino acid identity 
A23 
% amino acid identity 
Vaccinia 100 100 
Myxoma 65 58 
Canarypox 38 51 
Crocodilepox 31 40 
























Our plan was to analyze intermediate gene expression after infecting cells 
with a recombinant VACV lacking the gene encoding A8, A23, or both (ΔA8, ΔA23, 
and ΔA8/ΔA23 strains, respectively) and transfecting DNA encoding corresponding 
orthologs.  Because the A8 and A23 genes are essential, deletion viruses were 
previously constructed with the aid of a complementing cell line that expressed both 
intermediate transcription factors (118). We made new versions of these viruses that 
constitutively express the bacteriophage T7 RNA polymerase so that a T7 promoter 
could be used for expression of A8 and A23 genes from transfected plasmids. The 
starting virus vTF7-3 (126) contains the A8 and A23 genes from the VACV Western 
Reserve (WR) strain and will be referred to here as the wild type (WT). The VACV 
A8 or A23 gene or both genes were deleted and replaced by the green fluorescent 
protein (GFP) or Discosoma sp. Red fluorescent protein (DsRed) open reading frame 
(ORF) regulated by a VACV promoter to facilitate isolation in the complementing 
cell line (Fig. 3.1A). Loss of the A8 and A23 ORFs was confirmed by PCR, and the 
inability of the viruses to express viral intermediate proteins was demonstrated by 





























Figure 3.1 Transient expression of intermediate transcription factor orthologs. (A) 
Recombinant VACV that express T7 RNA Pol and contains the VACV A8 and 
A23 intermediate transcription factors (A8/A23), only A23 (ΔA8), only A8 
(ΔA23), or neither A8 or A23 (ΔA8/ΔA23) were constructed by homologous 
recombination using GFP and/or DsRed as a reporter. In the scheme shown, for 
example, A8/A23 virus expresses both A8 and A23, while ΔA8 virus expresses a 
GFP reporter and A23. (B) Expression of A8 and A23 orthologs. BS-C-1 cells 
were infected with ΔA8 or ΔA23 virus and transfected with plasmids that encode 
A8 orthologs with V5 epitope tags or A23 orthologs with HA epitope tags 
regulated by T7 promoters. Following cell lysis, proteins were resolved on SDS-
polyacrylamide gels, transferred to membranes, and detected with anti-V5 and 
anti-HA antibodies. The poxviruses from which the A8 or A23 orthologs were 
derived are as follows: lanes 1, VACV; lanes 2, MYXV; lanes 3, CNPV; lanes 4, 
CRV; lanes 5, SGPV. C represents a control plasmid not expressing a protein. The 
masses in kilodaltons to the left of each blot indicate the mobilities of marker 





For construction of the A8 and A23 expression plasmids, the orthologous 
ORFs were mammalian-codon optimized to minimize differences in G/C content, 
which might affect expression. Each plasmid of one set contained an A8 ORF with a 
V5 epitope tag, while each plasmid of the other set had an A23 ORF with a 
hemagglutinin (HA) epitope tag. Expression of the proteins following transfection of 
the plasmids into cells infected with recombinant viruses is shown in Fig. 3.1B. Some 
differences in the intensities of the bands were noted, but the weaker bands were not 
enhanced by altering the amount of plasmid transfected.   
A plasmid with the firefly luciferase (Fluc) gene regulated by the VACV G8 
intermediate/late promoter (3, 186) was used to monitor the activities of the 
intermediate transcription factors. The scheme in which cells are infected with one 
recombinant VACV of the group expressing T7 RNA polymerase (ΔA8, ΔA23, and 
ΔA8/ΔA23) and transfected with one or two plasmids of the group containing the T7 
promoter (A8, A23, and both A8 and A23) in which A8 and A23 are derived from 
VACV, MYXV, CNPV, CRV, or SGPV and a second reporter plasmid, G8-Fluc, is 
outlined in Fig. 3.2A. Only the VACV and MYXV A8 genes allowed substantial 
expression of Fluc (Fig. 3.2B, left). In contrast, all of the orthologous A23 genes 
except the SGPV A23 gene enhanced Fluc in the order VACV > MYXV > CNPV > 
CRV (Fig. 2B, middle). In the experiments described so far, one of the intermediate 
transcription factor subunits was from VACV, while the other was one of the 
orthologs. We considered that the activities of the transcription factor orthologs might 
be relatively low because they had to work in concert with the VACV factor. 





and A23 and transfected two plasmids expressing both transfection factors from the 
same virus. However, the ranking was similar to that obtained by transfecting A8 or 




























































Figure 3.2 Complementation of intermediate gene expression by orthologous 
transcription factors. (A) Experimental plan. Cells were infected with ΔA8, ΔA23, 
or ΔA8/ΔA23 VACV encoding T7 RNA polymerase and transfected with 
plasmids encoding A8, A23, or both A8 and A23 (A8_A23) regulated by the T7 
promoter and with Fluc regulated by an intermediate/late promoter. Fluc activity 
depended on expression of A8 and A23 proteins. (B) The plan depicted in panel A 
was carried out by transfecting plasmids into HeLa cells infected with ΔA8, 
ΔA23, and ΔA8/ΔA23viruses. Relative luminescence values are shown. 
Experiments were carried out in triplicate, and the bars indicate the standard errors 





3.3.2 Construction of hybrid viruses   
We made hybrid viruses in order to further investigate the effects of 
orthologous transcription factors. Our strategy was to start with viruses that had A8 or 
A23 replaced by GFP or DsRed and then exchange the fluorescent reporter gene with 
MYXV or CNPV A8 with an N-terminal V5 tag or with A23 with an N-terminal HA 
tag by homologous recombination. The recombinant viruses with MYXV genes were 
detected by formation of nonfluorescent plaques in BS-C-1 cells, and three separate 
clones with MYXA8 or MYXA23 designated A, B, or C were isolated (Fig. 3.3A). 
The presence of the MYXV genes was confirmed by DNA sequencing. The MYXA8 
hybrid made predominantly tiny plaques, whereas the MYXA23 hybrid made 
intermediate-sized plaques (Fig. 3.3B). The different plaque sizes of the hybrid 
viruses were consistent with the relative activities of MYXA8 and MYXA23 in 
transfection experiments (Fig. 3.2B). A similar attempt to make CNPV and CRV A23 









































Figure 3.3 Plaque formation by hybrid viruses expressing VACV and MYXV 
intermediate transcription factors.  (A) Diagram of viruses expressing the VACV 
WRA8 and WRA23 (WT), MYXA8 and WRA23 (MYXA8), and WRA8 and 
MYXA23 (MYXA23).  (B) Plaques were stained with crystal violet at 48 h after 
infection of BS-C-1 cells with WT or three independent clones of the hybrid 





3.3.3 Experimental evolution   
The inefficient replication of the hybrid viruses containing MYXV 
transcription factors suggested that beneficial mutations might arise, perhaps in the 
transcription factors themselves, during serial passaging. The scheme shown in Fig. 
3.4A was carried out starting with stocks of the three independent plaque-purified 
clones (A, B, and C) of MYXA8 and MYXA23, which we refer to as passage 0 (P0). 
Ten passages were carried out, and a portion of each was frozen as the “fossil 
record.” Plaques formed with the MYXA8 virus at passage 10 (P10) exhibited a range 
of sizes, including many plaques larger than those of P0 (data not shown). In contrast, 
the plaques formed with MYXA23 did not significantly increase in size after 
passaging (data not shown). The 24-h yields of the MYXA8 P10 viruses were 3 to 5 
times higher than those of the P0 viruses, whereas the yields of MYXA23 did not 




































Figure 3.4 Experimental evolution of MYXA8 virus. (A) Scheme for serial 
passaging in BS-C-1 cells of MYXA8 virus containing the MYXV A8 and VACV 
A23 genes. After each passage, a sample was saved to serve as the fossil record. 
(B) Three clones of MYXA8 virus, designated A, B, and C in Fig 3.3, were 
independently passaged at a multiplicity of infection of approximately 0.1 
PFU/cell. Plaques formed in 48 h on BS-C-1 cells by WT virus containing the 
VACV A8 and A23 genes and by hybrid viruses at passage 0 (MYXA8 P0) and 
passage 10 (MYXA8 P10) plaque-purified clones from serial passages A, B, and 





Large plaques were picked from each of the three independent A, B, and C P0 
and P10 MYXA8 passages, and the viruses were plaque purified several times. The 
plaque-purified viruses from the series A, B, and C passage P10 populations are 
referred to as P10 clones A, B, and C, respectively, to indicate their origin.  The 
plaque sizes of the P10 clones, relative to those of the P0 and the WT virus with 
VACV A8, are shown in Fig. 3.4B. The plaque-purified P10 clones were significantly 
larger than those of P0, and the P10 A clones approached the size of the WT clones. 
The enhanced replication of the MYXA8 A, B, and C clones from P10 compared to 
levels of P0 and the WT are shown in Fig. 3.5. At 12 h, the titers of the P10 A and B 
clones were significantly higher than those of the P0 viruses, and by 24 h all three 























































Figure 3.5 Replication of MYXA8 P0 and P10 clones. Triplicate BS-C-1 cell 
monolayers were infected for 6, 12, and 24 h with 5 PFU/cell of WT virus, and 
MYXA8 P0 and P10 clones from passages A, B, and C. Virus titers were 
determined in duplicate by plaque assay in BS-C-1 cells. Bars represent standard 





 3.3.4 Genome sequencing    
Whole-genome sequencing was performed on the population of viruses in P10 
of series A, B, and C and on plaque-purified clones from each series after 
amplification in BS-C-1 cells. Both synonymous and nonsynonymous changes in the 
viral genome were found, and the complete sequences have been archived. The 
genetic changes considered most significant are listed in Table 3.2. Single nucleotide 
nonsynonymous mutations of RNA Pol were detected in each of the passage 
populations. Two of the mutations are in RPO147 (ORF J6), the largest subunit, and 
three are in RPO132 (ORF A24), the second-largest subunit. Two of the RPO132 
mutations were found in relatively high frequency in the passage B population but 
were not in the plaque-purified clone from this passage (Table 3.2). The five 
mutations are all different, indicating that they arose independently in the three 
separate passages. Sequence changes that potentially increase expression of MYXA8 
were also found (Table 3.2) and will be discussed below.  The mutations in the 


































Table 3.2 Mutation abundance in MYXA8 P10 passage population and clones 
Passage Series AA change ORF Gene  Passagea Cloneb 
A M424I J6R RPO147e 30% 100% 
 L013M MYXA8c MYXA8 20% 100% 
 
B A1212V J6R RPO147 6% 100% 
 None -3 MYXA8d MYXA8 18% 100% 
 A1026V A24R RPO132 14% 0% 
 A1133T A24R RPO132 30% 0% 
 















aPassage 10 virus was amplified prior to DNA purification.   
bVirus from large plaques was clonally purified and amplified.   
cNew translation initiation codon within N-terminal V5 tag preceding MYXA8 
ORF.   
dImproved Kozak sequence consensus sequence preceding N-terminal V5 tag; 
carries a single nucleotide change at the -3 position relative to the start codon.   





In addition to whole-genome sequencing of the cloned viruses and the P10 
population, we performed amplicon sequencing of genomes from sequential passages 
to determine when changes in the RPO147 and RPO132 sequences occurred (Table 
3.3). The mutation K1046Q in RPO132 was detected in P2 of the passage series C 
population and steadily increased in frequency, reaching 55% of the population at 
P10. The mutation M424I in RPO147 was detected at P4 of the passage series A 
population and increased to 24% of the population by P10. The mutation A1212V in 
RPO147 was detected at P8 of the passage series B population and was only 1.9% of 
the total population at P10. Note that the RNA Pol mutations of passage series A, B, 
and C increased to 30%, 6%, and 69% of the population, respectively, with the 
additional passages used to purify DNA for whole-genome sequencing, indicating 









































        Table 3.3 Changes in abundance of RNA pol mutations during passages 
 Frequency of mutations (%)a 
Passage No. %RPO147 M424I %RPO147 A1212V %RPO132 K1046Q 
0 ND ND ND 
2 ND ND 1.7 
4 3.0 ND 10.1 
6 6.1 ND 17.6 
8 11.2 1.2 38.1 
9 16.8 1.5 50.1 
























 3.3.5 RNA pol mutations increase replication of the MYXA8 hybrid VACV   
The RNA Pol mutations were mapped to the homologous Saccharomyces 
cerevisiae RNA Pol II (RNAP II) subunits (Fig. 3.6A). The yeast amino acids 
corresponding to the mutated ones are located internally, rather than in the solvent-
exposed surface where interactions with transcription factors might be expected. To 
determine the significance of the RNA Pol mutations in the absence of other sequence 
changes in the hybrid virus genomes, homologous recombination with PCR products 
containing the mutations was used to directly modify the P0 viruses. DNA segments 
of approximately 1,000 bp that encompassed the single nucleotide RNA Pol 
mutations were derived by PCR from the DNA of the cloned P10 viruses and 
transfected into BS-C-1 cells that were infected with the original MYXA8 P0 viruses. 
After 20 h, virus was collected, and individual plaques were screened by PCR and 
Sanger sequencing. Approximately 20 to 30% of the plaques had the desired 
mutations, attesting to the high rate of recombination, and no additional mutations 
were found by whole-genome sequencing. Following plaque purification and 
amplification, the plaque sizes of the mutated and cloned viruses were compared with 
those of the MYXA8 P0 virus containing the WT RNA Pol sequences. The plaques of 
the viruses with the RPO147 M424I mutation and the RPO132 K1046Q mutation 
were larger than those of the original MYXA8 virus (Fig. 3.6B), whereas the 
difference was small in the case of the virus with the RPO147 A1212V mutation (data 
not shown). Plaque size measurements of all three recombinant viruses are presented 





We also determined the virus yields following infection with 0.01 plaque-
forming units (PFU)/cell of the MYXA8 P0 clones, recombinant viruses with mutated 
RNA Pol, and WT virus.  Notably, the yields of viruses with the RPO147 M424I 
mutation from P10 clone A and the RPO132 K1046Q mutation from P10 clone C 
were higher than those of the P0 MYXA8 A and C clones, which had unmutated 
RPO147 and RPO132 (Fig. 3.6C), indicating that these mutations were adaptive.   
A competition experiment was carried out to confirm the ability of the 
recombinant virus with the RPO147 M424I mutation to enhance replication relative 
to the level of the original MYXA8 P0 virus. Three BS-C-1 cell monolayers were 
each infected with 0.01 PFU/cell of a mixture comprised of 90% MYXA8 P0 virus 
with the WT RPO147 sequence and 10% RPO147 M424I virus for 48 h. The cells 
were then harvested and titrated, and the virus was passaged two more times. After 
each passage, PCR and Sanger sequencing were performed to estimate the ratios of 
the WT RPO147 sequence and the mutated sequence. In the three independent 
experiments, the percentages of mutated sequence after passage 3 were ~90%, 70%, 
and 100% (Fig. 3.6D), demonstrating the selective advantage of the mutation. In a 
parallel competition experiment with WT VACV (90%) and WT VACV that had the 
RPO147 mutation (10%), the relative amounts of the two remained constant during 
the three passages (data not shown). Thus, the advantage of the RPO147 M424I 






















Figure 3.6 RNA Pol mutations. (A) Mutations in RPO147 and RPO132 that 
occurred during passages of MYXA8 were mapped onto the S. cerevisiae RNAP 
II crystal structure. Green, RPB1; blue, RPB2. (B) Single nucleotide mutations 
were inserted by homologous recombination into RPO147 and RPO132 of 
MYXA8 P0 viruses.  Plaques formed by the cloned recombinant viruses and a 
MYXA8 P0 virus are shown. (C) Virus yields at 2, 24, 48, and 72 h after infection 
with 0.01 PFU/cell of WT, MYXA8 P0 clone A (MYX-A8-A), MYXA8 P0 clone 
C (MYX-A8-C), and the recombinant viruses with single nucleotide mutations in 
RPO147 (M424I) or RPO132 (K1046Q). (D) Replication competition between the 
MYXA8 P0 clone A virus and the recombinant virus with mutation in RPO147. 
BS-C-1 cells were infected in triplicate with 0.01 PFU/cell of a mixture comprised 
of 90% MYXA8 P0 and 10% MYXA8 with the M424I mutation in RPO147. 
After each of three rounds of passaging, an aliquot was removed for Sanger 
sequencing of the region including the M424I mutation. Graphs of the sequence 
are shown with a dotted oval around the mutated nucleotide. The approximate 





 3.3.6 Mutations of translation initiation sequences of MYXA8 gene   
The P10 clones of passage A and B had a mutation that introduced a new 
translation initiation codon with an optimal Kozak sequence within the N-terminal V5 
tag and a mutation that was predicted to improve the original translation initiation 
sequence of the MYXA8 ORF, respectively (Fig. 3.7A). The nucleotides around the 
translation initiation codon of the V5-tagged MYXA8 in the original P0 clones are 
CTTATGG, with the ones at -3 and +4 underlined. Although the G at +4 is consistent 
with good translation initiation, a purine rather than a C is optimal at -3 (195). The 
single nucleotide mutation in P10 clone A introduced a new translation initiation 
codon with preferred nucleotides at both -3 and +4 (GGCATGG) within the V5 tag of 
clone A, while the mutation in P10 clone B changed the C at -3 to a preferred A. 
Homologous recombination with mutated PCR product was used to introduce these 
mutations into the MYXA8 P0 clones, similar to the protocol used to make the RNA 
Pol mutations. Random plaques were selected for Sanger sequencing, and those with 
the expected mutation were cloned. Comparison of the plaques formed by a MYXA8 
P0 clone and the recombinant viruses revealed that the latter produced larger plaques 
(Fig. 3.7B).  As anticipated, the V5-tagged MYXA8 protein was expressed more 
highly in cells infected with the virus with the clone B mutation than with the 
MYXA8 P0 clone, whereas E3, another early viral protein, was expressed in similar 
amounts (Fig. 3.7C). A comparable Western blot analysis of the P10 clone A mutant 




















Figure 3.7 Mutations at translation initiation sites of the MYXA8 gene. (A) The 
nucleotide and amino acid sequences around the N-terminal V5 tag of the 
MYXA8 gene in the original construct and the nucleotide mutations in the P10 A 
and B clones are shown. The ATG start codon at the start of the tag sequence is 
shaded green, and the nucleotides at the -3 and +4 positions are underlined. The 
new ATG within the V5 tag of the clone A mutant is shaded yellow. (B) Single 
nucleotide mutations were inserted by homologous recombination into the 
MYXA8 P0 virus genome to introduce a new start codon within the V5 tag (clone 
A mutation) or at the -3 position relative to the original start codon (clone B 
mutation). Plaques formed in BS-C-1 cells after 48 h by the cloned recombinant 
viruses and the MYXA8 P0 virus are shown. (C) Expression of the MYXA8 
protein. BS-C-1 cells were infected with MYXA8 P0 and the virus with the clone 
B at a multiplicity of infection of 5 PFU/cell. At 8 and 12 hpi, the cells were 
harvested, and the proteins were analyzed by Western blotting with antibody to V5 





 3.3.7 Comparison of plaque sizes of clonal isolates and recombinants with 
single nucleotide changes   
The P10 clone A and B viruses had both RNA Pol and translation initiation 
site mutations. In order to determine the relative contributions of the individual 
mutations, we compared the plaque sizes of the P10 clones with those of mutants with 
single nucleotide changes in either an RNA Pol subunit or MYXA8 translation 
initiation sequence. The measurements in Fig. 3.8 are presented as box-and-whisker 
plots: the top and bottom of the box show the upper and lower quartiles, the 
horizontal line within the box is the median, and the vertical lines are the maximum 
and minimum values, with the dots representing outliers that are more or less than 3/2 
of the upper and lower quartiles, respectively. The plaque sizes of the viruses with 
individual RNA Pol mutations were each larger than those of the MYXA8 P0 virus. 
The plaques formed by the K1046Q mutant virus were similar in size to those of the 
P10 clone C virus, confirming that the latter had no other significant adaptive 
mutations, as indicated in Table 3.2. In contrast, the plaques formed by the M424I 
and A1212V RNA Pol mutant viruses were smaller than the clone A and B P10 
viruses, which also had mutations in the MYXA8 Kozak consensus sequences (Table 
3.2). Furthermore, the plaques of the mutants with changes in the Kozak consensus 
sequences were also larger than those of the MYXA8 P0 virus, indicating that the 
latter as well as the RNA Pol mutations were adaptive. However, none of the P10 
clones made plaques as large as those of the WT VACV (Fig. 3.8). The color coding 


















Figure 3.8 Comparison of plaque sizes of recombinant and passaged virus clones. 
The plaque sizes of recombinant viruses with RNA Pol or Kozak sequence 
mutations, of MYXA8 P10 clones, of MYXA8 P0 clone A, and of WT virus with 
the VACV A8 gene are shown. Three independent wells, for a total of 150 to 300 
plaques, were analyzed for each virus. Box-and-whisker plots are shown. Color 
coding: red, clone A and recombinant viruses with individual mutations in that 
clone; violet, clone B and recombinant viruses with individual mutations in that 
clone; yellow, clone C and the recombinant virus with the individual mutation in 






Experimental evolution studies are usually carried out with RNA viruses, 
which are facilitated by high rates of mutation compared to those of DNA viruses. 
The low mutation rate of VACV has been attributed to intrinsic 3`→ 5` exonuclease 
activity of the viral DNA polymerase (196-198). Nevertheless, recent studies have 
shown that adaptation of VACV host range mutants with deletions of genes involved 
in evasion of the PKR/eIF2α antiviral pathway can occur both by gene amplification 
and point mutations during serial passaging (69, 146, 174, 185).  We initiated the 
current project to investigate experimental evolution of essential genes and chose the 
A8 and A23 intermediate transcription factor genes for this purpose. Since there were 
no mutagenesis studies of these essential proteins, we replaced the VACV factors 
with orthologs from other chordopoxvirus genera. Transfection experiments indicated 
that the ability of orthologs to functionally substitute for their VACV counterparts 
corresponded directly with amino acid sequence identity values. We were able to 
individually substitute the genes encoding the MYXA8 and MYXA23 proteins, 
which had ~60% amino acid identity with the VACV proteins, but not those of CNPV 
and CRV, which had 51% and 40% identity, respectively. Both MYXA8 and 
MYXA23 hybrid viruses made smaller plaques than the WT virus, but MYXA8 
produced the smallest, providing a better model virus for experimental evolution.   
Viruses that made larger plaques and replicated to higher titers than the 
original VACV MYXA8 virus arose during each of three parallel serial passages. 
Since the hybrid viruses had an MYXV intermediate transcription factor, we had 





intermediate transcription factor subunit or in the RNA Pol. Although we found no 
mutations in either transcription factor subunit, two different single nucleotide 
mutations in two independent passage series predicted more efficient translation of 
MYXA8 mRNA.  More interesting was the occurrence of RNA Pol mutations in each 
of the three parallel passages: there were two independent mutations in RPO147 and 
three in RPO132, the largest and second largest of the eight subunits in VACV RNA 
Pol, respectively. The RNA Pol mutations were not detected in P0 but varied from 6 
to 69% of the entire population after P10, suggesting strong selection. Amplicon 
sequencing of specific RNA Pol mutations confirmed progressive increases in 
mutation frequency in successive passages. Although we did not detect gene 
duplications in the P10 populations, such changes could have occurred transiently in 
earlier passages that were not examined by whole-genome sequencing.   
Three MYXA8 viruses were clonally purified from the P10 populations, each 
of which formed larger plaques than the MYXA8 P0 clones. The P10 A and B clones 
each had mutations in RNA Pol and the translation site of the MYXA8 gene, while 
P10 clone C had only an RNA Pol mutation. To attribute phenotypic changes to 
single nucleotides, we mutated the RNA Pol of MYXA8 P0 viruses by transfection of 
~1,000-bp PCR products. The high rate of recombination, which allowed this simple 
procedure without a selection marker, is not generally appreciated and for this 
purpose is far simpler than the transient dominant selection method (199). The 
absence of any other changes in the mutant viruses was verified by whole-genome 
sequencing. These recombinant viruses allowed us to prove that RPO147 M424I and 





RPO147 A1212V mutation had a smaller effect.  Furthermore, a competition 
experiment carried out between the RPO147 M424I mutant and the MYXA8 P0 with 
WT RPO147 virus demonstrated that the mutant rapidly became dominant. The 
plaque size and virus yield of the RPO132 K1046Q mutant were similar to those of 
the P10 clone C virus, confirming the absence of other adaptive mutations in the 
latter.  While the RPO147 M424I and RPO147 A1212V mutant viruses made larger 
plaques than the MYXA8 P0 clones, they were smaller than those of the P10 A and B 
clones, suggesting that the MYXA8 translation site mutations in the P10 clones were 
responsible.  The MYXA8 gene in the starting virus has a C at the -3 position and a G 
in the +4 position relative to the first nucleotide of the translation codon. According 
to the Kozak model, G at +4 is a good context for high translation initiation, but a 
purine is preferred to the C at -3 (195). Interestingly, a C→A mutation in the -3 
position relative to the ATG start codon of MYXA8 occurred in one P10 clone. In the 
other P10 clone, the point mutation created a new ATG with a good Kozak consensus 
sequence within the N-terminal V5 epitope tag. Genome sequencing of the passage 
10 populations revealed a frequency of 18% for the C→A mutation and a frequency 
of 20% for the new ATG, suggesting that selection had occurred. Homologous 
recombination was used to make these exact mutations upstream of the MYXA8 open 
reading frame of the original virus.  In each case, the mutants enhanced virus 
replication, as shown by the presence of increased plaque size. In addition, Western 
blotting with anti-V5 antibody showed that the C→A mutation increased expression 
of MYXA8. Although the mutation within the V5 tag likely increased expression as 





detect the protein. Curiously, the Kozak mutation within the V5 tag conferred higher 
replication than the upstream Kozak mutation, suggesting the possibility that the V5 
tag is deleterious and that the disruption is beneficial.  However, previous studies 
showed that addition of a V5 tag to the VACV A8 protein did not have a noticeable 
effect (118).   
Based on homology with the yeast RNA Pol, the mutations in RPO147 and 
RPO132 were predicted to be located internally near the catalytic site rather than in a 
solvent-accessible region where interaction with other proteins might occur. This 
would suggest that the mutations do not directly enhance binding of the transcription 
factors.  Some mutations found by other investigators in RPO147 (A535V and 
S288Y) and RPO132 (Y462H) confer resistance to isatin-β-thiosemicarbazone (IBT) 
by reducing transcription elongation (121, 122). In addition, mutants in RPO132 were 
found during experimental evolution with E3 deletion mutants that have defects 
related to doublestranded RNA with activation of the oligoadenylate synthetase 
(OAS)/RNase L and PKR/eIF2α pathways. In one report, an RPO132 T1120M 
mutation partially reduced PKR phosphorylation and prevented eIF2α 
phosphorylation, resulting in increased viral protein synthesis and resistance to IBT 
(10), whereas in another report, an RPO132 Leu18Phe mutation increased levels of 
PKR and eIF2α phosphorylation; an RPO132 Lys452Asn mutation elicited no change 
in PKR and eIF2α phosphorylation compared to levels in the E3 deletion mutant 
(174). Thus, the previously described RNA Pol mutations appear to have diverse 





We plan to investigate the role of RNA Pol mutations in enhancing replication 
of MYXA8 in a follow-up study. We are considering several possibilities: (i) that the 
mutated RNA Pol is more promiscuous and less dependent on intermediate 
transcription factors for RNA synthesis, (ii) that the mutations slow down 
transcription, allowing more time for the heterologous transcription factors to act, and 
(iii) that diminished processivity may reduce double-stranded RNA and indirectly 
enhance replication. With regard to the last idea, it will be interesting to determine the 
effects on replication of MYXA8 of previously described mutations in RPO147 and 
RPO132. To conclude, we have shown that accelerated experimental evolution can be 
achieved by swapping orthologous poxvirus transcription factor genes and suggest 
that this approach is generally applicable to interrogating additional gene functions.   
3.5 Materials and Methods 
3.5.1 Construction of deletion and hybrid viruses 
RK13 A8-23 cells (118) in 24-well dishes were infected with 0.05 PFU/cell of 
vTF7-3, a WR strain of VACV that encodes the bacteriophage T7 RNA Pol regulated 
by a VACV early/late promoter (126). After 1 h, the cells were washed with fresh 
medium and transfected with 2 μl of Lipofectamine 2000 (Invitrogen) and 500 ng of a 
PCR product encoding GFP or DsRed regulated by the VACV p11 late promoter and 
sequences flanking the A8 or A23 gene, respectively.  In the case of the A8 deletion, 
all of the N-terminal nucleotides of as well as three nucleotides in the preceding 
intergenic region were deleted, but 28 nucleotides of the C terminus were retained 





nucleotides were deleted, but 47 nucleotides at the C terminus were retained because 
of overlap of the A24 gene. The medium was replaced after 24 h, and the incubation 
continued for 48 h. Diluted cell extracts were used to infect fresh RK13 A8-23 cell 
monolayers, which were then overlaid with 0.5% methylcellulose. After 48 h, 
fluorescent plaques were picked with sterile toothpicks. The viruses were clonally 
purified by repeated plaquing on RK13 A8-23 cells, and the purity was assessed by 
PCR. Deletion of both A8 and A23 from the same virus was carried out by successive 
deletion of the individual genes.   
Hybrid viruses containing orthologous mammalian codon-optimized A8 or 
A23 genes were constructed using a similar recombination protocol in HeLa cells, 
except that the mammalian-optimized ortholog replaced GFP or DsRed, and 
identified by formation of non-fluorescent plaques in BS-C-1 cells.   
3.5.2 Construction of expression plasmids 
Nucleotide sequences for the A8 and A23 orthologs were obtained from 
GenBank and included VACV WR (accession number NC_006998), MYXV-6918 
(EU552530), CNPV-VR111 (NC_005309), CRV (NC_008030), and SGPV 
(NC_027707). The genes were codon optimized for expression in mammalian cells 
and synthesized by Life Technologies GeneArt Gene Synthesis service. Primers were 
designed to amplify genes from the plasmids supplied by the company using Phusion 
High-Fidelity (HF) master mix with HF buffer (M0531L; New England Biolabs 
[NEB]). The PCR products were purified using a QiaQuick PCR purification kit 
(catalog no. 28104) and inserted into a Blunt TOPO vector (45-0245; Invitrogen). A8 





DNA was extracted using a QiaPrep Spin Miniprep kit (catalog no. 27106).  Colonies 
of transformed Escherichia coli were picked and grown, and the DNA was sequenced.   
3.5.3  Western blotting for analysis of plasmid expression 
HeLa cells were infected with 3 PFU/cell of vTF7-3 for 1 h and then 
transfected with 500 ng of plasmid in Lipofectamine 2000. Samples were incubated 
overnight at 37℃ and harvested. Anti-V5 (ab27671; Abcam) and anti-HA (H3663; 
Sigma) antibodies were used to detect expression of the viral proteins. Secondary 
antibodies were fluorescently labelled (1:10,000; Li-Cor). Bands were visualized 
using a Li-Cor Odyssey CLx.   
 3.5.4  Luciferase assays 
HeLa cells were infected in triplicate with 3 PFU/cell of the deletion viruses 
and then transfected with 500 ng of one or both A8 and A23 plasmids and the 
luciferase plasmid. Cells were incubated at 37℃ for 12 h, and luciferase activity was 
measured (catalog no. E1501; Promega) with a luminometer (Berthold Detection 
Systems) and normalized to the activity of the WR orthologs. Samples were diluted to 
keep readings in the linear range.   
 3.5.5  Serial passaging of hybrid viruses 
BS-C-1 cells in 10-cm-diameter dishes were infected with 0.1 PFU/cell at 
37℃, harvested at 48 h, and then resuspended in 1 ml of medium. The cells were 





 3.5.6  Whole genome sequencing 
DNA was purified as described by Esposito et al. (200) with minor 
modifications. T75 flasks of BS-C-1 cells (~1x107 cells) were infected and 2 to 3 
days later collected by scraping. Cell pellets were washed with phosphate-buffered 
saline (PBS) and resuspended in 400 μl of 20 mM Tris, pH 8.0, 5 mM EDTA, and 1% 
Triton X-100; 10 min later, NaCl was added to a final concentration of 0.2 M. The 
cell extract was centrifuged at 800 x g for 3 min, and the nuclear pellet was discarded. 
The supernatant was treated with proteinase K in 0.5% SDS for 1 h at 50℃, and the 
DNA was extracted with phenol. Two volumes of ethanol were added to the aqueous 
phase; the visible threads of DNA were collected by brief centrifugation and washed 
twice with 80% ethanol, and the pellet was dissolved in 100 μl of water. Genome 
sequencing was done with an Illumina Miseq 2- by 150-bp configuration by the 
Genewiz company or the NIAID core facility.   
 3.5.7  Amplicon sequencing 
Amplicon sequencing was carried out by either Illumina or Sanger 
sequencing.  For the latter, the PCR primers were designed to produce a product of 
about 400 bp with the mutation in the middle. Cells were lysed by three freeze/thaw 
cycles and sonication, and 4 μl of the lysate was used for PCR in 50-μl reaction 
volumes (Phusion High-Fidelity PCR Mix; NEB). PCR products were purified by a 
Qiagen PCR kit, and Sanger sequencing was performed with the original primers 
used for PCR. The percentage of a mutation was estimated based on the heights of the 
peaks corresponding to specific nucleotides. For better quantitation, primers were 





the PCR products were analyzed by ultradeep sequencing on the Illumina Miseq 
platform by Genewiz.   
 3.5.8  Introduction of single nucleotide mutations into the VACV genome 
BS-C-1 cells were infected with 3 PFU/cell of VACV and after 1.5 h 
transfected with a PCR product of approximately 1,000 bp with the desired nucleotide 
change in the middle. At 18 to 20 h after infection, the cells were lysed, and diluted 
virus was used to infect BS-C-1 cells. At 48 h, the virus from individual plaques was 
placed in 250 μl of medium and subjected to three freeze-thaw cycles, and 4 μl of the 
lysate was used for PCR with the original primers in a 50-μl reaction volume 
(Phusion High-Fidelity PCR Mix; NEB). PCR products were purified with a Qiagen 
PCR kit, and clones with mutations were identified by Sanger sequencing. The clones 
with the desired mutations were plaque purified once more; 100 μl of the virus from 
the plaque was used to infect wells of a 24-well plate of BS-C-1 cells, and virus was 
collected after 2 to 3 days when the cytopathic effect was complete. For the second 
passage, six wells of a six-well plate were each infected with aliquots from the first 
passage.   
 3.5.9 Plaque size determination   
BS-C-1 cells were infected and covered with 0.5% methylcellulose.  After 48 
h at 37C, the plates were stained with 0.1% crystal violet and scanned using a Canon 
9000F Mark II color image scanner. Plaque sizes were determined using ImageJ, 
version 1.51w, software.  Three independent wells, for a total of 150 to 300 plaques, 





 3.5.10 Statistical analysis 
Statistical analysis was carried out using GraphPad Prism (version 7.0c). 
Unpaired two-tailed t tests were performed and P values of <0.05 were deemed 
statistically significant.   
 
 3.5.11 Competition experiment 
Approximately 2.5x105 BS-C-1 cells were infected in triplicate with 0.01 
PFU/cell of a virus mixture comprised of 90% MYXA8 P0 clone and 10% MYXA8 
with the M424I mutation in the RPO147 gene. After 48 h, the cells were resuspended 
in 250 μl of medium. Virus was released by three freeze-thaw cycles and sonication, 
which was followed by two additional passages in BS-C-1 cells at 0.01 PFU/cell for 
48 h.   
 3.5.12 Mapping of VACV RNA pol mutations on the eukaryotic RNA pol 
structure 
Alignments between the VACV J6 (RPO147) and A24 (RPO132) gene 
products and S. cerevisiae RPB1 and RBP2 subunits of RNAP II were generated 
using the PRALINE web server (201) (http://www.ibi.vu.nl/programs/pralinewww/).  
Corresponding J6 and A24 variant residues were then mapped onto the S. cerevisiae 
RNAP II crystal structure (PDB accession number 5U5Q) by use of Chimera software 
(202) (http://www.cgl.ucsf.edu/chimera/).  Accession number(s). Data are available at 








Chapter 4:  Discussion and Future Directions 
4.1 Functional Compatibilities and Incompatibilities of Poxvirus Intermediate 
Transcription Factor Orthologs 
It was established that the promoters between different genera of POXVs were 
functionally interchangeable (36-38, 194).  In this project, we wanted to determine if 
this applied to the intermediate transcription factors.  We chose the intermediate 
transcription factors because little is known about them and both deletion viruses and 
a complementing cell line had previously been generated in our lab by Warren et al. 
(118).  The viruses used in this study were generated in a similar fashion except that 
instead of the VACV WR backbone being used, the vTF7-3 parental virus was used.  
This virus, also generated in our lab by Fuerst et al. (27, 126), constitutively expresses 
the T7 RNA Polymerase.  Our plan was to put the ITF orthologs used into a plasmid 
under a T7 promoter, so they could be expressed when transfected in with the 
knockout viruses.  The next step was choosing the orthologs to test.  We did not work 
with the closely related ones, such as CPXV and MPXV, since those were likely to 
work just as well as the native wild-type genes, which were going to be used as 
positive controls.  Our initial plan included using orthologs from Sheeppox (SPV) but 
biosecurity/biosafety concerns were raised by the company performing the codon 
optimization.  We then chose from a list of safer options and thus settled on our 
current list of orthologs which we felt would provide varying levels of rescue, 
including one which we thought might not work under the experimental conditions, 





ortholog plasmids were generated, we had to check that they all behaved as expected 
before proceeding with the initial experiments.   
The results of the luciferase assays turned out as we had expected, with the 
orthologs giving a spectrum of activities, with the SGPV orthologs having no activity.  
Even more fittingly, the level of complementation corresponded to the level of amino 
acid identity, relative to the WR genes, even when both subunits came from the same 
virus.  This meant that there were inherent differences between the orthologs.  
Building off these results, we then wanted to see if we could generate replication-
competent viruses with the compatible orthologs. We were able to do so successfully 
with the two MYXV orthologs but not the CNPV and CRV orthologs, perhaps due to 
reduced compatibility with the other components of VACV transcription system.  We 
then reasoned that, if passaged enough times, these hybrid viruses would accumulate 
mutations that increase viral replication.  We thought that the most likely candidates 
to mutate would be the orthologs themselves, followed by the vRNAP.  During and 
after the experiment, we observed noticeable increases in viral fitness associated with 
the hybrid virus containing the MYXV A8 ortholog.  WGS results confirmed the 
presence of mutations not present in the parental or starting viruses.  While we did 
discover mutations present in the two largest subunits of the vRNAP, we did not find 
any mutations within the MYXV A8 ortholog.  Additionally, those mutations that 
were in the vRNAP all seemed to map to the interior of the enzyme, making it 
unlikely they were involved in interactions with the ITFs.  These findings led us to 
speculate that these mutations may affect the processivity or promiscuity of the 





4.2  Characterization of Mutations 
Our initial focus was on the mutations found in the vRNAP.  We found it 
particularly interesting that independent passages had their own unique RNAP 
mutations with a total of 5:  2 in the largest subunit and 3 in the second largest 
subunit.  We had reasoned that the vRNAP would be the second likeliest place for 
adaptive mutations to arise.  Upon re-examining our sequencing results, however, we 
also found two independent mutations in upstream regions of the MYXV A8 ortholog 
in two of the three independent passages.  The nature of these two mutations, which 
improved the Kozak consensus sequence, led us to think that they might result in 
increased expression of the MYXV A8 ortholog, which should be of benefit to the 
virus.  Our first step, though, was to confirm that the RNAP mutations increased in 
frequency in their respective populations over the course of the experiment, which 
would be expected if they were indeed beneficial.  This was done using both Sanger 
and Amplicon sequencing, which supported the idea that these mutations increased 
viral fitness.  This still needed to be confirmed experimentally though, so each 
mutation was introduced individually into the starting virus via homologous 
recombination.  Each mutation on its own enhanced the ability of the virus to 
replicate, as measured by plaque and spread assays.  The mutations found related to 
the MYXV A8 ortholog expression were reassuring in two regards.  First, we had 
thought this would be the most likely place for mutations to arise, although we 
hypothesized they would be within the gene itself.  Secondly, they helped explain 
why our initial experiments introducing the RNAP mutations back into the starting 





passage-derived mutants.  These mutations only appeared to be beneficial in the 
context of the poorly-replicating hybrid starting virus, and not the wild-type virus, in 
the competition assay, at least regarding RNAP Mutation 1 or A.   
Our next step in the process of characterizing these mutations was trying to 
determine the mechanism(s) by which they enhanced viral replication and if there 
were any fitness trade-offs associated with them.  The A24R gene has been 
implicated in experimental evolution studies before as a prime target in which 
adaptive mutations arise (69, 174, 175).  We wanted to see if our hypothesis 
regarding increased expression of the MYXV A8 ortholog would be supported by 
data, so western blots were done to look at levels of expression compared to the 
viruses with no mutations.  In the cases of P10B, P10C, MutB, expression of the 
MYXV A8 ortholog was greater at certain time points compared to viruses without 
the mutation present, including the starting virus (see Fig. A3).  This is obviously 
beneficial to the virus, but how is still uncertain.  Unfortunately, we cannot say this is 
the case with P10A/MutA right now, as the V5 epitope tag is no longer expressed and 
thus cannot be recognized by the antibody.  D13 protein expression was not 
significantly different between WT, the P0 clones, and the P10 clones (see Figs. A2 
and A3).  Assays using ddPCR were also performed with the recombinant viruses, 
but the results did not show any significant differences in transcript levels between 
them and the P0 virus (see Fig. A4).   
IBT resistance results showed a range of phenotypes (see Fig. A5).  The IBT-
resistant mutant first characterized by Condit et al. (120) was used as a positive 





the P0 virus were used as negative controls.  What we found was that certain 
mutations, specifically MutC and the B Mut, conferred more resistance than MutA in 
comparison to the wt and P0 viruses.  The resistant mutant, IBTr90, grew the best in 
the presence of the drug.  The titer of the virus was only about a log or so higher than 
the titers for the MutC and B Mut (see Table A1) viruses.  MutA has mutation in 
RPO147, while MutC is an RPO132 mutation, just like IBTr90.  What these results tell 
us though is that even though these mutations all provide a growth advantage, they 
may do so using different mechanisms and with different fitness tradeoffs.  A plaque 
size reduction assay was also attempted but it was unsuccessful.   
Western blots were also done to see if PKR and eIF2 phosphorylation 
patterns/levels were affected compared to wild-type, but the results were 
inconclusive.  They would also have to be done and/or repeated with the recombinant 
viruses.  Various mutations in A24R have also been implicated in the PKR/eIF2 
pathway, with some found to increase activation while others had no effect, even 
though the mutations were all beneficial to the virus (69, 174).  This suggests a more 
complicated mechanism in which these mutations affect viral growth in different 
ways despite resulting in the same overall phenotype.  Theoretically, IBT resistance 
and the PKR/eIF2 could be connected, as those IBT-resistant mutants may be 
defective in transcription elongation, as was found with the Condit mutation (121).  
This should in turn to the less dsRNA being produced, which should reduce the 
amount of PKR activation.  As such, certain phenotypes could be tied together 
conceivably.  In this case, the more IBT-resistant the mutant is, the lower amount of 





4.3  Future Directions 
There are numerous avenues that could be explored on this project.  One 
would be to attempt again to generate the hybrid viruses with the CNPV and CRV 
orthologs, if it is indeed possible.  It would be interesting to characterize those viruses 
and then passage them similar to the MYXV hybrid viruses.  Would the same or 
similar mutations arise, or would we discover more drastic changes in the viral 
genome since neither of these orthologs worked as well as either of the MYXV 
orthologs?  Alternatively, it would be interesting to see if the mutations that enhanced 
MYXA8 replication would also enhance CNPV and CRV.   
The mechanism by which these various mutations benefit the virus still need 
to be determined.  Is there increased transcription or translation?  Is it specific to 
intermediate and late genes or are early genes affected?  This would be particularly 
interesting regarding the RNAP mutations, as we would be able to state whether they 
have a global effect or only affect certain classes of genes.  As for the transcriptional 
regulation, the ddPCR experiments would need to be repeated to get clearer results, 
but the answer seems to be no as of right now.  This appears to also hold true for the 
translational regulation.  Another possible way to examine transcription would be to 
do an in vitro assay.  This technique, however, requires a lot of purified materials and 
is more labor-intensive than ddPCR.     
While it seems these RNAP mutations do not benefit wild-type virus, it would 
be ideal if we could also test the A8 mutations but that is impractical in the case of 
Mutation A.  Perhaps mutation B could be tested, but we do not have antibodies 





tagged.  This problem could be solved if a revertant virus was made using the codon-
optimized and tagged VACV A8R gene.  This way we could actually measure 
expression of the VACV A8 protein and see if the mutation increases said expression, 
which we would expect it to.  Granted, this is not the same as looking at the native 
protein in the wild-type virus, but this would be the best we could do until antibodies 
against the native protein were generated.  Unfortunately, the nature of Mutation A 
rendered the V5 tag irrelevant, so as of right now we cannot test whether expression 
of the MYXV A8 ortholog is indeed increased in this case, as with Mutation B.  The 
secondary start codon would also negate the workaround mentioned above with the 
hypothetical VACV A8 revertant as the V5 tag would still not be within the coding 
region.  Checking expression with Mutation A would require an antibody to the 
native A8 protein itself or the codon-optimized version if it was attempted with a 
revertant.  The nature of Mutation A, however, may make it unnecessary in the wild-
type virus, as a secondary start codon would not be needed, and perhaps even be 
deleterious.   
All the experiments described relating to the blind passaging and the isolation 
and characterization of these various mutants were carried out in the same cell line, 
BS-C-1 cells.  Given this fact, it would be interesting to see if these mutations still 
provide a benefit to the virus outside of this cell line.  Such a phenomenon would not 
be unprecedented in this context, as this was observed by Cone et al. (174).  One of 
their A24R mutations, Lys452Asn, provided a benefit that was not species or cell 
type specific, whereas their other A24R mutation, Leu18Phe, did.  As such, it may be 





cell lines to see if plaque formation, spread, protein expression, and/or viral 
growth/yield are significantly affected.  Some of these other cell lines could include 
HeLa, A549, RK-13, and BHK 21.  While it would be easier if all the mutations 
provided a universal benefit, regardless of cell line, it would much more interesting if 
differences, especially significant ones, were seen between the different cell lines.  
The challenge would then be to determine why certain mutations are more beneficial 
in certain cell lines or why certain cell lines are able to, or better able to, negate the 
enhancement in replication provided by these mutations.   
Another aspect of the RNAP mutations that needs to be tested is the question 
of IBT resistance, which has previously been mapped to the A24R gene (69, 120-
122).  In the case of Brenan et al., the A24R mutation which conferred resistance to 
the drug also happened to be an adaptive mutation that arose during experimental 
evolution (69).  Other IBT-resistant mutants have been mapped to the J6R gene (122).  
IBT seems to act on the process of either transcription elongation or termination, as it 
causes read-through transcription leading to the production of transcripts longer than 
those found in wild-type virus.  These read-through transcripts are more likely to 
cause the accumulation of excess dsRNA, which activates the cellular 2-5A pathway 
and induces RNaseL activity, inhibiting viral growth (121).  J6R and A24R encode 
RPO147 and RPO132, respectively, the two largest subunits of the vRNAP, so it is 
not surprising that these genes would be involved in potentially counteracting the 
effects of this anti-POXV drug.  Since all the RNAP mutations found were in one of 
these two subunits, all should be tested to see if they provide any benefit in the 





presence of the drug and by testing both the P10-isolated mutants and the 
recombinant mutants.  It would be interesting to see how many provide a benefit.  It 
would also be interesting to see how MutB performed in this assay since it was not 
initially included.  If there are different phenotypes attributed to these mutations, it 
may then be worth investigating to determine the reason(s) for the differences.  It may 
also be of interest to compare these RNAP mutations to the other that have been 
previously characterized (69, 120-122, 174), especially those which were not tested 
for IBT resistance at the time of their initial characterization (174).  So far, only the 
mutation found by Condit et al. (120, 121) has been used for comparison.  All these 
mutations could then be mapped to the crystal structure of the yeast RNAP, which is 
homologous to the VACV RNAP and whose structure is used in place of the latter 
since the structure of the VACV one has not been solved yet.  A pattern or patterns 
may emerge regarding the phenotype observed in the presence of IBT and where 
these mutations are located and/or the nature of the mutations themselves.  
Regardless, the results could potentially provide insights into the mechanism(s) of the 
growth benefit provided by these RNAP mutations.  The MYXV A8 mutations might 
have no effect in the context of IBT resistance but should also be tested so that no 
interesting results are missed.   
As mentioned previously, adaptive A24R mutations have been implicated in 
PKR and/or eIF2 phosphorylation (69, 174), which had not been reported prior to 
the study by Brennan et al. (69).  The RNAP mutations isolated in this study should 
be examined regarding their effects on this antiviral pathway, as has been done with 





recombinant mutants.  As stated above, previously-characterized A24R mutations do 
not have a straightforward relationship with the PKR/eIF2 pathway (69, 174), so it 
will be fascinating to see if the mutations found in this study also have a range of 
phenotypes.  Then, as with the IBT characterization, it may be of note to map these 
mutations to the RNAP crystal structure and see if any patterns emerge.  As with the 
IBT screening, the MYXV A8 mutations should also be investigated, if for no other 
reason than to confirm that they do not affect this antiviral pathway, although it is 
possible there may be an effect.   
Another avenue that can be explored is to isolate additional adaptive 
mutations, either through additional passaging of the blindly-passaged viruses used 
here or new rounds of independent blind passaging of the starting viruses used, both 
of which have already been done (data not shown).  These have led to the 
identification of an additional mutation in the vRNAP (B Mut), another Kozak 
mutation, and mutations in other genes, such as G6, A26, and F10 (see Table A1).  
All seem to be beneficial, though the specific mechanisms are not yet known.  Two 
additional mutations were also found after virus amplification when samples were 
being prepared for WGS, both of which were also in the RNAP (see Table 3.2 and 
Fig 3.6A).  Some of these new mutations have already been introduced to generate 
recombinant viruses, with preliminary results showing that they are indeed beneficial 
(data not shown).  It would be prudent, however, to take a step back and characterize 
the library of mutants we currently have now instead of continuing to identify and 
isolate more and accumulating adaptive mutations for which we do not know the 





Lastly, it may be worth revisiting the initial luciferase assay experiments to 
determine if the RNAP mutations or mutations equivalent to the MYXV A8 
translation-enhancing ones increase transcriptional activity of all or any of the 
orthologs used.  Along this same line of thinking, perhaps these mutations could 
provide some benefit to the MYXV A23 hybrid viruses, which already grew well 
enough that no obvious adaptive mutations were found after blind passaging.  Perhaps 
then these viruses would grow just as well as wild-type virus instead of almost as 
well.  With regard to the initial goal of the study to investigate the structural 
composition of the transcriptional complex, perhaps IP/co-IP experiments could be 
done with these mutants to see if they have any effect on any potential binding 
affinities between the vRNAP (perhaps using the tagged version of this enzyme used 
in our lab by Katsafanas and Moss (1999) (203)), the ITFs, and/or the viral DNA, 
which could provide a bit more insight into the make-up of this complex and the roles 





Appendix A:  Characterization of RPO and MYXA8 Mutants 
A1  Introduction 
Once these mutations were identified and confirmed to be beneficial for the 
virus, via plaque and spread assays, we wanted to start trying to determine how they 
provided their benefits.  By introducing these mutations into viruses separately, we 
could isolate the effects and determine that a specific mutation was responsible for a 
particular phenotype, without the possible confounding effects of the other beneficial 
mutations.  An additional spread assay was performed to show the improvement in 
viral fitness for the P10-isolated viruses over the respective P0 viruses.  One of the 
first ways we sought to identify the benefit these mutations provided was gene 
expression.  The most obvious way these mutations would act would be increased 
gene expression at either the translational and/or the transcriptional level.  We then 
wanted to see if these mutations had any other effects, such as conferring resistance to 
IBT.  For the following experiments, the P10 Clones/Mut 1/2/3 refer to the plaque-
purified viruses that were picked from the P10 virus population following blind 
passaging.  Viruses referred to as Mutant1 or MutantA refer to the recombinant 
viruses generated by introducing individual mutations into the P0 starting virus via 
homologous recombination.  It should also be noted that these experiments were only 
done once.  As such, the results need to be confirmed by performing repeats of the 





A2  Results  
A2.1  Spread Assay  
A2.1.1 P0 and P10-isolated Viruses  
Once these P10 clones were isolated, we wanted to demonstrate that they 
grew significantly better than the starting viruses.  Even though viruses with the 
individual mutations had not been isolated yet, the mutations had been identified and 
had been found in these isolates.  If these mutations did indeed confer better growth, 
we would see spread closer to wild-type.  BS-C-1 cells were infected at an MOI of 
0.01, in triplicate, and samples were harvested at 48 hpi.  Viruses were also titrated on 
BS-C-1 cells.  The P10 isolates all grew much better than the P0 viruses, rivalling the 
titer of wild-type (Fig A1).  P10A had a titer that was actually slightly higher than 
that of wild-type.  This showed that the P10 clones had significant growth advantages 
over the starting viruses, demonstrating the blind passaging had led to the generation 
of beneficial mutations.  To help further confirm that the RNAP mutations were at 
least partially responsible for increased viral fitness, the individual mutations were 
introduced into the P0 viruses and the spread assay was repeated.  The recombinant 
viruses grew better than the P0 viruses but not as well as the wild-type virus (see Fig 
3.6C).  This was because these viruses only contained a single beneficial mutation, 
rather than the two found in the case of P10A.  These results also supported what was 
seen with the recombinants in the plaque assay, as they formed bigger plaques than 














































































Figure A1.  Viral spread of MYXA8 P0 and P10 viruses.  BS-C-1 cells were infected in 
triplicate at an MOI of 0.01.  Samples were harvested at 48 hpi and then titrated in 
duplicate on BS-C-1 cells.  Bars represent SEM.  This experiment was only performed 








A2.2  Gene Expression 
A.2.2.1 Deletion and P0 Viruses 
One of the simplest ways we thought to check how these adaptive mutations 
worked was by checking protein expression for both intermediate/late viral proteins 
and the MYXV A8 ortholog.  Increased production of these proteins seemed to be the 
most obvious way these viruses would have a growth advantage over the P0 viruses.  
First, we checked the expression level of D13 for the initial deletion and P0 viruses 
used.  BS-C-1 cells were infected at an MOI of 5 and samples were harvested at the 
indicated times.  All the viruses gave the expected results, as shown in Fig A2, top.  
The deletion viruses did not express D13, WT expressed normal levels of the protein, 
and the P0 viruses expressed intermediate levels of the protein, regardless of the 
timepoint.  We also wanted to check the level of expression of the A8 ortholog, via 
the V5 tag.  As expected, the only lane which had a band was that of the Myx A8 P0 














































Figure A2.  Protein expression of deletion and P0 viruses.  Expression of the 
viral D13 protein (top).  BS-C-1 cells were infected at an MOI of 5.  Cells were 
harvested at the indicated times.  Antibody against D13 was used to visualize the 
protein.  Expression of the MYXA8 protein (middle).  BS-C-1 cells were 
infected at an MOI of 5.  Cells were harvested at the indicated times.  Antibody 
against the V5 tag was used to visualize the protein.  Actin was used as a loading 

























A2.2.2 P10-isolated Viruses 
We wanted to check the protein expression levels for the P10 isolates.  First, 
we checked the expression level of D13.  BS-C-1 cells were infected at an MOI of 5 
and samples were harvested at the indicated times for both blots.  The A8 deletion 
virus again did not express D13, as expected.  D13 expression for WT, P0, and the 
P10 isolates were similar at both timepoints (Fig A3, top).  We then wanted to check 
the MYXA8 expression level.  Being an ITF, A8 would likely play a more direct role 
in the increased expression of intermediate genes, directly, and late genes, indirectly.  
As predicted, due to the improved Kozak sequence, we saw increased expression of 
MYXA8 for the P10B clone (Fig A3, middle).  This supported our hypothesis 
regarding the MYXA8 mutation in P10B (see Fig. 3.7A) resulting in increased 
expression of the A8 ortholog.  At the 8 h time point, we also saw an increase in 
MYXA8 expression in P10C, which does not have a MYXA8 mutation.  This 
experiment needs to be repeated since we did not see an increase at 12 h.  We were 
unable to detect the V5-tagged ortholog in P10A, as its MYXA8 mutation rendered 










































Figure A3.  Protein expression of MYXA8 P0 and P10 viruses.  Expression of the 
viral D13 protein (top).  BS-C-1 cells were infected at an MOI of 5.  Cells were 
harvested at the indicated times.  Antibody against D13 was used to visualize the 
protein.  Expression of the MYXA8 protein (middle).  BS-C-1 cells were infected 
at an MOI of 5.  Cells were harvested at the indicated times.  Antibody against the 
V5 tag was used to visualize the protein.  Actin was used as a loading control 































A2.2.3 Recombinant Viruses 
We also wanted to see if there were any changes at the transcriptional level by 
using digital droplet PCR (ddPCR).  The recombinant viruses had similar levels of I3 
transcripts at both timepoints and were about the same or lower than the levels of I3 
transcripts for the P0 and WT viruses (Fig A4, top).  They had the same or lower 
levels of D13 transcripts compared to the P0 virus, but those levels were not as high 



















































Figure A4.  Copy number of I3 and D13 transcripts.  BS-C-1 cells were 
infected at a high MOI and then harvested at the indicated times.  RNA was 
purified and reverse transcribed.  PCR was performed using primers 
specific to I3 (top) and D13 (bottom).  Results were normalized to rRNA 
transcript levels.  Each sample was assayed in duplicate, with the exception 





A2.3 IBT Resistance 
A2.3.1 Recombinant Viruses 
We then wanted to test if the RNAP mutations specifically granted the virus 
the ability to counter the effects of IBT.  We quantified how well viruses could grow 
in the presence of the drug.  Both the P0 and wt viruses were equally sensitive to the 
drug, with wt growing only slightly better (Fig. A5).  Mutant1 also grew poorly in the 
presence of the drug.  Mutant3 and B mut (an additional mutation found in RPO 147 
(G1145E)) from a new and independent blind passaging experiment, see Table A1) 
performed much better in the presence of the drug.  None of these viruses, however, 
grew as well as the virus with a known IBT-resistant mutation in RPO132, known as 













































Figure A5.  IBT resistance of RNAP mutations.  BS-C-1 cells were 
infected at an MOI of 0.01 either in the presence or absence of 60 μM 
of IBT.  Samples were harvested at the indicated times and then 





A2.4  Identification of Additional Mutations 
 A2.4.1 Blind Passaging 
The MYXA8 P0 virus was then subjected to three new independent blind 
passaging experiments.  This was done to potentially identify new adaptive 
mutations.  Frequencies of putative adaptive mutations at various passages in their 
respective populations were determined by Sanger Sequencing and WGS (data not 
shown).  The percent frequencies of potential adaptive mutations in P10 for all three 













































Table A1. Percent Frequencies of Additional Putative Adaptive Mutations 








p10A 8% 12.6% 74% 98% 










p10B 18% 61% 15.8% 98% 
     





















A2.5 Materials and Methods 
A2.5.1 Spread Assay 
BS-C-1 cells were infected at an MOI of 0.01.  Samples were harvested at 48 
hpi.  Cells were lysed by 3 freeze-thaw cycles and sonicated on ice.  Samples were 
then titrated on BS-C-1 cells.   
A2.5.2 Western blotting 
BS-C-1 cells were infected at an MOI of 5.  Samples were harvested at the 
indicated times.  Anti-D13 and V5 tag antibodies were used to detect expression of 
viral proteins.  Fluorescently-labelled secondary antibodies were used (Li-Cor, 
1:10,000).  Bands were visualized using the Li-Cor Odyssey CLx.   
A2.5.3 ddPCR 
BS-C-1 cells were infected at an MOI of 5, in duplicate.  Samples were 
harvested at the indicated times.  The RNA was purified and then reverse transcribed 
to obtain cDNA.  These samples were then used as templates for PCR using the gene-
specific primers indicated.  Samples were then put on the BioRad Automated Droplet 
Generator and read on the BioRad QX200 Droplet Reader.   
A2.5.4 IBT Resistance 
BS-C-1 cells were infected in duplicate at an MOI of 0.01, washed after 2h, 
and then fresh media, with or without 60 M IBT, was added to each well.  Samples 





A2.5.5 Statistical Analysis 
Statistical analysis was carried out using Prism GraphPad (Version 7.0c).  
Unpaired two-tailed T tests were performed on the indicated data.  P-values <0.05 
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